var title_f25_23_25968="Myopia steep cornea";
var content_f25_23_25968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myopia with steep cornea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When the cornea is steep, light is focused in front of the retina resulting in myopia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25968=[""].join("\n");
var outline_f25_23_25968=null;
var title_f25_23_25969="Scapular extension exercise";
var content_f25_23_25969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Scapular extension exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 193px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Start by holding the tubing with some tension when the arms are fully extended. Pull shoulder blades back together; imagine that you are pinching a pencil between your shoulder blades. Pull to a 2 count, and then slowly return to the starting position on a 4 count. Perform 25 repetitions to complete one set, rest 30 seconds, and repeat the set. Be sure to pull with your shoulder blades; your arms should follow the shoulder blade movement. Elbows remain straight throughout the exercise.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25969=[""].join("\n");
var outline_f25_23_25969=null;
var title_f25_23_25970="Skin metastasis of squamous cell carcinoma";
var content_f25_23_25970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma metastasizing to the skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal transplant recipient with locally recurrent squamous cell carcinoma and in transit metastasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25970=[""].join("\n");
var outline_f25_23_25970=null;
var title_f25_23_25971="Chest radiograph of left ventricular aneurysm II";
var content_f25_23_25971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of left ventricular aneurysm II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 269px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAENAVwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwHSdEvb25KwLK5LHpmu50vwfqCECRG3em7pXqOhaBDbabLc28Y8wcIuOc+tb1noTuqvjCsM5I/SgDzuy8MTIF3D5vQGtAaBdR9Y2A9Qa9JtNHKEArxWzb6OWHKjHvQB5TbaDOeRuf8a0IdJmjOCjqfevWLbQYiPmUA+1atvpEMagNEh/3uaAPLdO0GedhuRsV0a6Rb2MWJz83cZrtJLeGOM+UAhH8WOB9K5rU7KZ2Yk7kPf1oA5e/lafMVsNkfcjq1Z/9mdN5bPZfWupgsMn5QN38qe1qqthQGY9TQBy39nMBuZiFHYHgUjxEJkEqvrXRTQoiF5mAjX1rivEWtQbzFDuKj04zQA27vIYSRvLt7Gqg1Zk4QDPrXO3OpYzhB+NVU1J2Y8LigDs7XVJ2b77D6Gt2z1kx4Dyjb6sa4C21JV+8p/CqNxqpmlOx8AHAWgD2a011RgIC/uK27HU0uGww2kV4lp2tSwHAY59a6Ww1yYgMJAG9+9AHr8cofAUgj1FWY8Z689q4bRNbL7ROCD6iuyspkmAbOfQ0AbUOQgzSXkm2Nm7UkJJHbFVtYjZ7U4IFAGPcXAL8Nk/WtDSbhHO1vvdua5OWKZZidwCg9M1raOzechZgMHpQB01wSQFHTqayryQRg7iT6CtG4fBPPGKwtQlCIXJ4A6mgDndc1M24czOc/wAIzXmuueIgHdUkO761Z8c62Xu3SM8LxXmWo3p8xtxDE0AbM+tziQsszg/WhdcEyZ89g46gGuLuZ5JSRngdAKitZWSQFTjJ5zQB2T6tl/vyH3zU1trIHykyf99VzQzjLEU8PtG4McHjpQB3Wm+IPKYDzZAP9o5ruNA1+1uAI5JACfevFYpAUB3d+K2tHMkk6rExyTQB9CWFpvZXXmPrn1rVNmJANnD1yXhDUZILVLd2Lheua7uzkjePen4g9qAM51MUewgh+lP0y0YzqWzgd6tTxCZ9/fOBVq1XZjjB70AOuELMwA4FV490ThvmA7+9aL4Uk9T2FVNxYkSrkeo7UAQ3lnHeRFoT846isObTPmy6Et7V0yW5RgUPvViRFdPmFAHnl9pMsm48hB61yt3CY7h0U9DivUtZXyYSB1bpXGzWqPKzEDJ9qAILCyZtpxhR0xW7ZxtGNozjuO1WNPsyvBXjtWsLI44XnFAFOEMeBWraW7MAW5+tQ2tq4b5171sxR7FA70AIkSqOnNSFeMml24HI59KbIDg+tAFaeAyHk8DoBVQWrNJgcDvWgCwOCM1IAKAM+XT0kQhAF/rWZeWsdnCzSfe7V0TEBST0Fcn4muhMhQ8L65oA4bxTeIUbMhx2UGvOL945XJAOe/NdJ4njMLs/mrInc55FcbcXcKnHmigCtcRh+MsMe9RJCAeGO4GlmvIOcSDmo7WZGZiHBxQBfEbmL5QDn0NY8sbiX5lxW1bzoD83Haqs08SkgjkHvQAyCR0f5hn6Vq2V2d4weBWRLcwzP8uEY91rStLRtowwbjORQB3OhagpCqzEGu70e/CFdkgIPUV5Dp8LryCQc9M11Wh3bwzqZCcdKAPadMnEg69RU+oc27Vyeg32XUg7vxro768X7KxX1oA5m/jZZSdvBqxYrsdcnng5qtePKyguRn61HYSOZgCTj1NAHUX0yrGOeK898ba6LaMxxEFiOnpXU6zceVGR0BFeYeKNrytL95/egDgdXee5d3kwM881yl6qRtljubvXSa7PtDHOXPauG1S6GPvD3AoASaf5m6BenFQI438HnNZs127IQo202z3NJuYk4oA6pZ0QAO4BNO+0R55kHWsCZyxAzzSxB2fAyecACgDpYjG5ARwTXXeHrX7NH5hYGQ+/SuR06BLZEeUZkI6Vr2lyxOc4/HpQB6r4evGV+eBjvXZ6VrIaYIjAjvXitprM0YMcUu44xzXW+GtRSR1Bfy5c9D0NAHtcRDxb05B6irkB3getc74fu2BVHOciukCeXKGX7poAfKM1EEzmrDfSkCjrQA2EYBBp5HahRgUvWgDC1z5yE/u8CudaL5jxXRap/rHPfNYjKSxoA2dBbzogsg+cda3ViA60yCBIvuqM1eSIHBoAjSLHOOPSpFUZycVKRxxSbKAGbQT0psi9anAHY0zGW9qAK23AyRzSVLJyeOlZ2szNDaN5ZAJ4ye1AGD4j8Rw226CJue7V514h1JrlQTKx54wam8RsolYklq4+9vmjRigGB1B70AQX0mXPOSK53UbOOcll+R+vTg1qHU4Xb522OeM1GzqVfcRz2oA4u8gmgY7hlfUciq0UrKQV6HrXXOqncFZcHsw4rMuNOt5H5Xym9R0oApwXDheGP0zVe+nk87LrkHuK0V0tgCbeQOOmDVa4sp0Ta8Tcd6AKttJiQFTke9dFpV+33CeRXLcx5GCD6GrNnNKJAEU/UUAekaPcRTBRn5jxXVaYmHBQ/nXmejm882PERC9dx4xXp/hgCRl3MSB6dzQB2ejbo/LyoOTzgVs6jOotmCKAQeKq6dGCcjgKMfjTpIcxAOTye9AFKJ2mBBTLU+03eblxwKsW0UcZf0xVa5l8iMkcYGcmgCl4jugwJ7V5Z4m1RQXjjOSOpFdf4ivjJaZjP3uMd64DU9PJYLli55yKAOM1q6Ypgd+9cjeOMHPXqa7nWdFmj4aRR7VzF5p7I2RsGfegDnGDMDtBxnitCyjCxjIGasiwDqGaRV9hVm3ghhO4nfj+9wKAKcVm8rZHA9T2rVtoIraP5GLOeppj3EecK649qia5iAP7wDHNAGku0sCWJYe9Sy3CohWJ/nNc9NqSniJwTToJWyCcnPoaAOr0hZGBcNn1zXU6XLJHjPT1rktJlxGqc5NdXpkyjjGRQB6f4T1o7oopXyvAVvSvWLZ/MhU9a8F0YKzBosBs5x2r2LwnefabAq/Dpwc0Ab2OMUUds0A8ZoAXtTFP7wr+NKWGOtNjIZ89xQBl6nCSWwM55rIMQycitfUiwkODgVljqfrQB1qDkVbgOc1WQc1bgGKAJMVGTk8dKlPSmgUAN6LTexNPfpikA4zQBCVwCTXJeKrhi3lqeBXWXBwhJ4ryzxtrnlPIlocsOr9aAOQ8RzLCzNNKFHoTzXAavq0IVhErN7niptcumld2ZyXJ9cmuPv5XV2JyQfagCte6vKJMqEC+wqKPxDcxNgtkY+6RWRfyOrE7Dg+1ZrzMG6EUAddB4i3MBIq7verjaukkXQgr1INcD5pc+9SxXLp91j9DQB31peqzHbIM+nStq2v5RGMlSR/eGa8wi1FlflTn2rpNO1dDEBJuAHOSKAOyd4ncMYImHQ5UVctreMH5Io+mQAMVjaffW00ePMUfXirschcjy35HHBoA1ojIzfdJUdq7PwmrIokIO0dveuS06QblDZznmu70RRiIKSc9qAO00qRmjUkjJbP4VanfzFJABUHisq02szAMQBwcVt7IzAiqOtAFVV/dMcYPpWRrEZNs7kEjoAK6RoCtuwXrWfqkGYFAHFAHBT2iOsZZTnvmsXxA0VrHkKBx2612Gs7ba3LOBuUfKPWvO9ZnEyMxJdz1HpQBxOv3ksgOWworkbuZGbAYsa3NZSV7h1YYX/PWucvHtoDgNvP+zQBI0rC3QpgeoxVGeXajHd+dQz6kSpWFNvpmsa6lmcHcTQBfkv1RDhuvpVJ715FZd2BVJsrGOOpo28/KaALcchHA/Or9pO4kXDcCsnBxgEVctQyrz1oA6/T9SeNxyCoHQ11ejatDM6q/7t+gyeK84tXPO7Oa2bKZRg7uaAPaNGmkRlIPHb3r13wROJdw/iIx9a+efB+tG2kSG5IeE8ZP8Ne7eD2ELQyRsGRj1HcUAegwtlcHqKYXwSKcThgw6Gqk74egCdpAEOaigkzcKMnmoXfI680y2b/Sk5oAkutlw7L91x+tZcyiJ9pHNSXzkTEq3eqk92pf5yM470Adqi1aQYFVkBwBVmP7tADqDRSE8UANxk/WhuTigdSaPUmgDK1yR/s7xx9SCM14p4ojAkkDuS3oOlev65MVUgd815B4tUi5kH48UAeeal8jcABT1rmNRUKxAb5fU1u63c28W7zZgvt3rj9Q1eEgqqM2OMnvQBTvlGMDmsS4+Vip60+61NyTtVcVn3F8WXJjXJoAlxuI29fSm4XjcACDVL7Zh8lQPoacLhZG+9g+9AF948yBl7ir8GViyQeazLa4aPH3Tg81qrdBoxhcUAaenZIYYOeo54rZgEpxtYo46Y4rO0yRQoyRk9a17OUmYHZkZoA6LQ9RuomSO4USDs2K9V8K3azwOVjO/pmvNdLRDMu3g969G8PzrEgjVSM9eKAOoh2pBgd2ro4UHlx56AZrmYVZmijAzk112AkSgjtQA2VwIMiqExEoCk8N0qzcn5QFGSaLG0DnLE/L2oAwNT0VLuYeaTsA6Csa+8JWpB8uHqK9GktY+OOao3nygqo59KAPnXx/4GukgeWBtkeORnrXjV/aC0Z1YHd0Oa+xtbtRdQyRzL8jDBr5p+J2lR6dfOyZIB7CgDzhwAcnpVGRgZCOxq5LKCrkL9M1k3ErjocZoAV+QM/hTVfAOe9RyMSFOTnFR8mgC9ANxBHSr6EAjPfpWPHKyDGeKsrcMCM4NAG3bZ7Gte1TIBPB9q56xuFAJc47VuWspkK4wB04oA6PTGaNgTyPavevhtfmSCO0c/NHyhzXhOiA+aNwzjrXqngec22qQSJ64IoA+gY23x7e+Miqc33jUsD8Iw6EA1BdnbK3pQBH5nFELhZgTVPzuopYpcyUARXzgOfrWJeP+/PI6VpahJkk1h3Mw80564oA9aSpxwlVw2DUoPy0AO3U0nmkJpoPNAEo6VHO2EOKcTgAVVv5RDCWY8CgDmPFl5FZxFpW7ZxXhXjvXZblgYcwoOCV613XxB1Jprogt0GQK8j1mbzA6HkmgDhtVlkZ2Z249fWuevLkAc59q2dWikLMMHI45rmrmGTdg4yaAIbg7h8vNVHYg7X5qVo2RyN2cc1CyhiSzfjQBDIU35DcUjIwbHGPUUeQScKQRT3idYlIzxwaAJYyyABCcHqa0LG4YP5bnrVCzKj5ZM4PpWgYvLYNtyMcGgDoLKTYRnIArotHuNzY44PBrmbTzDCrYBG3j3q5pkrxzjcvHagD1bRJI2lUlQc8k4r0TS7f90pP3s968s8PSjdCNwxwcd69j0QLPbQ7Rz3JoA6fSLWMBJGzkADmtllDkAVUt4wqRqDya0FjAIz0oArSqS67egq1ZJtiPrmmlcHBAIqxHgIMUANmHy1mXAyxNaki7sCqk0ecjFAHOahEZFbP5V4h8YdNQ2TvtG7HNe/Xke1TXj/xOtHuYpkA4KnFAHzBKMblIrHc75QgHANdLqFo8M0gfpzmuehiLXDddvrQBWlGHI7CiJgjZIzV+e0UJuyc9/aqBUYY+lADT1p8YJyckAdTTACTipFRyCAp9aALEUi5CjOK19PuGjcFD+FYcIO4DFadmfmAwevWgD0Xw/PHKi/NhzyQa9A8NTtHexHJ4IrxywnZJEKtyP0r1DwderdSxLkeaDyPWgD6X0+YTadbSqeNuDT708hvasrwZJ5miCM9VNaV1nyvcUAZNzIVfjoaSGXdzTLxTjrzVeM7Qc0AOuZMnrWHdMGnfGOOKvXE2ASe1YBl3MxyeTQB7ep5qVT8tV161JnigCQt2oj65qINzT1OFOKAJM5NYXiaYiyIXkk4FbWfkJrnPEEoFlKAeQaAPJ/Gi8wzyNzypArzvVG3MSoH0xXoXiuRZLSUMeV+YV5dqVzGhOZMD3PNAHN6yquzPnn2rlr1T1XnNb+pXUZdsFSO5z0rldQmKSfIcLQBXfO7HbvVZk5PU0jylpM5JzVd5ZmJG7gcUASlDnAI5q/EivFsasjzJFbk5qZJZMk4HFAF9rVY2GOQav2pBUJnNUrafenzKQ3SrEAxKvzEHt6UAdBpSvHlX+aPoD6Vp/Y/L2ygZNUtJkw434IPHFdrp9tHcwqrAH6UAHhlCJlYnvyK9y8GjNqgHOTxXkek6esd2Ej37v4RjivX/BlrJBEu7JJ5PtQB20HzyKT0WtLYOveqNgP3YJ7mtECgCLblsfrT4hhMGnYpaAExTXA7089KjYDuaAM+8QbTXnXivT/PlbIypzXpFyAVIA+lctqsTSSkACgD5j8aeGjDPcbMjGcZFefW2kTJMcj5QOa+lPiHpO+waQd+uK8P1GJoi/J4HegDmLqzd32qOCtZkti0UTEqcE1bvbyXzisbdOKit7veJI5m3EjigCjDDuYseBirUaiNQV5J6mo94JK/w+gqaLa2F6NQAqQhvTntV2G28tQARTreIKRtAJ9atIhJIxQA22fawBXB9a7PwhdNBqMUyn7gzXNxWqyYHGetdBoMTW7DPG48Z7igD6j8B3Sz6akidH5NdNdr+53eteefCq4/4lzxsf4gR7V6Qw327AjtmgDAuVyKzZjitu4THOOtY9ypDEUAYuoT7Yn59q54SFSwBPWtLW5MNgdutYYnGTnPWgD6Hpc1HG4YU7NADgakz8gqGph0FACStthPrXGeIblYbK5eQgKBnJrsJyPLOTxXlPjC9+0tPEpwhBAAoA848Q615sjiPhDx9a8p1uTyrmQBi3Oc+1dhqrBshskqSDjtXJa6geIMgwV/M0Ac7cSb8so59Kzpk3jDDrVqRlDZJYGopkGQyAkYoAzDC6vgqQO2ajlRw2AMg960pQ7rz+BzVcxuoAcA0AUtpAwQMVMmCoBABq4keTwRj3FWEt9zYVVYmgCGxVM4YHJFasCLgblyKqQQGKb94Me1bNhDHKu0ttz60AFn8spO3GO49K7vwvMryjccD0rnLbTS7RxRkZP61uaXpN5a3GdhOD2oA9R0a0W5ljEPyynocdq9P0Owe2hUPycc1wnw/wBOnkkjuZVKIMAg16xbxZUYFAEtmpVSD2q2gyajRQvQVOgwOlACFaYRip8cVEwOaAG0hHtS0lAEE0eRwKx7m3Vw5Gd+elb56VmOm2dj2NAHB+JLUTW0kRXJwT+NeAeNNP8As25ymFPt0r6d1a0JkZscV4b8VtPaKKXaOH5A9KAPnm7X9/I69Kp8KWYDJxW09sdznGOcc1QnhIyR170ARWKtIJEIwduRUsUQBBLcimWUhifPduMGnSY3t1HNAF2KRoVyp+orRhu42UcbWIxWFCzA9Tj0q9bgE5z+FAHQWhJZVb+LvXY6ZCrMqZ4A71xmjTBXXzAWTt7V3ulKjOrKcqecigD1HwA7W0SgnnePxFevocxKc8MAa8f8Mj/RYj3HIr1ixfzdKt5O+3BoAp3gK5B7Vh3hIY89q6HUApwR3rldZk25Ck49qAOX1gszPz3rm95DNk963b+YMrCudK5djz1oA+i47jBq7G4ZQRWBbSEnk1s2ZyhzQBaqUfdFRVN2FAGZr8zQ6e5XvxmvHPEU5S6PTGa9e8SKX06ZR6ZFeTarZ+awlfn/AGaAPKPEEbRanKqqSrnPtzWLdWXmHDEE46V6L4vtFEMMwUAjKsAOnpXGOo/iHNAHD32nGF2O0YPQVWNszlQQPcV1uoRxmNtgGfU1zcjBZCpU574oAi+yxKpOMkVWlt0cHPDDmriSCWQqAMelBgkBOflHpigDIaJVBIyfrViDMZB5BHatE2LSIWBAI7GnQWmT88nagBIBHcDLD5jwM1oWUJEwUrnFRQWixnPFd34b0iG80/7S3X7pGaAMXTQsUyyB8EHA4r0vwhbve3kaSDenXdWJZ+HIZ5gkOcd+K9V8G+H/ALHZDGN3YmgDrtItIlRQmAB7VvooUAVU0608qEb/AL1XlXrQAqjJqcColHNTqKAGkUhXtUm3mgigCu6Y6Uw1Yfr0qFl9KAInO1SfSqD3B8zkAitF1yCDVGSNCpUnB7YoAzr2TzSyhQB61wPjbRftunyLt3OORXpLRRudq9R7VmajZBwwOMUAfHHjTSpLGb5Itobkcd65W2gJfbLx7ivoj4meHlkYlFDDk/SvF7nTo7SWRXB3Dp70AYZsBO+UC4Xv0NUrqzmhcsQSPUVuRI9uWkYHGOnrT3uYmi2uAWzxxQBzSDnH8Qq5apluc5rQEdtI37yPGT1Fej/BjwjaXer3uv64UXw7oi/aLgSf8tH6onv6/lQBw9lCAqkdPauw8OOIpArsPLY9+1Yur6kureINQv4bSK0guZmkSCIbVjU9ABWxoqCW4iAHyqelAHsGhII4YQOmByO9enaIc6Wyf3TkV5h4buDLCEIGVr0fw7JmN4++2gCbUBmFTXKawmUbFdjdjMB46GuW1QfK2BQB5/fE7iPestVJLfWtfVPlkPFZSyfez60Ae1Wjkn8a37D7tczZNg475rprD7ooAvr1FTDrUSdRUydTQBQ1AboZBjJIIryy9YQmaEn5gSVr1DUWO3A+teP+N742OpSrEBluS3t7UAYGtBHhlidwWYZ+leZ6jdMJWCg7gcV2N9cs85Zc4PNclrsHzmRcjd19KAMuSVMdc5rNvLcuGeM/N6Vc8plOGHB6VMLZnTPAQnqaAMGOORWB5DD0q7BHIZMuScc81ZlthGSUyx74qayQ+YCQevegBLe385iWO0j9avwaXnAxyetWIZIt3zw4boCO1acMpA+6dvsaAIF0FjEpO0E8+9dj4UXymjtfJVkP5k1jWU0uTlc5HFdj4Us5Lib7QVwqcDjqaAO70vS4hErx24Rj14ro7BPLXy8cDoao6csqwjIx7Vu2SBlww5oAuw5MYz1qdQMUxBUgFACqBnrUw4FRLUnt2oAdSHrSE4pBzQA16YRxUpFNxQBCVqJo1JzirJFRkdaAKogAckdKhuLfdnNX8ZppHqKAPOPFmliRWJAwfWvnPx/pElvdyzW2XVc52+lfWniO1WS3YdcjFeNeIdHWMTKULKc9qAPnh74qoRsAmnR+XcwYBGQa0/F2hfZLl3hR1TOcHtWDZKfnIOMetAG1oel3Opaja2NpH5tzcSCKIerE4r1n4n3Nr4d0bTvAejyBorQCfU5EP+tuDzgnuBzx9PSq3wztovBng688fatGDeSBrXRrdxy0h4Mv0/w964FpJbu7luZ3Mk87GR2Y8ljyTQBOltGOOORxW14cgeOVpGGNvFZllGzYDLz0rsLKyMVsuO3egDoNDvRBcIWOB/OvV/C0m+cEHhlrw1ZTG43A5FevfD658+1jY/eQYoA667GInBGea5rUkHzZHGK6q+UiNj61zOo8g5oA871oDe49DWHG64P1rb1wbZpD15rnVPLc45oA9rsBl+veursVxEDXMaapLj0zXWWoxGKALCdamTvUSdalJwDQBgeIbv7NHtX77D8hXjXxBQzRxzqeVO1voa9N8VzCVm2sARxXmep77uKeHbvyMdKAOF8xizIxB/u57VXlhknBUckVYNo0crCdSJEPSrWQyghQCOuKAOUmsHWQhycZ6VJBGeUEYb1z3rpLi33Lu4AqhJti4MQJ9cdaAIPssKxDf8rDqoqo8Gxt8a4j9cVt2zwMrCSMnPT2q9bW8MzBF+XPZhQBzUYOz7pIJzmr1tC7MMDANbd3p9vGcR/MOpA7VNZiJFKm3LE/dNABoWlTXdwiKxGTyR2r1rRNLW2VI1JJ7k9653wXY87zEVz19q9G0u0G8v1wKALVmilwhA4FacaBRgCs22VnuCQMID2rYhGT1oAVV4pe1TBDjg0jq2BxQBGvWpO3FIMg9KdnjO2gBoGQeaFBBpwwaUDmgBAMmk20/FLjigCErUZFWSPSmEe1AEAXFRt1q3tBBwKidOTigDPu4RMhGBXG6xo6OzB168V3u3mq11ZpMPmGPegDwDxZ4PNzC+1dwHOfUVzXwz+EsOveLrm01Qy/2VHbmRjG21txOFAP519F32iK6HHIrnNVM+i6TdxaUjQ3N2dssyDDIgHAX3680AeD/H3Uw/jSHRLC6t20jR4Ft7aC2JKxED5g3q/rXFwSIY8FgDwc+lbfirwnLYXTTRqzozFtx65Pr71hQWUrOyEEHtkUAdTosGZEeQfL/C/aurOY4whORXMaRmKFYSOMce1b8ReVcZBI6UAEyGQq/wDd616V8NZgoYZyCQK4CyVmDKy47EEV3PhNTaKmBwWyKAPU7wZt/pXLagOtdbLG/wBkQuMFlzg9RXLampANAHnPiBf3r/WuWPDN9a6rxBkTPnNcqfvt9aAPdtNzkYHeuog/1YrmtOGGGK6aH7goAlT7wpZm2xkmhOtQ6gwWEg0Aee+ICz6jNGOI25BNc66LbMUUcdx6103idT5quoxxxXL3dwrRbscjqaAOd1+1EsgmVQvqKxDCiMXMiqO4PeukvrgzRkIVVf7x71x9+JEnYhsJ2zQBpusQjBDFx2wKpXMYdWKx4FNsHdSMONp61qxW87L8yjDHgmgDAt0kaZUK4Ge1ayWrB8Kpwe/etFdNYEHI+XuK1NK08SMNxyRQBDpmlu8SyKjMfXFdBp/hwTurbQrZ5wK1tHsZQcYAXFdZpUEW8fL0oAg0/SUtYNqLkYxmtuwtvJtsA/M1WVjU/wAIAH61KBgUAMjQIMAAVNH1ojXJqZE5oAmVcjJpWFOAwKDQBEc0ZPNKw5pOlACnp2pUphqRBQACnCgCigBCKbin4pAKAALxTSvWn0UAVzHzQY8jpVjFGKAKEkZB6Vn6hYJdIQQA3vW6yAioHj6igDy7X/CiTb1eEEH8jXnmreADA7uqnnkN6V9HPCD94D8ay9S0qO6QjoTQB8nXVlcafcMrqWXOARUkEjkrtYl17qa9p8R+E0ZZMRkn+deW6joNxpd0zxrmP07igC/pt0blikgIkUc+9et+E9Pjs9NTVL1T5MI/coesjf4Vxfwf8OjVtce+vgGs7RNzK3RmPAB9sZNd5rl9b3V9FFYSBrKFdiKowoPfHrQBv2F499atLIcvuyfasrV05YfjUnh+T99LD2K8VLqy5UH2oA8t8SJh2rjyDub613fiePkmuGkyJG470Ae7acTvXiumgOY65TTGBfGeldRan5OtAFpTVHVn/dEVczgZrD1W6VYnLHgUAcx4klVbV3bkryK8zvL5mdiSSvp0ArrtZvjI7jOVIrzzVRtmdRxzQBM8xdc54HQDvVaa3+0KWVc56iq1tP5Um2RflIrThugPuBevegDIjt2hYoDwTmtuymkmURyMDt4GDzU6Wr3W5oFUnuKs2GmTRykuAhI/KgDX0qz81lHU+ldVY6GBgqMY5xWZo1sYolJ4Pr0ya6rT1YDDHCkc0AWLQKpEYxnocVv2tqqKOMZqlp9ihO/qAa2F+WgBwXinAA80wnPFPiGaAJVXvU8a4HvTVFSDpQAUGiigBjCmVKTxUbH1FABxxUi9KjHtUo6UAFFFFABRRRQAUUUUAFFFFABQQDRRQAxl4qB0GKtU1lyKAMy4tkmXDqCK5LxF4ZS6iYxoCfau8aP2qFouDQB43e2t1pWkPYWRaGCRy9wFOGkPTk+gHaqnh+68otCWOP4PrXrmo6ZBdqRIg3eoFeZeJPD02m3nn26kxZzkdjQB0mhyFblG9DWxqI/dsPQ5rntCmEojfv0YehrpLwZU/SgDz3xLGCjGuCePMj4Gea9G8Rx/u2ya4d4h5jckc0AepaWSJPxrqbN/lFcjpbknPvXT6fJkgY96ANO5cJA59q828Q6uPOKAkIOCfeuy8TXv2bT5cHDFTivGtavi4PIJoAi1G8CyFtx57Vz+r4lXzE6qOR60y6uzMGAI3r+tRWrSS7g5wvfNAGd5oYkcnjp6Vb00fvQJSSp6D0qXylhfasI2nv3NWJ5Y4QoSNA2OfagDpbGWOOLb5ijPYCtu0kDhVjQv6sRXC2N0pkA4JroLC/uFkKqCNwxj2oA61DEkw2sWl9OwrdtZFYJluAOa421dpFLs+3B59TWgt55e3aCOO/egD0azukWFQMAGtBHDgEZxXK6VKJ7dXCAADnmuphIMS46YoAsKA31qeNdp561DFxz2qZGywoAnooooAKKKKAENMJz2qSo8c0AOA5p1Rry1SUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABFRPUpqJu9AFaVf0rI1e0W5tZY25DjFbMlVLgZjagDz7TIDY6h5DdCeDXWTAtAD3HFYerRmO9SUdM1r2U4uLU9iev1oA5LxBH+5f2rhZl/etyOtd3rrjbJnHeuClf963A60Ad7o9wGHB711enSZGe5OK4PRJPlGfWuys5RHEGY4CqWNAHPeO9TG6aNWHygrXjWp37Fjhua67xdqAnnnOepNedyJJJcYUZYH8qAHW0c80+4HavcscVuIqxBVR1Y9jmn6Z4bubqFSzeWGOTnqa7bRfDtjYQgSRiWb+8/ODQBxlxIGjCoGd+5AzisW8a4EpDRuB2O0817Pb6XFklI0X1wK0F0iOZQGjQjtxQB4dZOYjvZWGOfmGOa2NL1CRrgM75A75r1S48PQeWUkt42H+7WVdeD7CeMhIPK44KnHNAHL2eoYkO98IpyB610enuLuZXXPuOwrLk8HXUUu63lWQDgI3etXQ4LyznCXFu6H1xxQB1Nm7R7VQYUfwjvXY2UvmRjcADjpXL2EO5xtBJ9fSuhG2JgzHDYwMUAaBPFSwsc1m20zNwTznvV6JufSgDQU5FLUcJyKkoAKKKKAA0lLRQA3GDThRiigAooooAKKKKACiiigAooooAKKKKACiiigBGqFz1qRjxVdzQAxzUTcjFOY5NMJoA5zWoQ0bgjkdKzdBnw8sRPOMjNdBrCB0OOorl4isF4smcHODQBm+JfkL+jcivPpZP3r/WvRPFAzbk+hxXmlxxO/zd6AOx0Fy8oAJxurpdavBZ6Jcy55I2jmuW8NPmQH0BNHxBvjDpUMIbG7LGgDgtUnee4YJk57etb3hrw/5eJrhSWYZwR3rO8K23227E0oO2M8fWvTrSBCoyMACgCG004RqGGAKvR23mY3AYzVuBd/yKMAVs2VmvyrgE0AVbCyEvG3GO5rWgswg6cdquRQKgAXHuasBQBwMUAZc1iZDnFQHTXAztrcxT1XNAHPJphLfdrRhskVdrqGPqRWkIx1puzNAFM6fHtHk/uz7CppbfIXPbvVkLtOKlJBHNAGO1q68q3Oc1dt88buvvU5VfSnRoN2cUATxDC0+gcCigAooooAKKKKACiiigAIphODT6a1AAGFOqEjjIoD4AzQBNmiow1ODZoAdRSZozQAtFIWFJvFADqazUheoXb0oAV2qu7U5nqJjQAjGqs0wQ8mi4kK8/lWNd3A+bJ5oAs3kwZDzXJ6g5jm46E5q619yVLDPasbUZhIGAPzDpzQA/X38yyY/3lzXmtzgztzXe30m/S4yTjgivOLh/38g9DQB1nhucAMfwrF+Id4bnUYrdOygVLoJYEjd/F6VRmj+068XlOSpwBigDpfDNslpbRKQOQM111o29gq8VydtlQuD9K6jSc+WGJyaAOjsoVAB7+lbUG1VAXqf0rEsnNX4XO8UAbCfdFPqrFITj3qynIoAlUU8VEKfnAoAfmkBGabmloABk0AHNOx8tAFACqPWp0FRL1qVDQA+iiigAooooAKKKKACiikY8UALTSaYzGm7qAHN7UlN3UjHigBW6ik3YppPNNJoAlDijf71FnigGgB5c0m+mHrTSTQBIH96azU3JxTTQAjHFRSOOR3qQ9KqTuVHHegCvdljwQa5rVGZGJ521uzzMM55rJvW3qwYAigDjdYvfKQsW5B4rMi1IXEe8MCe9L4siKOVVvlzjFcpZySRzOgf5SKAO0uLhW04civObuYfapef4q6p3f+z5Bu6DIrgrneZ3O4dfSgD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain frontal chest radiograph from an 80-year-old female demonstrates prominence to the left heart border, a characteristic location for a left ventricular aneurysm (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRGdgqKWY9ABk1N9juiMi2m/79mtHwggk8Q2qMMg7+2f4Gr0WLSYnOWj2/7tAHlQsLwni1uD/wBsz/hTxpl+elldH6RN/hXrqaRsHyYKj161cgWFQN0G4jrmgDxgaRqR6afeHnH+pbr+VP8A7D1b/oF33/gO/wDhXucUlssbhrNtpGCQ3H5VqRwWUqFYnaNs5UScc/WgD54/sTVc4/sy+/8AAd/8KU6FqwGTpd+B727/AOFfSR0vI6DnuvehLAINpAKn9KAPmj+ytR5/0C7/AO/Lf4UHS9QAybG7A/64t/hX0hc6Al0DJGAjd2xxVCXRVizGV57+poA+ezp16Bk2dyB/1yb/AApPsF3/AM+s/wD37Ney63pP2VwhXIblT6isv7GT1/AUAeX/ANn3v/Ppcf8Afpv8KUabfHpZXJ/7ZN/hXqK2pA5FWbe0JbOOKAPKU0bU3OE069Y+0DH+lWE8M68/3dE1RvpaSH+le46JYNnODn3ru7G2EEOCcsefp7UAfKw8KeIj00DVj/25yf4U/wD4RDxL/wBC7rH/AIBS/wDxNfWkK4OcZz2q6g3KCcLx0oA+Px4O8THp4d1n/wAAZf8A4mlHg3xOTx4c1r/wBl/+Jr7Ejz0HKj25qaJ8HnBoA+Nf+EM8Uf8AQt61/wCAEv8A8TUZ8J+Ih10DVx9bOT/4mvttVEiEAAjHFZU6gMRtAI/WgD47Hg/xMwyPDuskeosZf/iaevgvxSwyvhrWyPawl/8Aia+woZAhWPHDD5s1a09iwZQO+RQB8aHwV4qHXwzrf/gBL/8AE0w+DvEykA+HdZBPTNjLz/47X25IgZQqniqskOwgkL9KAPi3/hDvE+P+Rc1n/wAAZf8A4mkPhDxKBk+HtYA/68pf/ia+yLh+CD9Oec1kXt3FFnzCAfVj/SgD5MPhPxEOugauP+3OT/Co28M68v3tE1QfW0k/wr6dm8QWUbbS25fUdqhuNRtpNuWADdCD1oA+Y20LV0OH0u/U+ht3H9KjfSdRTG/T7tc+sLD+lfS1zaQXceEdQ/UCsa400q2yRAy+hHBFAHgH9mX/APz5XX/fpv8ACnJpGpOQE0+8YnoBCx/pXtz6Gd2+2BKk8x9T/wDXrqPD/h3aFeWM+aentQB85J4Z16THl6Jqbf7tpIf6VJ/wifiPn/iQavx/05yf/E19c2enJbAtgbyO3arDWgZlbbnaOKAPj/8A4RLxISAPD+r5/wCvKT/4mmy+FfEMQzLoOrIPVrOQf0r64uZfsa4AZnx1x0qg101yAt3Ekq54HTFAHyrB4W8QXDlLfQtVlcDJVLORjj14FSL4P8TMMr4d1kj2sZf/AImvqu1smhlM2nMA5XaUkQNwevXiuq1CWR5TdpqE5jknc+RHGqnZk4CtjgjjJPXtigD4pg8I+JLguIPD+sS7Dh9llI20++F4pZvCHiWCIyTeHtYjjBxueylAz9StfZ89lbxx6W91CkdsrN56xS/e3YIJGc54JNZOtCM+UuqXDXN7kmUo4ZMZXaWx1AXcNoweetAHx4dB1gZzpWoDHX/Rn/wpg0TVSMjTL4j/AK93/wAK+0Tt+12JjzIwD+UhmXKxlT9xhwi5/hbcfes3XLNmvWkaeWSZlG8SMrsuBgAuoCnjB4Ax0oA+PX0rUEzvsLtcesLD+lQSW08SlpIZUUd2QgV9Yy2TEMSeOua4b4p2+PBGpPk4Hl7R7eatAHgNFFFAHSfDuPzvGOnp6+Z/6Laval04AjaPrXjvwrXf490tcZ/1vH/bJ6+jI7FXILYDdCR3oA5xLHDYA6npVk6ZHIMMNrdjjmt42SAgsT9c1NHAgx8nPqTQBz0ejyE4IXy+mSOtWZNJMa7shh39q6a2hLkgqauxWAYZAwPSgDjbYTW7AQZxnBXqK3bOAXce4oqTDorcA1YNmkMjBYwSD1I4/wDr1BNFIxBZjkdPQUAWDbNFhFIwOvHWoLixWZcgfN6+lXbOQsm2Uc+verqwjqvbvQBxOq6WtxEIpR8wOQ2OlctLpjRSMsgww9uor1q5slmTGAGHesq+0pZl2uBvHRhQB5nJaYbhc+1aunaVkgzKQMdBXQf2K1tLmVMv1GemPWrlvY8EkZA5JoAZp1sNwCrhF56dK10VAeSM+9Z0l0kETGNwoH8WOvsDWW+qhA7qThc856mgDqN8YO1QS3t2p0U0ZYKXz656muDPiCRlKsxJJz/k0lpqMrvxIyEdCDQB6RDJET8sgz71aiwW5AOK4y0v5H/1h+Y98frW7YXhyMtkD17UAdNGAUwoAGKybsFJG6cdzVy3nV/uNx6VBeRiRhuJBzxmgDJuJgjli+09Kv6NJvY4/MnrSf2ZHLE7biSDkAVY0qBY5gMnHXFAGjGM/NyM+tRzhlZmLZJPp0H0q8UVQOBgnpWRqcz7mWIDGKAMHWL8W4ZYz8/Tce30ritXleQNvcjPU1v6vhXYE5bHJNc3qDK0R3naPrigDm7h9jleOnPOc1LbSRSIUYEFRlee3pVS6uIA2AS3PYdKqC8SKRT5ZJB596ANe3vHifAldMHoeQa6fS7lrh0hkCvuHy4Oea5SG2W5kXeHiUnO4jP6V2Gh2cUaEWjoWz8zvwQKAOk03RwriTGXJ4PpXQxWQRSVUbu+Kg0aYIio3I7v2rcRNwyD16Z5oAy1hLHJ6VFOc5WPOO9aF0hC/LnGecVRKYJz/wDroAy5IDzgkYJOTyOabsIGWwQPmAArSaLntz7VXkiw5HbvQBACee2egzV+zmbZtLZz2NVAgKgjB+lSxZUDqaALhtYbhiNvlufQZFUbjRlR8h1x14qXzGX7rYx6HFSQ3h4Rzx+hoAoLYJEuERcE56daFt88Dj9MVrbQy7o8jjoaIERsAgfhQBg3UYJ8sgY/rXB/GC32fD3VnHT90fp++SvTZrf524zXDfGqLZ8MdYyOgh/9HR0AfLFFFFAHY/CElfiJpJHUeb/6KevpqCE+WGyrf7oxXzP8HRu+I+kAjOfO/wDRL19T2Ee1yp6YoAbHCWHIytPjsIg2FZs/3cVbCnOB29KmO2FcnOP50AECRwrhucdhTxKvQdaqM5c5J47ClGSMGgB0mXbOcj0qvJEO469qse3GKcRk8kDvQBTSLY2QADnPSr1u42jd+NIsR6v19MYAqVVxjB5oAlEYYArjpxT1thIu4rz2NSRJ5qmNuBjGRwavbQFwOAP0oAx57JCMSgFR61yXiK4mijCWyMYj36fn6V2Gp3iAbAA3b/PrXGatFNK+8vuiP5D8KAOXvLgZVJZ1OOoXnFZeq3sUUARVdi3PJwMVtalZxv8APEvXn5elc1q9jOWjOOOmc0AUkvixIWMAdsGtCyuozywZSfTtVC3sgHHmOQDxhRmta3gjUARAYzzjmgDcsJXIBiKuB1Of0rorSbG1ZVKk8DPpWBZx4hyoBYnqOK07WZlJVju46Hk470AdPp+BJwcH/PNXb4sr7QNwPcGqFhho9y9Mc1cvG+bOPlx0oAfDJiJDjox71ctEAn3IOo71jRXBztKfKeRzWxprlicrjAoA05CAuPTpWTqH3G2nHJwa03ztGRyRnOKzL5SNx2nBORkUAcRrSybmyAAe5rg9aWbfh2LBugBr0nWISWZm4zx7VxOtqpQmMANjr3PNAHIvauQeM+1OitHAG6InBFaFrbzzN+4QsDx9K6DS9PEThpP3kg5A7LQAlhYSSiMyIyR4HJHJ+ldBaxlE8uJdqqMBcdT70xEkZy218Zx7flV6BjF13ZxzkUATWc7R9GIJ4Nb1hrMciiCUAr6j2rirrVI3LRoen3jjtT7OVWK+U2PY80AemxMsiBlIZD3/AMahmtjklFyuM89qxNKvJIyGDHn8q6WGRLiPMeQw5wKAKAhPTHfNV54MtkrWwY88jg+mMZFQTRAngZoAx9mACFLZPbtS7Nwznr6CrkkQC9MVEq89OMUAVnjz6Z6dKieI55z+FXmiJ+62OCBkZwe1DxewzQBXsGKOEclk9T2rRaAoxOODgj2ql5fPI/CtSzIlgKNyydD6igChJH8zHnB5rgPjguPhfrfBH+o/9Hx16W8ODkYDCvPfjrGF+FWuY4x5H/o+OgD5HooooA7f4LjPxL0YDP8Ay26f9cXr6rtRnnGMCvlT4LqH+JejqwyrecCPbyZK+srWMBQMdB0oAsRooO8n5VFU3JlfP8PUe1Xbk7Ylj6FvmYe1VgoPPpQAwJzTlQge3Ye9SDAZVyQzZwPUgZI/KpQvNAEJjwRjn3qVI+cj86cV59v51PDHz/Q0ACRAZ6YHPNSJFuPPTuasKmegH49qmCD6IOf/ANdAEIXy1+bgf54rPvdRChgx2jtipb653sypkBcDpj8R61zuoyKo+Z9xJzz2oAfKxmJIHXnNVTGA4yQefwrOnvWt3zIwRD0Hcj2FEGqxSY8kblz1c8j8KAH6jaLPzHmNhyeMggGsHVNOdIW80qADkEc1vTztNHy5I/SspPNSSbzWVkLfu154XAGDkdcgnv1oA5TYqkszx+yrn+dPjQMQqsP5VtXOnW8pO2FgWOSVqB9IEWGWQkgd15oAltDLGArAYxzg1tWabzkAegBrDhtJQcrKpA7EGtjTwyyAZGR6HNAHSWCGMoUJVTxitueIMc4XOM9KzbDnuTjv0rckXIXaAAVA/GgDPjhjZuIxnFalhCiZUDt0qO2hG4tgkDqa0IIgjH2FAD3UFVxge1Zd1HuYkjJ962wuBzyKoX+2O3aVRwB+RoA4PXoWaUruAQVyt3BaRgBmLMedp71v6vNJPLIBkg85PpWBcQSk5C5B4z3zQBQeUghIVEQ9B3q7ZRPIrFmOcUQ2Bd/3sqqF9OTV0tbwx7Vd/MYZ6c4oAhkcQwl3ZgE53g1l3GpyzBjFK6KOgB60y/ZZlffK+OgAXjNZM3lrGQs5zjuuKAJRqtwr4Lh+edwBrSstViZgHRo/9qPkfiDXLCJmbETqTmpovMiOCN3uDnFAHqWj3ZkTMcglHqDgj6iun067w4wwB9q8n0S4KpvV+p4IbvXZ6VqZIAnG7H8Q+9/9egD0eF1mj3KRn0oZN4OQc1i6deEFXRt6e3UV0KlZF3oRyOaAM6ZMrxggVVKBF6cj1rVlh2s7bnO85wx4XjoPQd/rmqUkZBYZ5IoApJIzJ8y7G7jOR+dSMuevJHfNPC4OMGhVAAB6epoAj2gMTn61LaEpOrZ9vwoKgfxZb3owcDjnPSgDQaNXXHGR2rzr4+QlfhLrxxgfuP8A0fHXorHKbhz/AFrz34+N/wAWi14HnHkc5/6eI6APjmiiigDufgiM/E/RR/12/wDRMlfW9qoUZOCe1fJPwRO34oaKf+u3/omSvraBicfXrQBHMd8zEjpxzQAc0KN0jHOcmpVX86AEVBuG4AnqD/WplXpTVwOxNS7QR74oAZGhLe3rVy3jI649qiiQ5wetXogPwFAD0XAx05yeKgvZBGu0dTzVossaBnPJ6D19awNQugpZpD16L3P/ANagCvdzcMdwVB3Ncvrt7sA+zjGT989RVnUrsuecnsB2/CsPUVeSAsQVA5560AYt3MWdiSS5OTzmobZ5EkMisV460tzKEG6NfmPHvVCS5ZTmVhGncMeaAOrsr6IoI5uWxkGr6yI2DGF254K1wa6rDG67d7+hzgVftdVcyfu0CY9KAOpumIjIwS1UQZDIpBJUjGc9KpxazJI5E+GUg5I4Iqa0voXcRuQsg/v8D8KANi2jDKuMD1q5aWolmCgd/SqyzKZcknJ/KtbTw27dgD3oA0bOJw3A+QdO5FbzJ90DAwMc+tZNipaRSN2Djt0rphGp5I7UAU7bKFlbAyOtX4Bvc9gB1pqwo5HAq9axhSdq4FAELZC49B1rG1HOJIyNquMj610sydQOD3rn9VQoWbr60AcDfWzK7bh8oPeqNyqCEvIRGq9Sa09WkjXdJI4CjsfSuN1fVopyURjhTwP8aAK093NdTNEgZUxjHdh70jTJHwGzjg85P41SMrp8wI3EHp/jVETgkqOHP8VAFnUJoEO1pHRiT2rAmuYlmG6ViOm0r1q3qCsVMzyREJww6H2rmp5/Ml3Ae2TQBrLcRPyJ0X0UnBFXrTeei7we681yruGJOfpmr9i8kW1kdlf2OMUAd1amJ4lDYGOp6HNbFiWDZjkJ46E81x9nqbblW4QTDjkcEfjXTabPCy5gcmT/AJ5scN/9egDqLC7aOcbXII9a7bQtQWQbScHuOxrzyzmV+GU++/qK6HTmaMhlJPt3oA7/AGgrg8elUZlK/KeMHrmpNPuRNCAfv49afIBKN6diR3GcUAZ7rhs9D3pMY4/LmrEg4Py8+9IqBiGoAg2HI9PTNIyjvU5ADKHwMnA560koHT0oAniJaIbutee/H0H/AIVFr3XgW/X/AK+I69Btxlcdf61wPx/z/wAKi1/j/n3/APSiOgD42ooooA7n4Jf8lP0X/tt/6Jkr63g4XkV8k/BH/kp+i/8Abb/0RJX1tF8qE4ycYyKAGRgH2z1qyF9elQxDBz/I1MDz6UAPCnB2gE9gTgVLtx/+qmoRuHY1Ix5/DtQA+BTnHGzrnvmr0a5HAAHSq0IzgDI96tM2yMtjGBQBV1O4EMWc8emeprir+V5JWK/MxOSTyK6LU5DLXOXQ3ZEeMdz6fWgChcSLFz95z39Kxb25hjINxIckfcHJP19Kn1HUBHmKAlnzzMf6Dt9a5W/lKMe79cGgCvqt48chEGyOJumOv4k1z8gkMrNkuf7xOc1qTbpRgjC9OazLmAwsCkhPoM0AQpPmPIHzdcH1rU0+4WRMbhuPTJrOjkRs74xkn0q/Zv8AZyjRqODngDmgDZjI83YiljwMim36MWOM47g9vf6Gte2nMtus0a7hkdKbbS7ZSJcSbicAjOKAF0a8aNAsr5HRQf4a6uzuZETKMWJ9axFS2KpiAZB4YHBxXR2ESSKvlkBscCgDpNGZnRRnD59OK6sHhcDqMEiuT0ZT5yqQQK6tMZUH8xQBLCmCPU9quwryOPrUNuvTODiriLg9cf1oAbIMZ6VzuvAmN8cnHSunccHIzWTqFoJSQV4IzyKAPF9ZjSSYpJk4OOtYN1pMW0yAM5/iUnAA/wA969O8SaGU3T2/DAfMuP5H1rjLiTykyF3NnBB/rQBzF5aPI3ysqIq4VBzj3zWJd2hjUSSSADB6Dp+tdhKYJ45XTMTgfMOxrjdddvmSNgBnkCgCjLbNcP5jS4jKYBY4rn2tykzh3DRj7oC4I/HPNblxxZwqTltx4B7VSaINJkspLDOM0AV7e1UgyOzY/hq0kRLARuc+460jPltqMvHHBFTW6jaG3KAD8xzQBatleEgldx9ewrSjnBwoOT7GqULvHMW+8D3XpWhAqScyIFY85HFAHR6RqTbhHODKox8x+8v49/xrr9OlztkjfzI84yO31rgbOEI37jLdiTxxXRaXcNC6lCdx4I7fjQB6Pp83KN0NdCCGjBXof0NcVp9xvxtABHYH+Vdbpc3nQlCfmAyKAEmUbs8nJxx2qAYVzntWg6HocZNUnXmgCI7UOVUbsYLHr9M9cUwnnj8afjnA/Co3HTHfvQBNb/UHiuE/aBK/8Ki10Ac4t/8A0ojruovvYPSuF/aB5+EevEdP3H/pRHQB8bUUUUAdz8Ef+SoaL9Zv/RL19aZIQjHOK+S/gj/yU/RcjPM3/ol6+sycJ9KAJIsHIHb2qVQcnOagiJHJOasxt6DBNAEobH4nBqVASwz19ai2g4zx68dangXJ7UAWYuAKZfOFUKSOmcZqeNct0461n30m522n260AZl2PlYbz1J+Y/dH4dq4/Wrv70cZwnf1b/wCtXQ390pBijPB+8fWuWvIQWYzAbsnv1/GgDnrwPIxwSB3Y1UcRiPrvfH3n4/Kr90WchFBJ/uKO1YV/LFbvukYu4/gU5x9TQBXunG0hmyeoxWe5JyW6eppLvUDKCAiIAeq9RWdMWcBtxbPWgC40kYIAdcdhU8N1Ggyylm/z2rHdXVucgYzSwNhh060Addpt6u9znYGB4Hf61v20AuAkqyqueOTzXFWU5WZSpK5BBHqKvLM0XypIY03ZABxQB2Em6E7CFUg8EHmt3RJTtBJ5rzuPWLlW2yBXx/F0NdX4c1ZZFzOpUjgY7UAer6M3mGM4HTmujt0Fc14XZXiDhtwI4NdXGRtBx+J70ATQxgMasKCeajiAAA6/jmphyefyoAHHHt61WmAx157VayMAAc1BJyOv60AYGox7kIwD+FeR+MJIbC9kRyMN8wxXrmryfI/JC9OK8D+ILifWZArZCrjA+tAGXJqZMm3BVHzjPPPauXuw+8g/NnnNXPm3HERJ6gHtT5rKRirqgKkE5z0oAzWX92ynICjtWY+AWPbFdHdQmFZEBRhjGeTzWTLYSALvkQMTnbjrQBmbRgk4HoO9CscDPQdBVia3YOQj7vU9BTGgCYaV93+yKALFndywMGjchu3cVv2N8shH2tcZ/jT/AANc4gO/iMgfmRV23l2t1IY9Ce1AHd2eDCWgAlQc7h2HuK2tMIZl8zjb0I6ivPtPuGjdTDJIr9mHHNdxpF0ksQS5KRXH94DAb2PpQB1NmXiZSDx/errdHu8tEVB64YelcjZsykLIMH0Irb09/LuEdW+XvQB2zqGy+T0qtKmH9R161PayBo0II6UTqQ/HQ0AZknDZ6CkKgYz0qxKnyk+npUJwwoAavXjGa4P4/kn4R69k/wDPA/X/AEiOu99s1wXx+/5JFruf+nfH/gRHQB8cUUUUAdz8Es/8LP0XHX99/wCiZK+r0J59PcV8n/BTj4m6L/22/wDRL19Wox2jIANAE6YyCcY6ZFWo+gH5VWj5PFWkXA7+tAEqkkgDoatwjHfntVaEfMMmrluu4njGBnntQBMSEj5POM4rA1CUqNijJPWty6fbCfTHSucvCAXY4LE/lQBk3X7vJBG4j8vpWFqbK0BeZlRB09T9BWvfOiLvcZx91fX/AOtXKajO8km+XDdhjsKAMXU795f3cY8lDyQp5b6mucvNpTamQ688963NRgyCyfLg5Hc1lXVjMcPIuMjjB/lQBhzEKcqcj6U1RIVDLnHXJrRnSKMZMYyeCD3qtKS6DA7cDHSgBhdZwscx2lRjI5qeGGIqE3AHPDY61R+YNyOfpR5m3ncAD1FAGxFCIpULjPPr0rRC27NyNqg8k84NZWmyRPE5Y7XTpjpVyKRxfOpXcrjAHX8aALz2OVDKAeST2FdJokKAKNhOcE471lQhksCrAlutdJ4btxPHHhsEdPrQB6R4ZT7PZr/DurrYeQCB161z1lEUWJOCVHODW/aglRkAUAXocAY9T1NTg4NQQjI5GCPWph90etADxyfSoZgQD6U9QQOc+/HWmyjsf50Ac14hPl2UrAjcRgE14JrKO95cSNuLjPIGc817v4rJ+zkA4rxTUQ0MtxCcEdQxHSgDk1IllIkO0AEnPFSM5jQKpYhMnIHYVBerErgpIZGc9BxUeoef5IIIIxg7c+lAEaTloJCFAVjgt3P0rMnkCE4cswzj1qO9dorFEjOATg1j72Zm5I7CgC27ux29CKbjnJY5HtzVMuyjAY+3vUizsMFsM30oA1IDsyzHr0APWrqBZHyygn1/pWPBNtOZACc9BWxp5jkYGSQxkcjI4/SgC7b2537ouV6BTW3p8gBCyghhzj1qnbgLwGBGf9ZjIrTgjQBfNdG75oA6XSdQKqI52yvRWPVa63TGI29CDyPeuAtomwDHhkBznOSPrXW6Dc5URMSFyACetAHoGlONqr6+/StGQFo+eo55/lWJp0hWRRnGCM5rcdgGxnOaAKrrkY9etVWXaxHWrsi4yAM1VlTLDpQBHjAHPB6V598fgR8I9eB/6d//AEojr0PaOffsOteefH85+Emu5GP9R/6PjoA+OaKKKAO4+Cn/ACU3Rv8Att/6Jkr6sj7cYr5S+Cxx8TNGP/Xb/wBEvX1ZG/zYGaALUXNW0PA659qqRgAknvjqeB9Ktx8EENn69qALUSjgsOhyMjvVqAEL06mq8Y46GrcQOcDg9aAIbp8ZyfwrnNQdUR3bgLW5dOHY45965bW5NzHbyoPIPrQBzepXJZyz5AP6VhyiVgSrDBPXsK2ZrffkyEgdl71QmSTIREYduRkke1AGcCY8hckngnHNZtzE6ghehOQSelaF88cBIMnmzDqqnhfrXP312875Y5UdAeBQBXnnhHErBnz1UVnlwXzGu0Hjceanl2zHLLtPqBVW8iMYG3LAjpQBDc2k6vgsCOzA8GqrwSYIwSRVtZpFj8vG4ZyBmpYXckMVVRnoelACaZZXMwPlqdijrjNanl+SIHyQxAySD71uaFJdRELEU8sLkAAZx71JPCt67uGwQPuE/rigCO3kndcI6t6gc5rvvCFsojgaVCrDn5q4C0gKgiIEn1BxXo/hkSi2j8xjyAAGoA7ewYs249e1dHa/w9T7YrlrFjgFDkeldLatlVHXjrQBprjA96fwBn371DF15BIx39am4YEH8hQADr2xUcxAB7cd6exI9MD9KgudwTv+VAHM+JmTyjuUe1eSa9btNMdqAgnnd0xXrusx+bgZGD+lcVq2n7y4jIU/T7xoA8uvNP2zllUYHIOOKq3VnMohZR1PIx613i2Um8JIAy54yvSnPpOZChj+VTgjtQB49q9ssTyhmZSD8qkfmc1iFVIxH0z+de3eIbWyns/skQgaRAQdyc/XpXll3pbxTMsJVlzjAB4oAxPIyBjG7rzTysajC/MehJ6Z9qum0MIx8rN/EQc1W8h25I+X0WgB9uEQBup9u1XEmwxOzO5cHPpVREI+ZkwB2qYAgAHJJ5FAGvptysGdnKkZIPT8q6KxuLW6bZEvly4/1bE4+oP9K5YQtCirMCHI3YA59q0tO2+ao2Fs9SxxQB2enNJAQu0EfSul0yMbvMVcEc4HrXKaVf8AmKqXGAvQOOCvsfaut0sNAqg9xkHqCKAOo0yXfjBIK9feuqiYvbqc4rjrT5WDpn3FdXYPui+negBzg9/zqvIvY45q5IMc44PSq8g9QPb1oAqE7e+K88+P5P8AwqbXc4/5YD/yYjr0NyVOOP8AGvO/j9/ySbXsf9MP/SiOgD47ooooA7b4Mf8AJStH/wC23/ol6+qoMbhnGcYzXyn8Gzj4kaP/ANtv/RL19U25wc9aANGM89OPX0q5BxgYxVGMkkAmtGAAYDA8+1AFqPGQAOAKsqdqEnjAPU1XiU59ulWJceUxB9KAMe/cqrdieAfSufmQqv7xixx1/rW1d/MxLZIHAHr71h6is0kUqwOqTYO1mG5FPbI70AZNypLEBQTnIPT8a57VLoYeO3ZyxHL+v0rZvbh5IFindc4wzrkAn19h7VzuoKoUlSAgH3h3oAwJl2H5mP8AM1TuHQYwfmB44zzV+VGdwEUgnPPXNVXs3bLECNfQ8k0AUWdpMqBtPrnFMa3kCDYCQc5Y9KvLboq4OM55yMn8qXcPlK5JXt70AZbWh9SDnqKmjskR/myQeR2wa0rVj5nzp8p5J9DWhFGs0m+VFEQ7k9aAH6LELVIzkANyynv9TWzFMJ5RiNFQc8LWJdyQbgkUqnb1X/69bfh795buj7SAQyMOcA9jQBq6ZaRM+/CqxPIA611mm27L95eh7Vz+mweY6+Uw2g8ketdrpEO6Ib8Zz3oAvWURD5I69RXQWkeMe1ULe3fCbNp5wc+ntWzAgA/woAlXO0AYzU2cA5pkfRc5qVRwSBxQAxhkdx/SorpSYjwM1Pgc0ki7lIoA5TUd3nDoQe2KyruyEq71HzD2rptRiAIKjHpWS4KklsrjqfWgDkruP/SEGzJJ5I4qy6xKAWT3b3FRazexwy5TGScZPbFVJLvzIwSFHNAHNeK4WDCWCMrI4PA7/hXJRW1zJGPtMZjkXIIxjI967TV4ZbuZJUBKqfvk4Uf59K5zVdRea58qCRSFJVpCPvkcflmgDm7nTU83cCoBPK5ziqc1uI3I+9j24q/d3lwlywmWNlXjGMiqctwowsq7foeTQAwDc4VIwcn+7k1IlqivnIjl9+g/Cn2uppGxWFgDj+7zTo5Y5nDsmcnj5v60AVnt50kLySeYufvZzVu1Dl8DBPfuAKuxzICFWGPaB7nFWliinclUEWepTjPtQBd0yIkq7YCg8DPJ/wDrV2Gk3WT5cmNh6YP3a5CK3EY+Q5UnqecVrWJ8vb8xJ9e1AHeWTlHUdq6rSOI+uVI4GelcRpU4lUAZ3KK7DSW5GSRnrQBsSYKfSq7jIGP0qdlzuzjPTPWqzEorZ5x6DNAFOcBSc9M5rzX4+Pn4U66Ov+oP/keOvTLtiVZexryz47n/AItbrg/64f8Ao+OgD5HooooA7L4QHHxF0g5xzLz/ANsnr6ot3BUeg6g18q/CRtvxC0kj1l/9FPX1DavgDGKANq2OT1HpWrAPQ9fasm07VqwtkcYoAuwYwWGDS3BHkNg89c0lvjH170t4G8lSABjJ569uKAMK6GTWBqc7fMoVSPWty7dYoztGMcAAdK5e8YENIVJx1oAybjO7kEZ6Lmsy5j8xmd23Adug+lbFyvmjLn5McjoTWTdM7SfIPlXhVX9KAMuddr7lPbqBWdM2SN/T2NaF7IsWS3bjaDWJfXDSZyQgHYdaAElZVbdkBh1APNQmcBJNgSMjncTkk+lUmb5WznPr/Sq/mHdnGeeaALwnmwZCzMh4z0Gas2Fz8xjcZWTg9yDWbJdySRbBxGvSMDpT7Jym5kJIx1PUUAaEkIDlWzkH6g10/hASfMqk47etYOhSvcyNHcp5iAckjqa9M8O2cEdis8aZ3ccjp2oAu2FqjM8qsqHjccdDXW6MX8kBvmGT0rAgSO3SRlIAxzWvoby+VgHPoG/xoA6uzYEhfQetake0g4wcHB+tZdgJMDeqhfUH9a04N5HzIB75zQBOo9BzTpPMELGBEeTIwHYge5P0pEJ47nsamXvQA04yQMYzxSEfIeKcSegJpG4HQ4+tAGbfIGHTk9xWFqKMiMR87fyrorpSSeOSePpWVdQkpkZyOtAHBa9bMtm8rRkcZU9g3vXMabJcXEZEqS4yOdpORXourWjvC6oM7uqnkGuYt92lu6xgqzcYYZAHpQBT1B4rWxKzuh3dAcde1ee/aITO5AVsE52jr612uvvHdAq+FGPvAc15xqVm1tfu3GCMlh0+tADbvzZlby0AY5we9YE0UqErcZ3ds1qx3kqlo1c89/Ws+acicI6kKT1I60AUWkKkqgx6kU+3dlfKkCpZkg83puB6EH+dKIzGwLKCDngD+dAGtp98wUiRdyH7x7/nXRWsYlZTbyAr1Cgc/SuQidz8oJA9PSr1tcfZpAUfc69weBQB2lp8shDKNmcEEZFX4oiMmJSFU8g9fw9axLDWVuSou1RD/wA9VGB+NdDaDa/RueeDxQBq6QxV1JyO+TXcafIfLDKCfYVxUKoXDRj94BkjFdTo83Kx57DigDrW/wBWrDHI71Wl5Jwc5/wqeP8A1QyG4/Ko5BjFAFGdQc569K8u+PYx8L9d69IP/R8derS4wcmvLv2gFH/CrNbI/wCmH/o+OgD4/ooooA6v4WEDx5peemZP/RT19O2rD5PWvmD4Ynb450s+hk/9FtX01YuWCEdKAOls+i8VqwKMZI596ybMnaM56VrW+SBxyaANGAHKqTzin3eCuOOODjnH1pIVw446Cn3f3CeDgZoA5TVW+YrnAHFc88WwAFiyjjLHJ61016q4LZ+b2rDlGWPA4BOT296AMSaPMjbMknJYngY9TWFqmojLJbMABwWArR1y6Z0aOMZhPfP3v/rVxV7IcnBwQw6dKAIrmTIJOWJ71lTBh6Yz61akuCi4bac8jA61CIWuE+Rck9PpQBDiQxN1J7VAY5GXAXIPHPArUttOLZ86URj0HJPtTktYemXOP73AoAzI4GVwFBLd62LGwLh1lRlI5yDjNWYljEfICntnrU4ZyqKgGCeDjmgDU0SyjRFdlCE8ggEiu+hgktLeNAGwRkH198YrC0C0ZbVFZXcgZYdq6C5kmZrdQoVVXnf3+lAFW7ul2rEVySfmJziuv8Ko8kZMiYOOlc9Bpy3EolwTjGB/Wuz8OxeWpUnPOOe1AG3bqcdOnar0YOB2/CoYkI/wqwq5xzk0ASKMZ/wqVTxTFHINSDnpkelACYPPHBpSDj5vT8KXGQfSlHTJzn0oApzjGB+NVjDnORwavSgHleAahC45OBQBl3FrySoGK5bX9N3fvFGGHOa7eRcFuv5daydRjR1PB3H9aAPHtQhJYxs2STyCw4NYWuWKNZnaUHZuxNdt4zsFtoGvFjm3KcnAAIFYOmix1DSZd7MZguDuHJH1oA8+XTIZJ9nnbe+Se9M1HSCkgEk6s7n5AeMjtW9d6WVut1v84XOSfSs0zbVMM0eY8kdct+dAGALF7cM8sahfrmonkJBxIOe2OlacrvG3ls27+6o7Cq91bAxBgoJbr6/WgCCJ0aPAkBbHOBU0KCPrjgdM9aoMvlZZfnx6danhuN/3Rtz04zmgDVtJAWDEAD+VdfoV75aKkpLxY4PQoa421kVpQcgHuBxXR6buABwvB6qOaAPQbIkEFnGwc7sjBFbtr8squv44rl9DuSIxHLgIeh/u109ouJVBBAoA7S2bdAjAnHWiXOcN1/SodM+a0IIBAP6VPKMp+PIzQBTlFeXftAf8kr13PrBj/v8Ax16nNyMdPwryz9oHP/Cq9cyO8HP/AG3joA+PqKKKAOn+Gv8AyO2m/WT/ANFtX0npLksi559K+bPhp/yO2m/9tP8A0W1fR+nHE0ZB70AdlY52LxWzbjgc/mKxtPOVHHPr0rbthkUAaMK9AM0zUCPIIPQ9alhHA646nmoNWbYFHqOfWgDnLhX8zgcmuf1t1MbJE3A6jP3j/hXQ37iJCc/Me57CuH1WfY7Z24x2PFAGBqbMpYlwvXjrXP3UsMjAmMtkZ+U4rdvoTPuKZyVyR61nLbxxfdA8wfw9t3rQBkrbxMN7B44x/e5P5Ug8tU/d7mX16VbkI3t5xTYeu0VRlMat+6Y7T1OOKAHFwWDH5MHnuKnimSaQKHAbu7DArMndNoXeB6kHrUSReYcmXKj88UAbPnWqtl5d46ExDr+NdLp0sSRK6IIoh/ERuP8A+uuJt4YwigF1JOOB1rqvtMTLBboWXGAFHc/TtQB0NnfvJchYGbYOcd2+tbuC1uJA7OR/tdBXLaTG0U8oU5AXHynAJ9K3JbkxW8cYIJC5JoAvQ6i8BEZcuF5AB/Su48OXcssYd8cDp0rzeO6Fw0NrDCic7mY/e/PtXofh9xGEAXgevWgDsoTuQGrKc9RVW1YMgJGKtR8Hk5yaAJQOeOfenj8DikHXOPenD1OKADPbv/KlAx70c8dz6Uv160AQSD5RUG3HNWpR0OMfSoG6n060AQN94Z/TmqNzbhxgjA9K0COcgEc1Ex2EjHPrQBz+oWKXELxSxhkYd6801LRX0ia4aFMQucbs8AHtivYblmyFCIc9icVg6vbi5gnhKqydOR1oA8O1AGIkxHL45xx+lYV8QjCT5cjqR6+ldJ4mtbnRbxzJCJbRidki8bT6GuNu5Ek+dGyHHIB6GgBt1dQSRAEDzAenc1XSUPGWVeB1XBJFVvMXcFkiJwf73SlKFgwgc/NwQev0oAmcMHDbFIPI96XykmfcdsR9VPT8KhtpSXaC4cYJ69atx26JJhW8wjv0zQA8xtAMqC3o/Y1uaTKVCmRQQR1PBzVS0QSsyhWAPVSeGA/rWlFYlSXjDYGOO9AHRafdbyNwBPTpXZ6TcedEOcsOh9q8/tJtjLj5D3x3rpdCuyJxgnjrx1/GgD1DQ3LQuD0HTmr7AbGBxxWRoTgE474ArXfg4OR3xQBTmHy4647V5V+0F/ySvXOnWD/0fHXqs2cE9a8q/aDx/wAKs1zkdYP/AEfHQB8e0UUUAdP8NOPG2m/WT/0W1fR1hkOvNfOPw0/5HbTfrJ/6Lavo+xXGznOPSgDrdPPyAnJzgcDP410VoOK52wPCnp7CugtDgcnmgDVhGQv061V1fnaxPAHWrduePWsvxA5S0ZhjduzkntQByOr3e+Qjdx+lc7eK0pIJG3rkVqXK+czbjgZ5NZsuIxiRv3YOOKAMGYlY8R5BJJ561nzxtMrDhW9uv/162NRRF3SB9ynoucE1zd3dNA7SJLiReAq9B/jQBnTgJG8kjqi54BHJrNnu2ddiSbV7gDGakvZZLlvnHsDj86qCEhgXzg8YoASOISuBvySeauxWhVC0mAnQY5pIBGqGTYdoyMZxSNO0hxjCDoM0ALukZtsO70rotAdbT99JmSYnByO9YqTtGoK8A9gK2tEtHnuVeT5U7lhwKAN+0uWnvMRDagXJGMc1swxbztZRhh1qjYQ28CkxYdS2N3pWs8bm5hCsSijOPagC1pGmKL9pcjYfau70qDBBydvpisDREZo0WMfLnOK7PT4Nh5PP8qANS1UCPnrV1V6DjnkVWgXCjAH4DFXEzwOmaAHKDnnPXsaeM/TFJz+PrTh6UAAo9KMfSlA9qAI5eozjGRioCPTPHU1Zf7tRFTyOc/XrQBAy446ZqGSPngdatlTkcYHvTCuDnqMUAUZYw2ARgiqEiEucqvz9q1ghKYc5OOo4z+FVngBY9sUAef8AivR4bmKRmjDQupDrjOD64r571rTLjRr10fLKSSknZh6V9Y3lpuLjg4BGD3zXmPjbw0t5azROu3+JSR37YoA8M3pOpVwPNXjOaghkaGfa5/8Ar1PfWUlldyQyod6k9ehFVirZEe7PHDZ4oAfOr28+5BkZyrAdvSr9k5aQN90AgtuqKzuJQVikVWVeu4dPcVLht3yuQrHmgDagOWDR52k54PWuh0qYR4LgsewzXF6dctDNsfcFPGK6KxmRxtV8ODwCelAG+6qVzAg3HmtPTZcIgIbjpng1kWG9XwwIJPBI5+tasMLGTegH+1jvQB6R4bnDWa72AO7HNdLMcAE4/OuN8NSBI0jIyrDBB9K68cqoA7YoAqzdD15/SvK/2gefhXrZHT9x/wCj469SnO1m9TXlv7QJ/wCLV63zn/Uf+j46APj2iiigDp/hp/yO2m/WT/0W1fSViOE5xXzb8NTjxtpp95P/AEW1fSFgWON2AvG3B5989qAOsshhQa3rdsJ1J79KwbLO0YBz7VuWnOAQOT+BoA2ISfMT7uzHPXOf8Kx9ZfeXUMMDitYsEjZueBgcdKxLw7twHJoA5W/AhkVE285IB6n1wPasa+kVVDSnc5/hFdFqYijj3yqpkAIQ4GR689QK4fUJ23ySSbsqMAds0AZeo3zJKVypGOcc5rDmCEM5UKueCO9Xr4ltzN8oA59axLnzJCGAwPSgB7urqFjQbyc7vQVFGEXJdOSeveliVIk3sCW7DPFRgtKy8nB74/lQBMQjIpUfKGxipo7VGTcY2RScAnmn2cO6QhF3KM9a3YLULbxvKdpLY45oAz7KxXzV2k7P4ie1bLFIT5YLZY4K+tBhReC6rH6kdfwqWC6t4kEyRlpz92RyOB6igC7b27Iu1m2qCPbHtXTR7DhlYtgD2BGP51yBkefflmDOclj3Fb1gx+xg7iTjAoA7HSrkCVI44x5aj6YrrbKUOFyAR15PSuH0eV0jRXwTjuOa7DS8MV2g8HvQB0MZyBn9KtJzyQTj061Uh6Z61bi4oAmHJzSgU3B6Dg/TNOHB9hQAv4Ud6MUtACHGPrxUbHk+tSHAHJ/WotwYnaCffPFACHjAFMY/Lgj6088k8Zx6Ux+OMAY7UARjAPyjBqFkBPGKm4BJznNRSDDAgYOe1AFK6izjrmsfULYyxuo79Qe9bs2QM5JzWddfeBHagDxTx74TW58+W3/dzLyo7N7V5isLBAvkBWU9Vr6X121SaMuQMj0rxvxZpptLsyx5AmJDegP/ANegDkZIPOhIRP369WHeqVszRExtzg556g1ovEdxeJsOB93PBqncQh5iSmDjODxigCSWQxnc/wAyN0OKu2xA2ypls84BrPhnjKASxludpG7FXIGWKIsgI+YEHrigDsNMuQ6qJNyseOTnFdLpimR1z06DtxXBafNuceW2w/xD1ru9JuP3CgcEj5SR2HagDrNOyjLtOFHT2rsraUSwIwIPHNcRYSAQAk/e+7XU6NIfKeI87ADxQBPdnDMOQDzXlfx/P/Fq9cBPP7j/ANHx16jeH5cn3HNeU/Hw/wDFrtbHB/1H/o+OgD5EooooA6X4cnb40049OX/9FtX0lpz/ACKfwr5o8Ats8W6ex7F//QGr6L0qZvLywXbxg9/xoA7XTjkAgfSt6yxvU+grmtKdXQFSCD3rpdPwSe3Hc0AaEsm21we9Yd3IoO9mOzbk5rVunBjCr78VyuuXJ8sKOVU4/H1oAytXuC8pYYweB3ArkNWIkkBU7SOntW1eXiujKWy4GOKwp3Vz9zOOQD2/GgDBuwxBQj5gck561RdBu5BVPcV0dxBHKmQRnoQOufb2qrNEIYiZVAkJyny9qAMaa1aQggEIvCgjr70+K3IbghiavSRu8W05AHzEnjFQyyhFUptOF7cYoAtF4bSJUXPmZwT1FWjeiGBVDJvXk57CsG03TTrucHJzuJ4FSX8u27IjKkg59etAFu4vXnbc5Ij9OhY1JDMrcMxLYwF7Zqgoluh8uflGCAO1XLOH5iZEdgD2GM0Ab1i7NAQ2DsGV/wAK29PZ1jQu5CYyQBWJYxlpFjgiIDkcH+Gt6dHjuo4IjuSPG70+n+fWgDrtNRZgssXyocY9RXW6amEB5JPrWD4cgHkqCvB5we1dPawkHB4xQBqQZKjJq+gwF449qpwIEwB6dKtxrhmPPzds0ASL7Y+lOHYUncd6UdRQAvWl9aTNKKABv8mozUhyBTMHINADM9c9qY44PHtUoH5Z5pH9cCgCA9CRnOKibGQSMGp2wBzj3qLA9SfegCvKDtP8qzbkAhiykDHTPNakobBxjNU54ywLAc0AYF2waJlABGOjV5v4qtlkSSOVTh/ukjpXpd9HkNgHIrjtWhW6do5MZP8AF/WgDxW5BtZ5EZc84PHXFWI4ElQBlG3qAD8wNT+JIJLS+Vjkrkq3HX3qhBMcBkZtwPAI/WgCLULCRULwp5gDcHHf3pmjq0Q+z3BMhd9zsegJ7D2HtW/bTG6gAcbSvBI4p4063WISiTy25O0jJb6UANtrf7K4G7LDoa2LK4ZLhWRiVJ6nIrCMu1lDcpnAPcVbhnRXVN+ex55FAHo9heLcqpB6cEe9dTpFz/pZB/jXFeYaNfmK4XngDkeo/wAa7TQ7o/bl9+5/nQB1d0f3cm3C856d68o+PT5+GWsjt+5/9HpXqkx3Bh6juK8m+O7Y+GusKc5Jh/8AR0dAHyhRRRQBu+CTjxPYn3f/ANAavoPSmDRL0/OvnfwiceIrQ+m7/wBANe+6M+Yo8cCgD0DTXyikkfhXT2BCwO3t3rktKY4QCumEgS2VFGTnB9qAC/nCQEE/fXGM9q46/l3xtGhHIwPb2rR8QagqzLhiQo2jP65rj9Ru2MrAEkeo45oAp3Uo3EbskdcHFU5JSVK5UORhcf4VFdMFJlODngE/570+1hkuG2QRPNck9V5x7UAPRMFeQHGC3oPX8fepZWDKC4w3QEnqP6V0Wk+FriX5tRkESDHyrz+ZrpbPw7Z28h8uBd2MFm5JoA8qOnahekLaW08qnqdu0fiTVu18FahI2yZkiy2TtyxJr2azsFTI2Dn25GPQ1bt9OQAnaMj17UAeYaX4ItYOZg8kinvwD+VasPg+zjcv5A3t1JFd+ttHH8pG4nv2FKLUGUxFSMY2v6+1AHFReHIU+7Gox0OKvf2BCefLXfjpjr712P2EY4XnI+UdqfHahQGlKovAyT+lAHJWfh1Y13hFyegI+7T10RT8569OetdmlvuztJwenFItnk9OvegChp8CxKgUY7c1vQqCAT07VQMSQnLttXOBn1rQhwFwORQBaRRwKtp09/5VVQ5x296sIM4IPH86AHjkdc04deOlIODjrQM57Y9qAHdvalPXn+dIKUdMCgBD+tNPuadimtwKAGkgn/61L3OfyqJjnn8qTdjIoAVxkjk4HYd6iYc/060pYYwajYgg0ARyHnpx37Yqo7ZOQePWrMp3DgZPvWfdNtYgjJPpQBSvkBDYOAw6k1xOpQssrvkcdRng12l2FkRlP159a5jU4C0m73zzQB594qsDLbyBF+ZhkHHQiuEtbd0nKyoxYcE+let3cYljKSHnqpHavPdfhW21B8EYbkKDjmgCqkyxSNnkggfL0Iq8pHmAqS2R0z0rBmuFUMVCkZOcnkcVDHqAA/dtls9Qe9AG5f5ADR4808FcYB+vv71QjuEQ8Aoyj7pPSlt78FPLm5yMgZ6GqN2okYNC2T39/wD69AG9b6gREGLAE9RjtXZ+DtS82UKSN0Y4yc5FeWR3QXGGG31963/Dupm1uVcEZzg+470Ae+wy+amSevBryf46n/i3usj0MX/o5K9F0i4ErBVztddw5rzf47N/xQOsDH8UX/o5KAPlqiiigDX8KHHiC0Pu3/oJr3XRn+ROegrwfwyca5an3b/0E17bojKUTIyMcj1oA9L0JtxQ9cDNbuoT+XaFtwyBgc+tc94dJ8kspUD7p4OfwqbxLd+XGIsnjnI7UAc/4hvAWReo2muUvLoEgKwL55I9ava7c7kV0J5O0Y+8a0vCmgGMrd3aBpP4UPIX/wCvQAuh+H5dQVZLsbExwnfH9K7rTNKhs0EcUSxx9MKOvvViziEacKWAGSF6n6VrW8KvhkI2thsgfeFACRw7UVTx9aswwhR82SexApkU0LXptfmaReuOinrWokPI4oAbBGBnOMn17VYVMZHYdzT4o8Hlh6fjVmJAePyyaAKjWkZDr5XMgOc9CenNSwRp1K4bGBx2qwgSSJipV1IIORwQMg5/WpbUpJFHJH8yOoKnBGR2680ANWLOM/lT2jU8EA/UfrUuML93npgUpXk7sEDoPSgCILuI4G31z1poXPUEHnvVgjPJ6dKXbzQBVaHcOQD655zUkaZ68ip9nFAQjHHGOaABBtzjg+9WF4AGc47k81Go5+lSjrkUALnBxinD86QUv4HNAC+9Ln0pPxwOvNKOmRigBDj86idc9alzikJ56UAVz19c9MUwqxAwD68VZbBGCOvb1pCTj2NAFZoyBycAfjQsSnqxIqxyOoGaZzjLEAevtQBEbaNjk89+tMe0hb7yZ/GrCg5LHAz0HpRgAHofrQBnPptocfuunuarTaRYOTm2U/Uk/wBa2GXnkEn+dNZMgkcUAYB0exQgrZw5B4ytZuraHp8mWaxgZhyD5Y4NdW6k9eT0qGeJSmMDNAHll14c0uaRt9lEN3/TMAVi3XgrRZCxFqiv6qSK9LubIB328Cs24smOXA+tAHj2p/D7JL2NxIMnoecVhaj4d1LTYy0kXmJjlk7Ad8da9xNowbdjA9D0qO4hWVCsqg574oA+bbnCkvGMr/Fjp9al02dpLmJg2cEAe1eo+LPBkF2jzWiCK5I4YDr9a8wi0+fTNUW3uIyjA8elAHtnhK+MnlDOTG2PwNc18e+PBGrDJ5MR/wDIqUeC7sx6xHC5xvBXH8qT47nzPh5qEn+3Gv8A5FSgD5cooooA0vDxxrNsfc/+gmvZdCl/dqQcivF9DONUgPuf5GvXdBfdHgjnGeaAPVtAYiCFORuXf+Oaw/FF+G1O9UE4RgOvQDitjRQubcgkbQPx46V5zqN9JLrVwFIZppGULnuTxQB0vhnTjqlyZ5FBjiPyA9zXodnaxhAqKuxRgewHasnwtZfZbGKIKTtGWIxyf0rqrdEjxtXGT2U0AS2kJUAdMetaEafK+GK8HBAzioIgu/GV9cE81dh4PGce9AEOm232dJ2lBYs+8MwG7PfnvyTWtEoz71V2q/lhyCynII4Gf89qvoFwCCDxjg54oAWEKxAxh8dMfyqXy8PuH3T8p4oQqGVc8nkD1qdAv3Tn+dAD1XPOMe1PA5OaRRz708DAxigBAMdOQKXbgnjqaXHp/OnYwenFACBcgdPrQAOemfSnLg5AzQB3PGP0oAFBzRjp/Klxz2x2zSj1/H6UAJt9+fapBz6VHGiooRFwo6DtUgGeTn6mgBR1PIwPSl+gpBx1I/Cl+hoAOMY6+oNKPfFICO3b0paAF7YpmOT2+lO5/wAikzknnpQAgGP/AK9IMsoLKVPoSDj8RSsQAR1+vemFjjPWgByqAXwWOTnBPA+lIyDOdufTnpSKxLELjH1qQcev0oAYVwO2aY/HU9KlI45OaYRlfegBhyPp9KafvH1p3PakyoYLuUNg4GaAIXDNIoAdVHzF1YYJ5G0jqRzn8uaZKBtPGRjGasHI64qJ/mTjOOnSgDKkiA4A+UDAqq0JYnIP41qyLtBLAn6daikXj0IFAGLPCrjBGPYcYrKmgMb7hnA710UqjeRzn6VRnjyCDyKAMN4g/Xn271yPi7wzHqVq8kSgXEeWRh612s0flNlRgd+KYYw6EHOOmaAPBdGvWtNWjlmJVo2AbPYg966X4zsH+G2r8E/6hwT/ANdU/wAay/iVpTaXqv2qNQIrg4OP71Xfi4/mfCy7kAPz29sTn/rpHQB8z0UUUAXNIONRh+p/ka9V8PSfKvJ9DXk1jIsN1G7nCr1P4V2+k+ItOt1Aludvf7jH+lAHvGmyhIgx4AQY/KvPdCtWvPE4YDcY3LDHr2/rVq1+InhtLRFfUiH2gEeRL/8AE1B4V8beFNPmnnutUCySMcf6PKePXhaAPbNLj2RIBj1JxWxGOcj6c15fa/FnwXGBu1oA/wDXrP8A/EVfi+MPgdf+Y7j/ALdJ/wD4igD0tFIX5Aue2RxVmCNCdyqATxnvivM0+MngQYZtfIPTi0n/AD/1dTp8Z/AKgD+3hjPIFncD/wBp0AeoRYwAzOe5BORVpA20dz2BHH515cnxr+HoIJ1/n1Flcf8AxurEfxw+HYPPiE4HpZXH/wAboA9Py3JVY8++akRiTggE9evSvMF+Ofw7CADxDnAxzY3H/wAbqQfHT4c4wfEXB6j7Dc//ABugD1JW4p4IOK8tX46/Dgf8zFj/ALcrn/43Sr8d/hz1/wCEj69f9Buf/jdAHqgxjHWlAB5wK8sHx4+HGP8AkYvzsbn/AON07/hfPw3/AOhjP/gDc/8AxugD1E+oJ47Cg9MivLv+F8/Dft4jx/243P8A8bpsXx6+HDJufxAY25BX7Fcn15/1f+c/hQB6ljPelwQDzzXl/wDwvr4b5/5GPp/043P/AMbpf+F8/DYAf8VH/wCSNz/8boA9QViMbsA/Wn5zzjmvLB8evhtnP/CRken+g3P/AMbp3/C+/htj/kYx/wCANz/8boA9Txn396d0PSvLB8fPhtnnxJ/5I3P/AMbpR8fPhr/0Mn/kjc//ABugD1LnHH60jAl0bceM5AJwfqO9eX/8L9+Gv/Qyf+SFz/8AG6P+F+/DXP8AyMn/AJIXP/xugD1Ln1xQ3XmvLf8Ahfvw1wf+Kk/8kbn/AON0x/j58N8HHiQ5P/Tjc/8AxugD1I845oIH4+prytfj38N8c+JP/JG5/wDjdOHx8+G3/Qyf+SNz/wDG6APTwMHNSfQYNeXf8L8+GvGfEmfX/Qbn/wCN0D4+fDUf8zJ/5I3P/wAboA9RA444NNIODgYavMD8fPhr/wBDJx/143P/AMbpv/C/PhtjnxHz3xY3P/xugD02RRICjYxxkA/lSnDHI/OvLJfjv8NSHK+IVDkdRYXIJOOMny+aVfj18OMAt4jG7HJFjc9f+/dAHqPrUbjBztya8x/4Xz8N/wDoYiP+3G5/+N0n/C+fhx1/4SM5H/Tjc/8AxugD0pxznoarSryB09PevO5Pjv8ADg9PEWff7Dc//G6rT/HL4duQB4hHHf7Dccf+Q6APQpMMDg5qpIvBBHNcE/xu+HjD/kP8/wDXlcf/ABuqh+NXgPB/4qLfx3srjP57P6UAdxcxgsRVKTKk5OSK4uT4z+BWB/4nuD/16XHP/jlULn4veCXI2a4SB/06TjP/AI5QBueNtLi1jRpInI3qNyt6GuD+LCtF8KJ0Y5ZYLdD9RKlar/FfwVIrK+sZUjBBtZjn/wAcriPif468Oa14PvtP0rUvPuJBGETyJFziRWPLKB0BoA8MooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25971=[""].join("\n");
var outline_f25_23_25971=null;
var title_f25_23_25972="Branchial cleft cysts";
var content_f25_23_25972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Branchial cleft cysts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25972=[""].join("\n");
var outline_f25_23_25972=null;
var title_f25_23_25973="Efavirenz, tenofovir, and emtricitabine: Patient drug information";
var content_f25_23_25973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Efavirenz, tenofovir, and emtricitabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/25/23961?source=see_link\">",
"     see \"Efavirenz, tenofovir, and emtricitabine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/4/36937?source=see_link\">",
"     see \"Efavirenz, tenofovir, and emtricitabine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3053105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atripla&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5505100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atripla&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done in patients taking this drug for HIV infection. A hepatitis B infection may get worse after this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to efavirenz, emtricitabine, tenofovir, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11637 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25973=[""].join("\n");
var outline_f25_23_25973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053105\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505100\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027476\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027478\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027477\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027482\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027483\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027485\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027480\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027481\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027486\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027487\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/25/23961?source=related_link\">",
"      Efavirenz, tenofovir, and emtricitabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/4/36937?source=related_link\">",
"      Efavirenz, tenofovir, and emtricitabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_23_25974="Complications of idiopathic nephrotic syndrome in children";
var content_f25_23_25974=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of idiopathic nephrotic syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25974/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25974/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25974/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25974/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25974/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25974/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/23/25974/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome is caused by renal diseases that increase the permeability across the glomerular filtration barrier. It is classically characterized by four clinical features, but the first two are used diagnostically because the last two may not be seen in all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nephrotic range proteinuria &mdash; Urinary protein excretion greater than 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Hypoalbuminemia &mdash; Serum albumin concentration less than 3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      Edema",
"     </li>",
"     <li>",
"      Hyperlipidemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Almost all children with nephrotic syndrome have idiopathic nephrotic syndrome. Idiopathic nephrotic syndrome is characterized by diffuse foot process fusion on electron microscopy and minimal changes (called minimal change disease [MCD]), primary focal segmental glomerulosclerosis (FSGS), or mesangial proliferation on light microscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Idiopathic nephrotic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications in children result from abnormalities directly related to the nephrotic syndrome and secondarily from therapy used for its treatment.",
"   </p>",
"   <p>",
"    The five major complications directly related to the underlying nephrotic syndrome in children with idiopathic nephrotic syndrome will be reviewed here:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Thromboembolism",
"     </li>",
"     <li>",
"      Renal insufficiency",
"     </li>",
"     <li>",
"      Anasarca",
"     </li>",
"     <li>",
"      Hypovolemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, etiology, and treatment including complications due to therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with idiopathic nephrotic syndrome are at increased risk of infection. The following factors may contribute to this problem:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced serum concentrations of immunoglobulins [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impaired ability to make specific antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased levels of the alternative complement pathway factors B and D [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immunosuppressive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency and types of infection were evaluated in an observational study from India of 60 children with nephrotic syndrome, who were not receiving glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/6\">",
"     6",
"    </a>",
"    ]. There were 57 episodes of infection, which included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Upper respiratory infection &mdash; 16 episodes",
"     </li>",
"     <li>",
"      Urinary tract infection &mdash; 13 episodes",
"     </li>",
"     <li>",
"      Peritonitis &mdash; 9 episodes",
"     </li>",
"     <li>",
"      Pneumonia &mdash; 8 episodes",
"     </li>",
"     <li>",
"      Severe acute gastroenteritis &mdash; 6 episodes",
"     </li>",
"     <li>",
"      Empyema &mdash; 3 episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with idiopathic nephrotic syndrome are at increased risk of developing serious bacterial infection, especially with encapsulated bacteria. This may be due in part to the loss of opsonizing factors, which may specifically increase susceptibility to encapsulated bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. In addition, ascites and pleural effusions provide a natural culture media for bacterial growth. Thus, as noted in the above study, pneumonia, empyema, and peritonitis are infections seen in children with nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review, 24 episodes of peritonitis occurred in 351 children with idiopathic nephrotic syndrome over a 10-year period from 1970 to 1980 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/7\">",
"     7",
"    </a>",
"    ]. Streptococcus pneumoniae was the most common infectious agent, seen in 12 patients, followed by Escherichia coli in six, and negative cultures in four. Peritoneal signs of irritation were present in all patients, including 16 who were receiving corticosteroid therapy.",
"   </p>",
"   <p>",
"    In a more recent retrospective study, eight episodes of peritonitis in seven patients over a five-year period were reported in 268 patients with NS that was initially diagnosed as steroid sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/8\">",
"     8",
"    </a>",
"    ]. In three cases, the causative microorganism was identified, Streptococcus pneumoniae. Streptococcus hemolyticus, and alpha-hemolytic Streptococcus.",
"   </p>",
"   <p>",
"    Sepsis, meningitis, and cellulitis are other serious infections that can occur in children with nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Although not as serious, urinary tract infections are common [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to 1940, the mortality rate in children with nephrotic syndrome was 40 percent, primarily due to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/12\">",
"     12",
"    </a>",
"    ]. Although the mortality rate has been significantly reduced with the introduction of corticosteroid treatment and antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], infection still remains a cause of death in children with nephrotic syndrome. This was illustrated in an International Study of Kidney Disease in Children report of 10 deaths in a group of 389 children with minimal change disease (MCD) who were seen between 1967 and 1976 and were followed for 5 to 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/15\">",
"     15",
"    </a>",
"    ]. Six of the deaths were due to infection, five from sepsis (peritonitis as the primary site of infection in two), and one to peritonitis with pancreatitis. Streptococcus pneumoniae was isolated in two cases and Escherichia coli in two other cases.",
"   </p>",
"   <p>",
"    Because children with nephrotic syndrome are at increased risk for serious complications and potentially death from pneumococcal infection, they should receive 23-valent polysaccharide vaccine (PPSV23) pneumococcal vaccine if not previously immunized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections, particularly varicella, may be observed in children with nephrotic syndrome, especially those receiving immunosuppressive therapy. Varicella can cause significant morbidity and mortality in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Treatment including vaccination is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\", section on 'Immunocompromised host'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors contribute to an increased risk of thromboembolic complications in children with nephrotic syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoconcentration",
"     </li>",
"     <li>",
"      Immobility, especially in patients with anasarca",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these abnormalities, the nephrotic syndrome is associated with a hypercoagulable state due to thrombocytosis, and hemostatic abnormalities including decreased levels of antithrombin, free protein S, and plasminogen (due to urinary losses), increased platelet activation, hyperfibrinogenemia, and the presence of high molecular weight fibrinogen moieties in the circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link&amp;anchor=H6#H6\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported incidence of thromboembolic complications in nephrotic children is between 2 and 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a retrospective study of 326 children with nephrotic syndrome from any cause diagnosed between 1999 and 2006, 9 percent had one thromboembolic event (TEE), resulting in an overall incidence of 20.4 patients with TEEs per 1000 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/20\">",
"     20",
"    </a>",
"    ]. The median time to TEE was about 71 days after diagnosis of nephrotic syndrome. Deep venous thrombosis was the most common TEE and was associated with the use of a central venous catheter. Multivariate analysis demonstrated that the risk of TEE was greater in children older than 12 years of age, and increased with increasing urinary protein excretion.",
"   </p>",
"   <p>",
"    However, the true incidence of TEE may be higher as many TE events are asymptomatic. This was illustrated in a case series of 16 children with steroid-dependent minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/21\">",
"     21",
"    </a>",
"    ]. Evaluation by ventilation-perfusion scans showed defects consistent with pulmonary embolism in seven patients, residual changes in 10, and normal findings in only nine.",
"   </p>",
"   <p>",
"    Both arterial and venous thromboses have been reported in children with nephrotic syndrome. The most common sites include the pulmonary artery, renal vein, deep leg veins, inferior vena cava, and",
"    <span class=\"nowrap\">",
"     femoral/iliac",
"    </span>",
"    artery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/19,22,23\">",
"     19,22,23",
"    </a>",
"    ]. Other reported sites include the cerebral and meningeal arteries, mesenteric and hepatic veins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/19,22,24,25\">",
"     19,22,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thromboembolic complications in children with nephrotic syndrome may be associated with significant morbidity including pulmonary embolism and renal vein thrombosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary embolism &mdash; As mentioned above, many pulmonary emboli are silent in children with nephrotic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/21\">",
"       21",
"      </a>",
"      ]. However, there are several case reports of significant morbidity from pulmonary embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. Pulmonary embolism should be suspected in patients with pulmonary or cardiovascular symptoms and can be confirmed by angiography or radioisotope scanning [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal vein thrombosis &mdash; Infants with congenital nephrotic syndrome are at increased risk for renal vein thrombosis. Otherwise, renal vein thrombosis is rare in children with nephrotic syndrome, especially in comparison to adults. However, some children develop acute complete venous occlusion, which is characterized clinically by the sudden onset of macroscopic hematuria, flank pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tenderness, and, in children with bilateral disease, acute renal failure. In such cases, Doppler ultrasonography shows an increase in kidney size and the absence of blood flow in the renal vein. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link&amp;anchor=H6#H6\">",
"       \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylactic anticoagulation is not recommended unless the patient has had a thromboembolic event or has a high risk of thrombosis with albumin concentration of less than 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    a fibrinogen level of more than 6",
"    <span class=\"nowrap\">",
"     g/L,",
"    </span>",
"    or an antithrombin III level less than 70 percent of normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6679?source=see_link&amp;anchor=H6#H6\">",
"     \"Symptomatic management of nephrotic syndrome in children\", section on 'Hypercoagulability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At presentation, children with nephrotic syndrome can have reduced glomerular filtration rate (GFR) because of one or more of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemia &mdash; Children with idiopathic nephrotic syndrome, especially those with minimal change disease, can have a transient decrease in GFR due to hypovolemia that returns to normal after repletion of their vascular volume [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The underlying glomerular pathology &mdash; In children with nephrotic syndrome, primary renal disease (eg, primary focal segmental glomerulosclerosis and primary membranoproliferative glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/30\">",
"       30",
"      </a>",
"      ]) or secondary renal disease (eg, postinfectious glomerulonephritis or lupus nephritis) can present with renal insufficiency due to glomerular injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Severity of renal dysfunction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"       \"Poststreptococcal glomerulonephritis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minimal change disease, which is the most common form of nephrotic syndrome in children, particularly those younger than age 6, may present with mild elevations in serum creatinine but substantial declines in GFR are uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progression to chronic or end-stage renal failure can occur in some patients especially those who with steroid-resistant nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link&amp;anchor=H174702423#H174702423\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Outcome based upon response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANASARCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anasarca (generalized and massive edema) can be associated with the following complications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inability to walk because of severe scrotal or vulvar edema",
"     </li>",
"     <li>",
"      Respiratory distress from large pleural effusions,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      massive ascites, which can impair diaphragmatic movement",
"     </li>",
"     <li>",
"      Tissue breakdown and cellulitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some circumstances, patients with anasarca can be treated with salt-poor albumin with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    to improve their edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6679?source=see_link\">",
"     \"Symptomatic management of nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPOVOLEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the marked increase in extracellular fluid volume, some children with nephrotic syndrome, primarily those with MCD, present with or develop signs of a decrease in effective circulating volume such as tachycardia, peripheral vasoconstriction, oliguria, decreased glomerular filtration rate, and elevation of plasma renin aldosterone, and norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/32\">",
"     32",
"    </a>",
"    ]. Hypovolemia typically occurs early at onset of nephrosis or during a relapse. In such children, a further insult such as diuretic therapy, sepsis, or diarrhea can lead to hypotension and rarely shock [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25974/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth can be adversely affected in patients with persistent nephrotic syndrome, especially as a complication of long-term steroid therapy in patients with steroid-dependent nephrotic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications result from abnormalities directly related to the nephrotic syndrome. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection &mdash; Children with nephrotic syndrome have increased susceptibility to encapsulated bacterial infection, particularly peritonitis because of defects in humoral immunity. Although antibiotics have reduced the mortality rate of nephrotic syndrome due to infection, infection still remains a cause of death in children with nephrotic syndrome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anasarca &mdash; Anasarca (generalized and massive edema) can cause respiratory distress (eg, large pleural effusions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      massive ascites), skin breakdown with an increased risk of cellulitis, and increases the risk of bacterial peritonitis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Anasarca'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Bacterial infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thrombosis &mdash; Children with nephrotic syndrome are at increased risk for thrombosis due primarily to hypercoagulability from thrombocytosis and hemostatic abnormalities. Arterial and venous thromboses occur and involve a variety of different sites. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Thromboembolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal insufficiency &mdash; Children with nephrotic syndrome can have transient impaired renal function at presentation because of hypovolemia or persistent renal insufficiency because of glomerular injury from the underlying disease process. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Renal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypovolemia &mdash; Significant hypovolemia in children with nephrotic syndrome can be associated with hypotension, abdominal pain, and cold poorly perfused extremities. In rare and severe cases, shock can occur. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hypovolemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Growth &mdash; Poor growth can be seen in patients with persistent nephrotic syndrome or in patients with steroid-dependent nephrotic syndrome who are treated with long-term steroid therapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/1\">",
"      Giangiacomo J, Cleary TG, Cole BR, et al. Serum immunoglobulins in the nephrotic syndrome. A possible cause of minimal-change nephrotic syndrome. N Engl J Med 1975; 293:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/2\">",
"      Spika JS, Halsey NA, Fish AJ, et al. Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics 1982; 69:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/3\">",
"      McLean RH, Forsgren A, Bj&ouml;rkst&eacute;n B, et al. Decreased serum factor B concentration associated with decreased opsonization of Escherichia coli in the idiopathic nephrotic syndrome. Pediatr Res 1977; 11:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/4\">",
"      Anderson DC, York TL, Rose G, Smith CW. Assessment of serum factor B, serum opsonins, granulocyte chemotaxis, and infection in nephrotic syndrome of children. J Infect Dis 1979; 140:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/5\">",
"      Ballow M, Kennedy TL 3rd, Gaudio KM, et al. Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome. J Pediatr 1982; 100:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/6\">",
"      Alwadhi RK, Mathew JL, Rath B. Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health 2004; 40:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/7\">",
"      Krensky AM, Ingelfinger JR, Grupe WE. Peritonitis in childhood nephrotic syndrome: 1970-1980. Am J Dis Child 1982; 136:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/8\">",
"      Uncu N, B&uuml;lb&uuml;l M, Yildiz N, et al. Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study. Eur J Pediatr 2010; 169:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/9\">",
"      Wilfert CM, Katz SL. Etiology of bacterial sepsis in nephrotic children 1963-1967. Pediatrics 1968; 42:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/10\">",
"      Sleiman JN, D'Angelo A, Hammerschlag MR. Spontaneous Escherichia coli cellulitis in a child with nephrotic syndrome. Pediatr Infect Dis J 2007; 26:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/11\">",
"      Gulati S, Kher V, Arora P, et al. Urinary tract infection in nephrotic syndrome. Pediatr Infect Dis J 1996; 15:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/12\">",
"      Barness LA, Moll GH, Janeway CA. Nephrotic syndrome. I. Natural history of the disease. Pediatrics 1950; 5:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/13\">",
"      LAWSON D, MONCRIEFF A, PAYNE WW. Forty years of nephrosis in childhood. Arch Dis Child 1960; 35:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/14\">",
"      ARNEIL GC. 164 children with nephrosis. Lancet 1961; 2:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/15\">",
"      Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation. Report of the International Study of Kidney Disease in Children. Pediatrics 1984; 73:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/16\">",
"      Close GC, Houston IB. Fatal haemorrhagic chickenpox in a child on long-term steroids. Lancet 1981; 2:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/17\">",
"      Scheinman JI, Stamler FW. Cyclophosphamide and fatal varicella. J Pediatr 1969; 74:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/18\">",
"      Resnick J, Schanberger JE. Varicella reactivation in nephrotic syndrome treated with cyclophosphamide and adrenal corticosteroids. J Pediatr 1973; 83:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/19\">",
"      Egli F, Elmiger P, Stalder G. [Thrombosis as a complication of nephrotic syndrome]. Helv Paediatr Acta 1973; 30:Suppl:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/20\">",
"      Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 2009; 155:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/21\">",
"      Hoyer PF, Gonda S, Barthels M, et al. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence. Acta Paediatr Scand 1986; 75:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/22\">",
"      Cameron JS. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol Necker Hosp 1984; 13:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/23\">",
"      Sullivan MJ 3rd, Hough DR, Agodoa LC. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J 1983; 76:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/24\">",
"      Appenzeller S, Zeller CB, Annichino-Bizzachi JM, et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clin Neurol Neurosurg 2005; 107:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/25\">",
"      Igarashi M, Roy S 3rd, Stapleton FB. Cerebrovascular complications in children with nephrotic syndrome. Pediatr Neurol 1988; 4:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/26\">",
"      Deshpande PV, Griffiths M. Pulmonary thrombosis in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2005; 20:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/27\">",
"      Apostol EL, Kher KK. Cavitating pulmonary infarction in nephrotic syndrome. Pediatr Nephrol 1994; 8:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/28\">",
"      Jones CL, H&eacute;bert D. Pulmonary thrombo-embolism in the nephrotic syndrome. Pediatr Nephrol 1991; 5:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/29\">",
"      Rai Mittal B, Singh S, Bhattacharya A, et al. Lung scintigraphy in the diagnosis and follow-up of pulmonary thromboembolism in children with nephrotic syndrome. Clin Imaging 2005; 29:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/30\">",
"      Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/31\">",
"      Agarwal N, Phadke KD, Garg I, Alexander P. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2003; 18:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/32\">",
"      Vande Walle JG, Donckerwolcke RA, van Isselt JW, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25974/abstract/33\">",
"      YAMAUCHI H, HOPPER J Jr. HYPOVOLEMIC SHOCK AND HYPOTENSION AS A COMPLICATION IN THE NEPHROTIC SYNDROME. REPORT OF TEN CASES. Ann Intern Med 1964; 60:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6102 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25974=[""].join("\n");
var outline_f25_23_25974=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Varicella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANASARCA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPOVOLEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6679?source=related_link\">",
"      Symptomatic management of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_23_25975="Definition and evaluation of abnormal uterine bleeding in adolescents";
var content_f25_23_25975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and evaluation of abnormal uterine bleeding in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25975/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25975/contributors\">",
"     Nirupama K De Silva, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25975/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25975/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25975/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25975/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25975/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/23/25975/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual disorders and abnormal uterine bleeding (AUB) are among the most frequent gynecologic complaints of adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Abnormal uterine bleeding (AUB) refers to bleeding that is excessive or occurs outside of normal cyclic menstruation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/3\">",
"     3",
"    </a>",
"    ]. AUB is described by a variety of terms and may be caused by a number of genital and nongenital tract conditions, systemic disorders, and medications (",
"    <a class=\"graphic graphic_table graphicRef62751 \" href=\"UTD.htm?29/4/29773\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common cause of AUB in adolescents during the initial 19 months of menstruation is anovulatory cycles, which are related to immaturity of the hypothalamic-pituitary-ovarian axis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Other common causes include pregnancy, infection, the use of hormonal contraceptives, stress (psychogenic or exercise induced), bleeding disorders, and endocrine disorders (eg, hypothyroidism, polycystic ovary syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link&amp;anchor=H6#H6\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\", section on 'Irregular bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14937?source=see_link\">",
"     \"Evaluation of oligomenorrhea in adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment for these disorders ranges from observation to pharmacologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical therapy. Potential sequelae of AUB include anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. With appropriate management of the underlying problem, these sequelae may be prevented. Thus, it is crucial to establish the correct diagnosis before any therapy is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of AUB in adolescents will be discussed here. The management of AUB in adolescents is discussed separately, as is the evaluation of AUB in premenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link\">",
"     \"Management of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL MENSTRUAL CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal menstrual cycle results from a complex feedback system involving the hypothalamus, pituitary, ovary, and uterus. The cyclic changes in the major pituitary and gonadal hormones are illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 1",
"    </a>",
"    ). Although the development of secondary sexual characteristics varies by race and geographic location [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], the average age of menarche in the United States is 12.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The average adult menstrual cycle is 28 days, with a range of 24 to 35 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and lasts four to six days. The median blood loss during each menstrual period is 30 mL; the upper limit of normal is 80 mL. However, during the first five to seven years after menarche, there is considerable cycle variability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ]. In the first postmenarcheal year, approximately 50 percent of cycles are anovulatory. According to a study by the World Health Organization, the median length of the first cycle after menarche was 34 days, with 38 percent of the cycles exceeding 40 days and 7 percent occurring less than 20 days apart [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/18\">",
"     18",
"    </a>",
"    ]. Nonetheless, 80 percent of cycles occur within a predictable range of 21 to 45 days and last two to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/16,17,19,20\">",
"     16,17,19,20",
"    </a>",
"    ]. By the third postmenarcheal year, 95 percent of cycles fall into this range.",
"   </p>",
"   <p>",
"    The duration of time that it takes to establish regular ovulatory cycles appears to be related to age at the time of menarche [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In girls who begin menses at &lt;12 years, between 12 and 13 years, and &gt;13 years of age, 50 percent of cycles are ovulatory by one year, three years, and 4.5 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/21\">",
"     21",
"    </a>",
"    ]. The normal menstrual cycle is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ABNORMAL UTERINE BLEEDING (AUB) IN ADOLESCENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine bleeding refers to uterine bleeding outside of the normal parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/19,23,24\">",
"     19,23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration greater than seven days",
"     </li>",
"     <li>",
"      Flow greater than 80",
"      <span class=\"nowrap\">",
"       mL/cycle",
"      </span>",
"      or subjective impression of heavier-than-normal flow (ie, more than six full pads or tampons per day [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/19\">",
"       19",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Occur more frequently than every 21 days or less frequently than every 45 days",
"     </li>",
"     <li>",
"      Intermenstrual bleeding or postcoital spotting",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various terms have evolved to describe patterns of abnormal uterine bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .) In clinical practice, it is helpful to consider several major categories of AUB in adolescents:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amenorrhea (absence of menses)",
"     </li>",
"     <li>",
"      Irregular bleeding (metrorrhagia), which may be of reduced, normal, or excessive volume (menometrorrhagia), and may occur at intervals of less than 24 days (polymenorrhea), or greater than 45 days (oligomenorrhea)",
"     </li>",
"     <li>",
"      Menorrhagia (excessive flow)",
"     </li>",
"     <li>",
"      Acute bleeding due to anatomic defects or medicines (may originate from the cervix, vagina, or perineum)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term dysfunctional uterine bleeding (DUB) classically has been used to describe excessive noncyclic endometrial bleeding unrelated to anatomical lesions of the uterus or to systemic disease. It may be more useful to think of dysfunctional uterine bleeding as anovulatory bleeding, since this is the primary cause. \"Anovulatory uterine bleeding\" is the term preferred by the American College of Obstetricians and Gynecologists to describe this pattern of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/3\">",
"     3",
"    </a>",
"    ]. Anovulatory uterine bleeding is a diagnosis of exclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the adolescent with abnormal uterine bleeding begins with a careful history and physical examination. Information from the history usually can be used to classify the abnormal bleeding into one of the following categories: amenorrhea, irregular bleeding, menorrhagia, breakthrough bleeding due to anatomic defects or medicines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link&amp;anchor=H2#H2\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\", section on 'General approach'",
"    </a>",
"    .) The physical examination further helps to narrow the differential diagnosis and to direct subsequent laboratory or radiographic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should be obtained with and without the patient's guardian in the room. The patient's guardian may be more precise about the nature of the patient's menstrual patterns and may share details that the patient would omit. In addition, many girls are uncomfortable discussing menstruation and desire to have a parent present. However, some girls prefer to be interviewed alone, particularly if they have been sexually active. Speaking with the patient alone and with her guardian present facilitates obtaining a thorough history and maintains the patient's confidentiality on subjects that she may not be comfortable discussing in front of her parents.",
"   </p>",
"   <p>",
"    It is important to obtain as much information as possible regarding the patient's menstrual history. This includes detailed information about menarche; the timing, duration, and quantity of bleeding during recent menstrual cycles;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal bleeding episodes. In girls who describe a change in their menstrual pattern, it is important to ask about other events that coincided with the change [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/25\">",
"     25",
"    </a>",
"    ]. Several specific questions may aid in the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef70444 \" href=\"UTD.htm?32/39/33403\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We always recommend the use of a menstrual calendar (",
"    <a class=\"graphic graphic_figure graphicRef76376 \" href=\"UTD.htm?36/52/37710\">",
"     figure 2",
"    </a>",
"    ) in patients with irregular cycles. In fact, we encourage mothers or other caregivers to teach girls to track their own periods right from menarche and encourage healthcare providers to ask about a patient's menstrual cycle at each visit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/24\">",
"     24",
"    </a>",
"    ]. Keeping track of their periods helps girls to take control of their health and to anticipate menstrual symptoms, such as dysmenorrhea. Doing so can allow them to consider treatments, such as antiinflammatory therapy a day before the actual onset of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=see_link\">",
"     \"Primary dysmenorrhea in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is important to try to quantify the volume of menstrual blood flow in girls who report heavy menstrual flow, neither patients nor clinicians can accurately estimate the amount of blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/5\">",
"     5",
"    </a>",
"    ]. The large variety of sanitary products on the market makes quantification challenging at best. In addition, there is little correlation between the number of pads or tampons used and actual menstrual blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/26\">",
"     26",
"    </a>",
"    ]. In adolescents, hygiene preferences and school limitations can affect the quantity of sanitary products used. Nonetheless, the history should include the",
"    <span class=\"nowrap\">",
"     type/size",
"    </span>",
"    of pad or tampon used, the number of pads or tampons used per day (or the hours each item is worn [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/27\">",
"     27",
"    </a>",
"    ]), and an estimate of the degree to which the pad is soaked [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of a practical means to measure blood loss, the clinician must rely upon indirect indicators of heavy flow, such as passing blood clots, the need to change sanitary protection during the night, signs or symptoms of volume depletion during the menstrual period, and measurement of hemoglobin or hematocrit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/9,29,30\">",
"     9,29,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Laboratory evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The sexual history should be obtained without the guardian present. History should include information regarding contraception and condom use; number of partners; new partners; history of sexually transmitted infections or current symptoms (eg, vaginal discharge, pelvic pain); previous pregnancy or abortion; whether sexual activity was forced or consensual; and whether the adolescent has a history of sexual abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The past medical history should include information about systemic illness, hematologic or renal disease, and current or recent medications (including over-the-counter medications and",
"    <span class=\"nowrap\">",
"     complementary/alternative",
"    </span>",
"    agents) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     Aspirin",
"    </a>",
"    and aspirin-containing over-the-counter medications should be asked about specifically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the child with bleeding symptoms\", section on 'Medication'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The review of systems should include information about social stressors, weight change, self-induced vomiting as a means of weight control [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/33\">",
"     33",
"    </a>",
"    ], athletic competition, substance use, hirsutism, acne, visual changes, and headaches. Girls with complaints of heavy menstrual flow (especially during the first two to three cycles) should be asked about bleeding from other sites and symptoms of acute or chronic anemia (eg, epistaxis, gum bleeding, easy bruising, postoperative bleeding, lightheadedness, syncope, fatigue, weakness, headache) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The family history should include information about bleeding disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/34\">",
"     34",
"    </a>",
"    ], infertility, menstrual disorders, and thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/25\">",
"     25",
"    </a>",
"    ]. A predisposition to diabetes mellitus and or disorders of lipids or triglycerides may be suggestive of polycystic ovary syndrome (PCOS).",
"   </p>",
"   <p>",
"    Information regarding the age of menarche in mother and sisters should be obtained in girls in whom constitutional delay of puberty is a consideration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information from the physical examination may be helpful in determining an etiology of AUB in adolescents (",
"    <a class=\"graphic graphic_table graphicRef66045 \" href=\"UTD.htm?7/42/7853\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general examination should include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/25,31,32\">",
"     25,31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of height, weight, and arm span.",
"     </li>",
"     <li>",
"      Assessment of body type and fat distribution (eg, Cushing syndrome, Turner syndrome).",
"     </li>",
"     <li>",
"      Vital signs, including orthostatics.",
"     </li>",
"     <li>",
"      Palpation of the thyroid gland for enlargement or other abnormalities.",
"     </li>",
"     <li>",
"      Evaluation for signs of androgen excess: hirsutism; acne; male pattern balding.",
"     </li>",
"     <li>",
"      Examination of the optic fundi and visual field testing to evaluate the possibility of a pituitary tumor.",
"     </li>",
"     <li>",
"      Tanner staging of the breasts (",
"      <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"       picture 1",
"      </a>",
"      ) and assessment for galactorrhea. Breast development provides evidence of estrogenization.",
"     </li>",
"     <li>",
"      Examination of the skin for acanthosis nigricans or signs of abnormal bleeding (eg, petechiae",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bruising) should be noted, particularly in girls with menorrhagia.",
"     </li>",
"     <li>",
"      Palpation of the abdomen for uterine or ovarian mass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     External genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An examination of the external genitalia is recommended in all patients. This should include evaluation of clitoral size, pubertal hair development (",
"    <a class=\"graphic graphic_picture graphicRef79782 \" href=\"UTD.htm?29/33/30227\">",
"     picture 2",
"    </a>",
"    ) , and the hymen (",
"    <a class=\"graphic graphic_figure graphicRef57977 \" href=\"UTD.htm?8/20/8514\">",
"     figure 3",
"    </a>",
"    ). It is also important to look for nonuterine sources of bleeding (eg, perineal trauma, vulvar lesions, signs of sexually transmitted infections). Girls who have signs of perineal trauma should be questioned privately about sexual abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pelvic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic examination is necessary to assess the M&uuml;llerian structures: the depth of the vagina and the presence of a cervix, uterus, and ovaries. However, pelvic examination may be traumatic for girls who are not sexually active. In such cases, unless the bleeding is severe, the pelvic and rectal examination may be deferred until after a trial of medical therapy, if such therapy is warranted. Pelvic ultrasonography can also provide clinical information. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link\">",
"     \"Management of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When warranted, many adolescents (even virginal ones) can tolerate a one finger digital examination (provided the hymenal opening is wide enough to admit one finger [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/32\">",
"     32",
"    </a>",
"    ]) and examination of the vagina with an appropriately sized speculum. A rectoabdominal examination may be helpful if the digital examination is uncomfortable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/32\">",
"     32",
"    </a>",
"    ]. Pelvic examination under anesthesia may be necessary if pelvic examination is inadequate or an appropriate diagnosis cannot be established despite imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pelvic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic ultrasonography may be indicated in adolescents in whom the physical examination is limited (ie, if a normal vagina, uterus, or ovaries are not obviously present). Pelvic ultrasonography also may be indicated to evaluate structural abnormalities (ie, vaginal or cervical outlet obstruction in girls with cyclic pain, fibroids, polyps, or ovarian masses). If multiple follicles around the periphery of the ovary are seen, PCOS should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every adolescent who presents with AUB should have a pregnancy test, a hemoglobin or hematocrit with a platelet count, and measurement of thyroid-stimulating hormone. In addition, blood should be obtained for cross-matching in girls who have acute hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excessive menstrual flow and signs and symptoms of volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25975/abstract/35\">",
"     35",
"    </a>",
"    ]. In girls in whom transfusion is necessary, blood should be obtained for evaluation of a bleeding diathesis before the transfusion is received or treatment initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link&amp;anchor=H10#H10\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\", section on 'Menorrhagia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the event that a pregnancy test is positive, the etiology of the bleeding should be identified using serum beta-HCG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasonography. Vaginal bleeding with pregnancy may be a result of threatened, incomplete, missed, or complete abortion, as well as ectopic or molar pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link&amp;anchor=H31#H31\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Diagnostic evaluation of threatened abortion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The additional evaluation for adolescents with AUB depends upon the findings of the history and examination, which are used to categorize the bleeding into one of several clinically relevant categories of differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common cause of abnormal uterine bleeding (AUB) in pubertal adolescents is anovulation due to an immature hypothalamic pituitary axis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dysfunctional uterine bleeding is defined as AUB without an identifiable pathologic condition. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of all adolescents with AUB should include exclusion of pregnancy (especially ectopic pregnancy), assessment of hemodynamic status (blood pressure, heart rate), and hemoglobin or hematocrit and platelet count to evaluate the presence of anemia or thrombocytopenia. Additional evaluation depends upon findings from the history and physical examination, and is discussed separately. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link\">",
"       \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28347912\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Robert Zurawin, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/1\">",
"      Caufriez A. Menstrual disorders in adolescence: pathophysiology and treatment. Horm Res 1991; 36:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/2\">",
"      Deligeoroglou E, Tsimaris P, Deliveliotou A, et al. Menstrual disorders during adolescence. Pediatr Endocrinol Rev 2006; 3 Suppl 1:150.",
"     </a>",
"    </li>",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/4\">",
"      Lemarchand-B&eacute;raud T, Zufferey MM, Reymond M, Rey I. Maturation of the hypothalamo-pituitary-ovarian axis in adolescent girls. J Clin Endocrinol Metab 1982; 54:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/5\">",
"      Hallberg L, H&ouml;gdahl AM, Nilsson L, Rybo G. Menstrual blood loss--a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/6\">",
"      Revel-Vilk S, Paltiel O, Lipschuetz M, et al. Underdiagnosed menorrhagia in adolescents is associated with underdiagnosed anemia. J Pediatr 2012; 160:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/7\">",
"      Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983; 61:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/8\">",
"      Southam AL, Richart RM. The prognosis for adolescents with menstrual abnormalities. Am J Obstet Gynecol 1966; 94:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/9\">",
"      Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 1993; 269:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/10\">",
"      Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 2002; 110:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/11\">",
"      Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics 1997; 99:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/12\">",
"      World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. I. A multicenter cross-sectional study of menarche. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health Care 1986; 7:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/13\">",
"      Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr 2005; 147:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/14\">",
"      Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/15\">",
"      Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975; 55:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/16\">",
"      Flug D, Largo RH, Prader A. Menstrual patterns in adolescent Swiss girls: a longitudinal study. Ann Hum Biol 1984; 11:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/17\">",
"      Widholm O, Kantero RL. A statistical analysis of the menstrual patterns of 8,000 Finnish girls and their mothers. Acta Obstet Gynecol Scand Suppl 1971; 14:Suppl 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/18\">",
"      World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. II. Longitudinal study of menstrual patterns in the early postmenarcheal period, duration of bleeding episodes and menstrual cycles. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health Care 1986; 7:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/19\">",
"      Slap GB. Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 2003; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/20\">",
"      Adams Hillard PJ. Menstruation in young girls: a clinical perspective. Obstet Gynecol 2002; 99:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/21\">",
"      Apter D, Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab 1983; 57:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/22\">",
"      Vihko R, Apter D. Endocrine characteristics of adolescent menstrual cycles: impact of early menarche. J Steroid Biochem 1984; 20:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/23\">",
"      Elford KJ, Spence JE. The forgotten female: Pediatric and adolescent gynecological concerns and their reproductive consequences. J Pediatr Adolesc Gynecol 2002; 15:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/24\">",
"      American Academy of Pediatrics Committee on Adolescence, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz A, et al. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 2006; 118:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/25\">",
"      Rimsza ME. Dysfunctional uterine bleeding. Pediatr Rev 2002; 23:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/26\">",
"      Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 1984; 149:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/27\">",
"      Strickland JL, Wall JW. Abnormal uterine bleeding in adolescents. Obstet Gynecol Clin North Am 2003; 30:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/28\">",
"      Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/29\">",
"      Adams Hillard PJ, Deitch HR. Menstrual disorders in the college age female. Pediatr Clin North Am 2005; 52:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/30\">",
"      Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol 2004; 190:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/31\">",
"      Mitan LA, Slap GB. Adolescent menstrual disorders. Update. Med Clin North Am 2000; 84:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/32\">",
"      Bravender T, Emans SJ. Menstrual disorders. Dysfunctional uterine bleeding. Pediatr Clin North Am 1999; 46:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/33\">",
"      Austin SB, Ziyadeh NJ, Vohra S, et al. Irregular menses linked to vomiting in a nonclinical sample: findings from the National Eating Disorders Screening Program in high schools. J Adolesc Health 2008; 42:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/34\">",
"      Jayasinghe Y, Moore P, Donath S, et al. Bleeding disorders in teenagers presenting with menorrhagia. Aust N Z J Obstet Gynaecol 2005; 45:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25975/abstract/35\">",
"      Aksel S, Jones GS. Etiology and treatment of dysfunctional uterine bleeding. Obstet Gynecol 1974; 44:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 116 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25975=[""].join("\n");
var outline_f25_23_25975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL MENSTRUAL CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ABNORMAL UTERINE BLEEDING (AUB) IN ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - General examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - External genitalia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pelvic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28347912\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/116|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/26/35246\" title=\"figure 1\">",
"      Hormones and menses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/52/37710\" title=\"figure 2\">",
"      Menstrual calendar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/20/8514\" title=\"figure 3\">",
"      Hymen anatomic variations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/116|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/43/10932\" title=\"picture 1\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/33/30227\" title=\"picture 2\">",
"      Sexual maturity rating of pubic hair in girls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/116|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/4/29773\" title=\"table 1\">",
"      Causes abnormal uterine bleeding teen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/39/33403\" title=\"table 2\">",
"      Hx abnl uterine bleeding teen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/42/7853\" title=\"table 3\">",
"      PE AUB adolescent",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=related_link\">",
"      Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14937?source=related_link\">",
"      Evaluation of oligomenorrhea in adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=related_link\">",
"      Management of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=related_link\">",
"      Primary dysmenorrhea in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_23_25976="Laparoscopic surgery for repair of pelvic floor defects";
var content_f25_23_25976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laparoscopic surgery for repair of pelvic floor defects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25976/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25976/contributors\">",
"     Peter L Rosenblatt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25976/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25976/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25976/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25976/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25976/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/23/25976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical reconstruction of pelvic organ prolapse may be performed by a variety of techniques. Many gynecologists prefer a vaginal approach to pelvic reconstruction because it is associated with reduced length of hospitalization and postoperative pain, as well as a faster return to normal activities and a better cosmetic result. However, some data suggest that these advantages may be offset by less than optimal anatomic outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopic techniques have been developed to mitigate the morbidity associated with the abdominal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/3\">",
"     3",
"    </a>",
"    ]. One of the primary goals of laparoscopic reconstruction is to reproduce proven abdominal techniques, but in a minimally invasive fashion and without compromising safety or efficacy. As surgeons gain more information about the pathogenesis of prolapse, and as device innovations are introduced that improve surgical outcome, surgical procedures will likely evolve.",
"   </p>",
"   <p>",
"    On the other hand, altering or compromising traditional surgical techniques for the sole purpose of accomplishing the repair in a laparoscopic fashion should be avoided.",
"   </p>",
"   <p>",
"    Compared with open abdominal surgery, laparoscopic surgery is associated with a number of advantages, including shorter hospital stay, decreased postoperative pain, smaller scars, and a potentially reduced time before resumption of work and other normal activities. Technical advances include rapid carbon dioxide insufflators, three-chip and high definition cameras that improve picture clarity, ultra-bright light sources, safer energy sources, and changes in laparoscopic needle drivers and automated suturing devices. In addition, the widespread use of robotic surgery has fueled a renewed interest in a minimally invasive approach to pelvic reconstructive surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=see_link\">",
"     \"Robot-assisted laparoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful preoperative assessment should include anatomic and functional aspects of the pelvic floor. It may be helpful to have an understanding of the defects responsible for an individual patient's prolapse to achieve an optimal anatomic outcome and to determine the surgical approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence can develop de novo or worsen following prolapse repair. The urethra may be anatomically kinked in patients with Stage III or Stage IV prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Following prolapse repair, insufficient urethral sphincter function may result in new onset stress urinary incontinence.",
"   </p>",
"   <p>",
"    Patients with concomitant prolapse and incontinence may not volunteer that they are incontinent out of embarrassment or because they are unaware of the relationship between incontinence and pelvic support. Some pelvic surgeons perform a preoperative cough stress test with a full bladder after manual reduction of any prolapse (anterior, posterior, or apical) that protrudes beyond the hymen with straining. However, the predictive value of such testing is not well understood. Thus, it should only be performed to aid individual clinical decisions, such as whether to proceed with complex urodynamic testing of urethral function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32120?source=see_link\">",
"     \"Urodynamic evaluation of women with incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17319?source=see_link\">",
"     \"Stress urinary incontinence in women: Preoperative evaluation for a primary procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Choice of surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A laparoscopic procedure may not be appropriate if there is a history of multiple abdominal surgeries or pelvic infection (eg, ruptured appendicitis, pelvic inflammatory disease) suggesting the presence of adhesions. A previous vertical abdominal incision extending to the umbilicus may lead the surgeon to consider either an open laparoscopic approach, or an alternative location for Veress needle and initial trocar placement, such as the left upper quadrant in the ninth intercostal space. Other factors that should be considered include the overall health of the patient (including her ability to undergo general anesthesia and abdominal insufflation), body habitus, and previous approaches to prolapse surgery, such as retropubic procedures. Transvaginal surgery may be preferable in elderly, obese, and other high-risk patients, or in those who prefer to avoid general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent should include the possibility of having to change the surgical approach intraoperatively to an open laparotomy or vaginal procedure in the event that adhesions or other factors preclude completion of the procedure laparoscopically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Informed consent and patient expectations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H8420779#H8420779\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Bowel preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BASIC SURGICAL TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Suturing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic suturing is considered by many surgeons to be the most difficult and tedious aspect of reconstructive surgery, and has significantly contributed to the slow adoption of these techniques. Technical skill in suturing can be obtained by the use of a laparoscopic simulation trainer. Laparoscopic suturing may be accomplished using traditional laparoscopic needle drivers and curved or straight needles that may be introduced either through trocars or directly through the skin. Several types of self-righting needle drivers are also available that will maintain curved needles in a perpendicular position, even through dense tissue, such as Cooper's ligaments which are utilized in the Burch procedure for stress incontinence. The surgeon should use enough accessory trocars to allow for both retraction of tissues and transfer of needles from one needle driver or grasper to another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Knot tying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic knot-tying techniques have been developed to ensure consistently secure knots. The most common technique is extracorporeal knot tying, in which half-hitch knots are created outside the abdomen in standard fashion, and then tightened down individually using an open or closed knot-pusher device. Intracorporeal knot tying techniques may be necessary when delicate tissues are being sutured, and tension on the sutures must be avoided. A number of automated suturing devices are also available, although these and other disposable instruments add to the increased costs of laparoscopic procedures compared to non-laparoscopic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic surgery for pelvic organ prolapse can be divided into the anterior, posterior, or apical vaginal compartments. Several procedures are usually required for any individual case since multiple defects in the pelvic floor often occur, resulting in symptomatic and clinically evident prolapse of more than one organ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anterior",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common defect leading to cystocele or anterior vaginal wall prolapse is secondary to primary apical descent resulting from a transverse defect between the pubocervical fascia and the apical vaginal support (uterosacral ligaments).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Paravaginal repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some surgeons believe repair of paravaginal defects is beneficial; however, there is no evidence supporting the superiority of anatomic outcomes with paravaginal defect repairs.",
"   </p>",
"   <p>",
"    Paravaginal repair of cystocele may be performed after gaining access to the space of Retzius, or retropubic space. Most commonly, transperitoneal laparoscopy is performed and the retropubic space is entered using sharp dissection with electrocautery or another energy source, such as the ultrasonic cutting and coagulation device (eg, Harmonic Scalpel&reg;) or carbon dioxide laser. It is helpful to backfill the bladder with 200 to 300 mL of indigo carmine-stained fluid to facilitate identification of the superior margin of the bladder and to locate and repair any defects in the bladder dome caused by the dissection.",
"   </p>",
"   <p>",
"    After Cooper's ligaments are identified, the bladder should be drained to allow blunt dissection and exposure of the paravaginal fascia. Paravaginal repair involves placing a series of interrupted permanent sutures between the arcus tendineus fascia pelvis (ATFP) and the detached pubocervical fascia, starting near the ischial spine and working distally towards the pubic bone&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/8\">",
"     8",
"    </a>",
"    ]. As with open procedures, care must be taken to avoid the obturator neurovascular bundle, which enters the obturator canal 3 to 4 cm anterior to the ischial spine. With one hand in the vagina, the surgeon elevates the endopelvic fascia and takes a full-thickness bite of tissue with a curved taper needle, while attempting to exclude the vaginal epithelium itself. The surgical assistant should gently retract the bladder medially with an atraumatic grasper or suction-irrigator device. If a laparoscopic Burch procedure is performed for stress incontinence, the final paravaginal sutures are placed at the bladder neck [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/9\">",
"     9",
"    </a>",
"    ], whereas if no Burch procedure is performed, the paravaginal repair is continued up to the insertion of the ATFP on the posterior-inferior surface of the pubis.",
"   </p>",
"   <p>",
"    There are no studies documenting equivalence of open abdominal versus laparoscopic paravaginal repair. One series of 73 consecutive women treated laparoscopically for symptomatic genital prolapse included 32 women who had a standard laparoscopic paravaginal repair, five with a modified paravaginal repair in which a third bite was placed in the iliopectineal ligament (nonanatomic elevation was avoided), and 17 who underwent transvaginal anterior colporrhaphy for midline defects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/10\">",
"     10",
"    </a>",
"    ]. The objective success rate was 87.5 percent, with a mean follow-up of 8 months (range 0 to 26 months). Objective cure was defined as POPQ stage zero or one (ie, the most distal level of the prolapse was above the hymen). In a retrospective series of 125 consecutive patients undergoing laparoscopic paravaginal repair (along with concomitant pelvic reconstructive and stress incontinence procedures), the objective success rate for the anterior compartment was 85 percent at a mean follow-up of 11 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Uterine prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;While hysterectomy is the traditional procedure for uterine prolapse, uterine suspension should be considered as an option for women who either are considering future childbearing or who would prefer to avoid hysterectomy for other reasons. Cure rates for utero-vaginal prolapse are based on hysterectomy plus a prolapse repair; however, there is little evidence that hysterectomy improves the outcome of either incontinence or prolapse surgery and may, in fact, predispose to future prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Likewise, there is no evidence that prolapse repairs that preserve the uterus have cure rates equal to or superior to prolapse repairs that include hysterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Uterosacral ligament uterine suspension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate degrees of uterine prolapse may be approached with uterosacral ligament uterine suspension. Although techniques such as round ligament suspension were used with only modest success in the past, a more anatomic approach using the uterosacral ligaments could be more successful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While no randomized-controlled trials have evaluated laparoscopic uterosacral ligament plication, uncontrolled case series have suggested the procedure may improve uterine prolapse. Further studies are necessary to confirm these reports [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedure is performed based on the site-specific theory of pelvic floor defects. The surgeon identifies the proximal portion of the uterosacral ligament at the level of the ischial spine and uses permanent sutures to bind it to the distal aspect of the ligament, near its insertion into the lower uterine segment and cervix (",
"    <a class=\"graphic graphic_figure graphicRef52304 \" href=\"UTD.htm?12/33/12818\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/15\">",
"     15",
"    </a>",
"    ]. This reapproximation of the avulsed or attenuated ligament restores Level I support (",
"    <a class=\"graphic graphic_figure graphicRef60888 \" href=\"UTD.htm?42/61/43987\">",
"     figure 2",
"    </a>",
"    ) of the proximal vagina in a horizontal position over the levator plate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/19\">",
"     19",
"    </a>",
"    ]. The use of a uterine manipulator may assist with identification of the uterosacral ligaments by deflecting the uterus sharply to the contralateral side. Displacement and retraction of the bowel from the posterior cul-de-sac is best accomplished with a laparoscopic fan retractor.",
"   </p>",
"   <p>",
"    The pelvic ureter must be identified before placing sutures in the uterosacral ligament. If needed, a releasing incision may be made in the peritoneum just lateral to the ligament (and medial to the ureter) to prevent kinking of the ureter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Sacrocervicopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical role of sacrocervicopexy is not known. It is an alternative procedure for uterine suspension that involves suturing the posterior vagina and cervix to the sacrum using an intervening graft, which may be either synthetic (eg, polypropylene, polyester) or biologic (eg, fascia, dermis) (",
"    <a class=\"graphic graphic_figure graphicRef68338 \" href=\"UTD.htm?38/5/38994\">",
"     figure 3",
"    </a>",
"    ). In one retrospective series, 40 women who underwent laparoscopic sacrocervicopexy were followed postoperatively with the standardized pelvic organ prolapse quantitation system evaluations. There was a significant improvement from baseline in Point C (location of the cervix in relation to the hymenal ring) in those patients who were examined at 12 months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/20\">",
"     20",
"    </a>",
"    ]. This procedure may be appropriate for specific patient populations (eg, young women with Stage III or IV uterovaginal prolapse) or may be considered intraoperatively when the surgeon cannot identify any substantial uterosacral ligament for suspension.",
"   </p>",
"   <p>",
"    Some surgeons recommend supracervical hysterectomy when the patient is found to have significant anterior wall prolapse due to a transverse apical defect. By removing the uterine fundus, the surgeon has the option of using a \"Y-shaped\" mesh, in which one mesh segment is attached to the posterior rectovaginal fascia while another mesh segment extends over the cervix and may be used to support the anterior pubocervical fascia.",
"   </p>",
"   <p>",
"    To perform this procedure with uterine conservation, the peritoneum and rectum are dissected off of the posterior vaginal wall, followed by placement of a series of sutures in the rectovaginal fascia, distal uterosacral ligaments, and cervix. We use a solid plastic rectal probe or and end-to-end anastomotic sizer to help identify and avoid injury to the rectum during dissection in the rectovaginal space. After the ureter and common iliac and middle sacral vessels are identified within the presacral space, the peritoneum is opened over the sacral promontory and dissection is carried down until the anterior longitudinal ligament of the sacrum is exposed. The peritoneal incision is continued inferiorly, medial to the right uterosacral ligament and lateral to the rectum, until it meets the peritoneal incision over the posterior vaginal wall. The graft is then sutured, without tension, to the sacrum with several permanent sutures and buried underneath the peritoneum to prevent internal bowel hernias and intestinal obstruction (",
"    <a class=\"graphic graphic_picture graphicRef55086 \" href=\"UTD.htm?0/52/836\">",
"     picture 1",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef76020 \" href=\"UTD.htm?38/44/39618\">",
"     picture 2",
"    </a>",
"    ). Alternatively, some surgeons have used titanium coils [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/3\">",
"     3",
"    </a>",
"    ] or stainless steel tacks for affixing the graft to the sacrum [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vaginal vault prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal vault prolapse (",
"    <a class=\"graphic graphic_picture graphicRef70607 \" href=\"UTD.htm?19/54/20320\">",
"     picture 3",
"    </a>",
"    ) may occur after any hysterectomy, although it appears to occur more frequently in women whose hysterectomy was performed for prolapse, perhaps because the vaginal apex is insufficiently suspended following hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/21\">",
"     21",
"    </a>",
"    ]. A variety of procedures are available for treatment of vault prolapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\"",
"    </a>",
"    .) The two most common laparoscopic techniques are:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Uterosacral ligament vault suspension",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure is similar to the one described above using the uterosacral ligaments for uterine prolapse. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Uterosacral ligament uterine suspension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no studies documenting the comparative efficacy of the laparoscopic route to the vaginal approach. When compared to vaginal hysterectomy with vaginal vault suspension, laparoscopic uterosacral ligament uterine suspension was associated with better support and fewer recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main difference between vaginal vault and uterine prolapse repair is that in vault suspension it is important to include both the pubocervical and rectovaginal fascia to prevent development of post-operative enterocele, which may result from bowel dissecting between these two fascial layers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/22\">",
"     22",
"    </a>",
"    ]. Therefore, dissection of the bladder off the anterior vaginal wall (and underlying fascia) is performed and permanent or delayed-absorbable sutures are used to unite the anterior and posterior fascia before anchoring the vaginal apex to the proximal uterosacral ligaments (",
"    <a class=\"graphic graphic_figure graphicRef50966 \" href=\"UTD.htm?27/47/28401\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sacrocolpopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic sacrocolpopexy is an option when POP-Q stage II to IV vault prolapse is present. In these patients, it is often difficult to identify any useful remnants of the uterosacral ligaments for suspension.",
"   </p>",
"   <p>",
"    Large trials comparing the traditional abdominal technique with the laparoscopic technique have not been published. In small nonrandomized studies, objective cure rates for the laparoscopic approach procedure of 93 to 100 percent have been reported at six months to five years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. In one retrospective cohort study, the laparoscopic approach to sacrocolpopexy demonstrated longer operating times, but decreased hospital stay, compared with open sacrocolpopexy. There were no differences in reoperation for recurrent prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/27\">",
"     27",
"    </a>",
"    ]. In another comparative retrospective study, the laparoscopic approach was associated with decreased intraoperative blood loss and length of stay, although operating times were once again longer compared with open surgery. The failure rates, however, were not significantly different between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of this laparoscopic procedure, like the others mentioned above, is to duplicate the steps performed in the open procedure, as closely as possible, so that the results reported with the traditional surgery may be reproduced with minimally-invasive techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/22\">",
"     22",
"    </a>",
"    ]. A retrospective chart review of 56 patients compared the outcome of laparoscopic versus abdominal sacrocolpopexy. Surgical time was significantly increased in the laparoscopic group; blood loss was decreased. Rates of perioperative complications and subsequent procedures for pelvic floor defects were similar between the two approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To perform laparoscopic sacrocolpopexy, after the bladder and rectum are dissected off the anterior and posterior vaginal walls, respectively, a Y-shaped synthetic graft is sutured to the anterior and posterior endopelvic fascia with a series of permanent sutures (",
"    <a class=\"graphic graphic_figure graphicRef66883 \" href=\"UTD.htm?11/54/12130\">",
"     figure 5",
"    </a>",
"    ). The graft is fixed to the anterior longitudinal ligament of the sacral promontory (",
"    <a class=\"graphic graphic_picture graphicRef79388 \" href=\"UTD.htm?1/57/1943\">",
"     picture 4",
"    </a>",
"    ), after dissection is performed in the presacral space as described for sacrocervicopexy (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Sacrocervicopexy'",
"    </a>",
"    above). The procedure is typically completed by burying the graft under the peritoneum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Enterocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterocele refers to herniation of bowel and the lining of the peritoneal cavity through the cul-de-sac of Douglas, without an intervening fascial layer (",
"    <a class=\"graphic graphic_figure graphicRef57126 \" href=\"UTD.htm?29/41/30367\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/29\">",
"     29",
"    </a>",
"    ]. This most often occurs at the vaginal apex after hysterectomy, due to either a failure to properly reapproximate the anterior and posterior endopelvic fascia or breakdown of this repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic steps of laparoscopic enterocele repair are dissection of the bladder and bowel off the vaginal wall and endopelvic fascia, reapproximation of the anterior and posterior fascia, and support of the angles of the vagina by attachment apically to the uterosacral ligaments [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/30\">",
"     30",
"    </a>",
"    ]. Standard sacrocolpopexy technique does not require additional enterocele repair. Some authors recommend resection of the enterocele sac (redundant vaginal epithelium) whereas others simply plicate fascia over the redundant tissue. The use of a solid vaginal probe or EEA sizer (US Surgical Corporation, Norwalk, CT) may help delineate the enterocele sac and position of the vagina relative to the adjacent organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rectocele (Posterior vaginal wall repair)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the ease of access via the vaginal route, there is no role for laparoscopic rectocele repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4857?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and nonsurgical management of posterior vaginal defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44424?source=see_link\">",
"     \"Surgical management of posterior vaginal defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Levator ani muscle plication repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pelvic surgeons no longer recommend levator plication, due to the risk of post-operative dyspareunia. This is not recommended as part of a laparoscopic reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ROBOTIC SACROCOLPOPEXY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned earlier, the introduction of robotic surgery to gynecologists has fueled a renewed interest in minimally invasive sacrocolpopexy and other procedures for prolapse that require endoscopic suturing. A number of small series have been published that appear to demonstrate the feasibility and short-term success rate of this approach to sacrocolpopexy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. There have been no prospective, randomized trials published comparing open to robotic sacrocolpopexy for vaginal vault prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the complications associated with any laparoscopy or the prolapse repair itself, there are no complications that are specific to the laparoscopic approach to pelvic organ prolapse. Vascular and bowel injuries are the most common complications encountered during access in any laparoscopic procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=see_link\">",
"     \"Complications of gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional potential complications that should be considered in this patient population include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Urinary tract injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the bladder and ureters occurs more frequently in laparoscopic reconstruction procedures than in general gynecologic laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/34\">",
"     34",
"    </a>",
"    ]. Due to these risks, intraoperative cystoscopy should be a routine part of these procedures, and management of these problems, including urologic consultation, should take place immediately to prevent fistula formation or renal damage from obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=see_link\">",
"     \"Diagnostic cystourethroscopy for gynecologic conditions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Urinary retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more commonly associated with suburethral sling procedures, any antiincontinence surgery (including Burch colposuspension) or vault suspension procedure may result in voiding dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urinary retention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Continuous bladder drainage or intermittent self catheterization may be used until normal voiding returns, as determined by a standard voiding trial with measurement of residual volumes. We recommend instilling 300 mL of saline into the bladder on the first post-operative day before catheter removal. The patient is then instructed to void and the volume is measured. The voiding trial is considered successful if the patient is able to void greater than 75 percent of the total volume instilled.",
"   </p>",
"   <p>",
"    Women who do not meet the voiding trial criteria described above are discharged home with catheter drainage and follow-up care is arranged within a few days. Prophylactic oral antibiotics, (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    100 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    100 mg at bedtime) are given to reduce the risk of lower urinary tract infections for the duration of catheter use. Permanent urinary retention, requiring surgical urethrolysis, is rare in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link&amp;anchor=H22#H22\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\", section on 'Neurogenic bladder dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing laparoscopic pelvic floor reconstruction are usually discharged on the same day or the day after surgery. A prescription for oral analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ) is given and stool softeners are recommended until normal bowel habits resume.",
"   </p>",
"   <p>",
"    We suggest that the patient refrain from heavy lifting for eight weeks postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25976/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. We recommend that patients refrain from intercourse for six weeks. Driving is permitted as soon as the patient is feeling well and is no longer taking oral opiates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laparoscopic pelvic reconstructive surgery is believed to reproduce the anatomic outcomes of open abdominal reconstructive surgery. The laparoscopic approach may offer better visibility of the pelvis than an abdominal or vaginal approach. Additional benefits of laparoscopic pelvic reconstructive surgery include potential for reduced postoperative pain and length of hospital stay and faster return to normal activities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful preoperative assessment of the defects responsible for an individual patient's prolapse is necessary to achieve a comprehensive and site-specific surgical repair and to determine the optimal surgical approach. It is particularly important to consider continence status in order to minimize de novo stress incontinence following surgery. In addition, the surgeon should consider the individual's risk from laparoscopic surgery, including previous pelvic surgery, adhesions, and her overall medical condition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preoperative considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic uterine suspension procedures (eg, uterosacral ligament uterine suspension or sacrocervicopexy) may be considered when there is Stage II to III prolapse (POP-Q classification), as an alternative to hysterectomy. The surgeon may wish to consider uterosacral ligament uterine suspension if intraoperative evaluation demonstrates adequate integrity of the uterosacral ligaments, and reserve the more complicated sacrocervicopexy for patients with attenuated uterosacral ligaments, or for those with more advanced prolapse who desire uterine preservation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Uterine prolapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal vault prolapse can be repaired laparoscopically by uterosacral ligament vault suspension or sacrocolpopexy with synthetic mesh (polypropylene or polyester). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Vaginal vault prolapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enterocele most often occurs at the vaginal apex after hysterectomy, due to either a failure to properly reapproximate the anterior and posterior endopelvic fascia or breakdown of this repair. Laparoscopic enterocele repair consists of dissection of the bladder and bowel off the vaginal wall and endopelvic fascia, reapproximation of the anterior and posterior fascia, and support of the angles of the vagina to the proximal uterosacral ligaments. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Enterocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most rectoceles can be treated via a vaginal approach by site-specific repairs. Laparoscopic repair has been described as an alternative approach, but may not provide any advantage over traditional vaginal repair.",
"     </li>",
"     <li>",
"      Vascular and bowel injuries are the most common complications encountered during access in any laparoscopic procedure. Injury to the urinary tract is an additional complication of procedures for repair of pelvic floor defects. Intraoperative cystoscopy should be a routine part of this surgery, and management of urinary tract injury, including urologic consultation, should take place immediately to prevent fistula formation or renal damage from obstruction. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary retention may occur postoperatively. Women who experience this may be discharged home with catheter drainage and follow-up care with a repeat voiding trial is arranged within a few days. Prophylactic oral antibiotics, (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      100 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      100 mg at bedtime) are given to reduce the risk of lower urinary tract infections for the duration of catheter use. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Urinary retention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the patient refrain from heavy lifting for eight weeks postoperatively. We recommend that patients refrain from intercourse for six weeks. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Postoperative care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/1\">",
"      Benson JT, Lucente V, McClellan E. Vaginal versus abdominal reconstructive surgery for the treatment of pelvic support defects: a prospective randomized study with long-term outcome evaluation. Am J Obstet Gynecol 1996; 175:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/2\">",
"      Maher C, Baessler K, Glazener CM, et al. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev 2004; :CD004014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/3\">",
"      Paraiso MF, Falcone T, Walters MD. Laparoscopic surgery for enterocele, vaginal apex prolapse and rectocele. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/4\">",
"      Lo, TS, Wang, AC. Abdominal colposacropexy and sacrospinous ligament suspension for severe uterovaginal prolapse: a comparison. J Gynecol Surg 1998; 14:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/5\">",
"      Mueller ER, Kenton K, Mahajan S, et al. Urodynamic prolapse reduction alters urethral pressure but not filling or pressure flow parameters. J Urol 2007; 177:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/6\">",
"      Richardson DA, Bent AE, Ostergard DR. The effect of uterovaginal prolapse on urethrovesical pressure dynamics. Am J Obstet Gynecol 1983; 146:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/7\">",
"      Kohli N, Jacobs PA, Sze EH, et al. Open compared with laparoscopic approach to Burch colposuspension: a cost analysis. Obstet Gynecol 1997; 90:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/8\">",
"      Richardson AC, Lyon JB, Williams NL. A new look at pelvic relaxation. Am J Obstet Gynecol 1976; 126:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/9\">",
"      Miklos JR, Kohli N. Laparoscopic paravaginal repair plus burch colposuspension: review and descriptive technique. Urology 2000; 56:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/10\">",
"      Seman EI, Cook JR, O'Shea RT. Two-year experience with laparoscopic pelvic floor repair. J Am Assoc Gynecol Laparosc 2003; 10:38.",
"     </a>",
"    </li>",
"    <li>",
"     Pulliam, S, Chelmow, D, Weld, A, Rosenblatt, P. Laparoscopic Paravaginal Repair: A Case Series 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/12\">",
"      Petros P. Influence of hysterectomy on pelvic-floor dysfunction. Lancet 2000; 356:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/13\">",
"      Kjerulff KH, Langenberg PW, Greenaway L, et al. Urinary incontinence and hysterectomy in a large prospective cohort study in American women. J Urol 2002; 167:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/14\">",
"      O'Brien PM, Ibrahim J. Failure of laparoscopic uterine suspension to provide a lasting cure for uterovaginal prolapse. Br J Obstet Gynaecol 1994; 101:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/15\">",
"      Lin LL, Phelps JY, Liu CY. Laparoscopic vaginal vault suspension using uterosacral ligaments: a review of 133 cases. J Minim Invasive Gynecol 2005; 12:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/16\">",
"      Schwartz M, Abbott KR, Glazerman L, et al. Positive symptom improvement with laparoscopic uterosacral ligament repair for uterine or vaginal vault prolapse: interim results from an active multicenter trial. J Minim Invasive Gynecol 2007; 14:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/17\">",
"      Yen CF, Wang CJ, Lin SL, et al. Combined laparoscopic uterosacral and round ligament procedures for treatment of symptomatic uterine retroversion and mild uterine decensus. J Am Assoc Gynecol Laparosc 2002; 9:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/18\">",
"      Diwan A, Rardin CR, Strohsnitter WC, et al. Laparoscopic uterosacral ligament uterine suspension compared with vaginal hysterectomy with vaginal vault suspension for uterovaginal prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/19\">",
"      DeLancey JO. Anatomic aspects of vaginal eversion after hysterectomy. Am J Obstet Gynecol 1992; 166:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/20\">",
"      Rosenblatt PL, Chelmow D, Ferzandi TR. Laparoscopic sacrocervicopexy for the treatment of uterine prolapse: a retrospective case series report. J Minim Invasive Gynecol 2008; 15:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/21\">",
"      Marchionni M, Bracco GL, Checcucci V, et al. True incidence of vaginal vault prolapse. Thirteen years of experience. J Reprod Med 1999; 44:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/22\">",
"      Miklos JR, Kohli N, Lucente V, Saye WB. Site-specific fascial defects in the diagnosis and surgical management of enterocele. Am J Obstet Gynecol 1998; 179:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/23\">",
"      Nezhat CH, Nezhat F, Nezhat C. Laparoscopic sacral colpopexy for vaginal vault prolapse. Obstet Gynecol 1994; 84:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/24\">",
"      Agarwala N, Hasiak N, Shade M. Laparoscopic sacral colpopexy with Gynemesh as graft material--experience and results. J Minim Invasive Gynecol 2007; 14:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/25\">",
"      Higgs PJ, Chua HL, Smith AR. Long term review of laparoscopic sacrocolpopexy. BJOG 2005; 112:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/26\">",
"      Ross JW, Preston M. Laparoscopic sacrocolpopexy for severe vaginal vault prolapse: five-year outcome. J Minim Invasive Gynecol 2005; 12:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/27\">",
"      Paraiso MF, Walters MD, Rackley RR, et al. Laparoscopic and abdominal sacral colpopexies: a comparative cohort study. Am J Obstet Gynecol 2005; 192:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/28\">",
"      Hsiao KC, Latchamsetty K, Govier FE, et al. Comparison of laparoscopic and abdominal sacrocolpopexy for the treatment of vaginal vault prolapse. J Endourol 2007; 21:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/29\">",
"      Richardson, AC. The anatomic defects in rectocele and enterocele. J Pelv Surg 1995; 1:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/30\">",
"      Ross JW. Apical vault repair, the cornerstone or pelvic vault reconstruction. Int Urogynecol J Pelvic Floor Dysfunct 1997; 8:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/31\">",
"      Elliott DS, Krambeck AE, Chow GK. Long-term results of robotic assisted laparoscopic sacrocolpopexy for the treatment of high grade vaginal vault prolapse. J Urol 2006; 176:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/32\">",
"      Daneshgari F, Kefer JC, Moore C, Kaouk J. Robotic abdominal sacrocolpopexy/sacrouteropexy repair of advanced female pelvic organ prolaspe (POP): utilizing POP-quantification-based staging and outcomes. BJU Int 2007; 100:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/33\">",
"      Akl MN, Long JB, Giles DL, et al. Robotic-assisted sacrocolpopexy: technique and learning curve. Surg Endosc 2009; 23:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/34\">",
"      Ferland RD, Rosenblatt P. Ureteral compromise after laparoscopic Burch colpopexy. J Am Assoc Gynecol Laparosc 1999; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/35\">",
"      Nguyen JK. Diagnosis and treatment of voiding dysfunction caused by urethral obstruction after anti-incontinence surgery. Obstet Gynecol Surv 2002; 57:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/36\">",
"      Nguyen JK. Current concepts in the diagnosis and surgical repair of anterior vaginal prolapse due to paravaginal defects. Obstet Gynecol Surv 2001; 56:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/37\">",
"      Gerten KA, Richter HE, Wheeler TL 2nd, et al. Intraabdominal pressure changes associated with lifting: implications for postoperative activity restrictions. Am J Obstet Gynecol 2008; 198:306.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25976/abstract/38\">",
"      Weir LF, Nygaard IE, Wilken J, et al. Postoperative activity restrictions: any evidence? Obstet Gynecol 2006; 107:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8082 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25976=[""].join("\n");
var outline_f25_23_25976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Choice of surgical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BASIC SURGICAL TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Suturing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Knot tying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Paravaginal repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Uterine prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Uterosacral ligament uterine suspension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Sacrocervicopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vaginal vault prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Uterosacral ligament vault suspension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sacrocolpopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Enterocele",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rectocele (Posterior vaginal wall repair)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Levator ani muscle plication repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ROBOTIC SACROCOLPOPEXY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Urinary tract injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8082|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/33/12818\" title=\"figure 1\">",
"      Uterosacral ligament suspension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/61/43987\" title=\"figure 2\">",
"      DeLancey levels pelvic support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/5/38994\" title=\"figure 3\">",
"      Sacrocervicopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/47/28401\" title=\"figure 4\">",
"      Uterosacral vault suspension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/54/12130\" title=\"figure 5\">",
"      Sacrocolpopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/41/30367\" title=\"figure 6\">",
"      Enterocele and rectocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8082|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/52/836\" title=\"picture 1\">",
"      Sacrocervicopexy intraop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/44/39618\" title=\"picture 2\">",
"      Sacrocervicopexy complete",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/54/20320\" title=\"picture 3\">",
"      Complete vaginal vault prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/57/1943\" title=\"picture 4\">",
"      Sacrocolpopex sacral suture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4857?source=related_link\">",
"      Clinical manifestations, diagnosis, and nonsurgical management of posterior vaginal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=related_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=related_link\">",
"      Diagnostic cystourethroscopy for gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=related_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=related_link\">",
"      Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=related_link\">",
"      Robot-assisted laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17319?source=related_link\">",
"      Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44424?source=related_link\">",
"      Surgical management of posterior vaginal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32120?source=related_link\">",
"      Urodynamic evaluation of women with incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_23_25977="Neuraxial analgesia and anesthesia for labor and delivery: Drugs";
var content_f25_23_25977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuraxial analgesia and anesthesia for labor and delivery: Drugs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25977/contributors\">",
"     Gilbert J Grant, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25977/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25977/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/23/25977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural and spinal (intrathecal) techniques are the most effective means of providing pain relief for labor, which can be the most severe pain that a woman experiences during her lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/1\">",
"     1",
"    </a>",
"    ]. The epidural and spinal approaches are known as regional techniques because pain relief is limited to a specific anatomical region. These modalities are also known as neuraxial techniques, since both approaches involve administration of drugs that exert their effect in the axial portion of the central nervous system.",
"   </p>",
"   <p>",
"    In the context of obstetric pain relief, the term \"regional analgesia\" refers to the inhibition of labor pain, whereas the term \"regional anesthesia\" implies the use of a greater concentration of local anesthetic, which results in more intense ablation of all sensation and is used to facilitate instrumental or cesarean delivery. However, the two terms are sometimes used interchangeably and there is considerable overlap between them. As an example, in some patients epidural analgesia may provide sufficient pain relief for instrumental delivery, obviating the need for more potent anesthesia.",
"   </p>",
"   <p>",
"    The drugs used for these procedures will be reviewed here. Neuraxial techniques, the prevention and treatment of adverse effects of neuraxial analgesia and anesthesia techniques, and an overview of labor pain and its management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37574?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Options\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=see_link\">",
"     \"Pharmacologic management of pain during labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE \"GOLD STANDARD\" FOR LABOR ANALGESIA AND ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional techniques (epidural, spinal) provide unparalleled pain relief in labor with a minimum of maternal and neonatal side effects. These techniques differ from systemic techniques in that the drugs are administered into a specific region, the lower neuraxis, to interrupt pain pathways, thereby producing pain relief. Relatively small doses are needed because the agents exert their effects locally, thus systemic drug concentrations are low. The analgesics may be administered via epidural, spinal, or a combination of both routes. Epidural and spinal utilization rates are greater in hospitals where a large number of deliveries occur and where anesthesiologists or nurse anesthetists are readily available as skilled personnel are required to perform these techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Drugs used for epidural and spinal techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various classes of analgesics used for epidural and spinal block include local anesthetics, opioids, adrenergic agonists, and cholinergic agonists. Local anesthetics inhibit neural conduction by reversibly blocking axonal sodium channels. Opioids exert their effect by reversibly binding to opioid receptors in the dorsal horn of the spinal cord. Alpha-2 adrenergic agents interact with alpha-2 adrenergic receptors in the spinal cord, and cholinergic agonists produce analgesia by increasing the concentration of acetylcholine proximate to muscarinic and nicotinic receptors in the superficial layers of the dorsal horn of the spinal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Differences between epidural and spinal routes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are distinct differences between the epidural and spinal routes of administration. Except for local anesthetics, which inhibit nerve conduction in both the epidural and intrathecal space, all other neuraxial analgesics exert their effect primarily by interaction with structures within the spinal cord. Analgesics administered into the epidural space must first diffuse through the dura to gain access to the intrathecal space. Therefore, the onset of action is delayed with the epidural approach compared to the spinal approach, in which the dura is penetrated with a needle and drugs are deposited directly into the cerebrospinal fluid (CSF). Moreover, only a fraction of the injected dose crosses the dura into the CSF because much of the drug given via the epidural route is absorbed via the epidural veins and distributed systemically. A much lower dose is used for the intrathecal route, and the risk of systemic drug toxicity is nearly eliminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LOCAL ANESTHETICS USED FOR NEURAXIAL TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics used for neuraxial techniques during labor and delivery include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    , procaine, 2-chloroprocaine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"     tetracaine",
"    </a>",
"    . Each local anesthetic has distinct properties that confer clinical advantages for particular situations (",
"    <a class=\"graphic graphic_table graphicRef71605 \" href=\"UTD.htm?2/25/2460\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bupivacaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     Bupivacaine",
"    </a>",
"    is an amide-linked local anesthetic. A characteristic of bupivacaine that has made it a popular choice for labor analgesia is its favorable sensory-motor block differential at low concentrations; it produces analgesia with motor sparing, thus enabling ambulation. Although the basis for this differential block is not well understood, it is a highly desirable effect and accounts for its widespread use as a component of labor epidural techniques.",
"   </p>",
"   <p>",
"    Relatively high concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    were formerly administered in the epidural space for labor and cesarean delivery (0.25 to 0.75 percent). For laboring patients, these doses resulted in motor block and, more ominously, the 0.75 percent concentration was implicated in multiple cases of cardiac arrest in parturients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, in 1984 the Food and Drug Administration (FDA) recommended that bupivacaine in concentrations greater than 0.5 percent not be used in obstetric patients. However, a large volume of 0.5 percent bupivacaine may also be cardiotoxic because toxicity is a function of the total dose administered.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     Bupivacaine",
"    </a>",
"    cardiotoxicity is particularly difficult to reverse. A reasonable approach to treat arrhythmia and cardiovascular collapse in this circumstance is to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and epinephrine, respectively, and to immediately initiate lipid rescue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .) An intravenous bolus of 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    lean body mass of 20 percent lipid emulsion is given over one minute, followed by an infusion of 0.25",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    until at least 10 minutes following successful achievement of circulatory stability. If circulatory stability is not obtained within 5 minutes, a second 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    bolus may be administered, followed by an infusion of 0.5",
"    <span class=\"nowrap\">",
"     mL/kg/min.",
"    </span>",
"    Emergency cardiopulmonary bypass may be a life-saving intervention by providing temporary cardiac support while bupivacaine dissociates from the cardiac tissue, but there are considerable practical impediments to initiating this therapy.",
"   </p>",
"   <p>",
"    Current labor epidural analgesia regimens employ much lower concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , usually less than or equal to 0.25 percent, and often less than or equal to 0.125 percent. The use of low concentrations of bupivacaine by the epidural route reduces the likelihood of systemic toxicity (eg, cardiac dysrhythmias, seizures). The likelihood of bupivacaine-induced cardiotoxicity can be essentially eliminated by using the spinal route, as this route requires a relatively low drug dose compared to the epidural route.",
"   </p>",
"   <p>",
"    Low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    has a relatively slow onset of analgesic action and a gradual onset of sympathetic block, which may limit the incidence and severity of hypotension. As an example, a solution containing 0.06 percent concentration of bupivacaine combined with an opioid will begin to provide epidural analgesia 5 to 10 minutes after injection, and maximum effect may not be achieved for 15 to 20 minutes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37574?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Options\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     Bupivacaine",
"    </a>",
"    may also be administered via the intrathecal route. The dose for spinal labor analgesia is 1.0 to 2.5 mg, as an isobaric solution. At these relatively low doses, the motor-sensory differential is apparent. It is thus an appropriate choice to provide profound analgesia while preserving the ability to push effectively during the second stage of labor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     Bupivacaine",
"    </a>",
"    (10 to 15 mg) administered intrathecally is a popular anesthetic choice for cesarean delivery. Many clinicians add an opioid such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    20 mcg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    5 mcg to enhance the quality of the spinal block, and to reduce the dose of bupivacaine needed. Bupivacaine is associated with a much lower incidence of transient neurological symptoms (TNS) than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    is an amide-linked local anesthetic that was formerly used extensively by the epidural route to provide labor analgesia. Lidocaine is infrequently used today as the primary agent to provide epidural labor analgesia, as most practitioners now prefer agents with a sensory-motor differential (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Five percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    in dextrose (hyperbaric solution) injected intrathecally was a popular means of achieving rapid-onset spinal block for instrumental vaginal delivery. When injected in a parturient in the sitting position, the hyperbaric solution spreads within the cerebrospinal fluid (CSF) to its most dependent portion, effectively blocking conduction in the sacral nerves that mediate pain of the second stage of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Local anesthetic neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    has been used for spinal anesthesia since 1948, and hyperbaric lidocaine since 1954, during the 1990s there were numerous reports of neurotoxic effects of intrathecal lidocaine in non-obstetric patients. The neurotoxic effects were manifested as either transient neurological symptoms (TNS) or the more serious cauda equina syndrome. TNS is pain or dysesthesia in the buttocks or legs that persists for up to five days after intrathecal local anesthetic administration. The precise incidence of TNS is unknown, but it has been estimated to be 1 in 1300 non-obstetric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/3\">",
"     3",
"    </a>",
"    ]. In obstetric patients, TNS are either not seen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] or only infrequently observed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis found that in non-pregnant patients, the incidence of TNS was seven times more likely following spinal administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    than following spinal administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    or procaine, and similar to the incidence seen after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/55/40821?source=see_link\">",
"     mepivacaine",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/7\">",
"     7",
"    </a>",
"    ]. A prospective study of TNS associated with spinal mepivacaine in non-pregnant patients reported a relatively low incidence (6.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/8\">",
"     8",
"    </a>",
"    ]. Although this study did not include a group receiving lidocaine, the 6.4 percent incidence of TNS compares favorably to the approximately 14 percent incidence reported in studies of spinal lidocaine, although it is still considerably greater than the overall 1 percent incidence of TNS reported following spinal bupivacaine.",
"   </p>",
"   <p>",
"    A more ominous concern is the association of intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with cauda equina syndrome. This devastating neurologic complication occurred in patients in whom hyperbaric lidocaine was administered via intrathecal catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The neurologic injury was attributed to exposure of sacral nerve roots to a high concentration of lidocaine as it emerged from the intrathecal catheter without adequate mixing with the CSF. In response to these reports, in 1992, the FDA prohibited the use of intrathecal catheters. Despite this, cauda equina syndrome has been reported to occur after single shot administration of hyperbaric spinal lidocaine via a needle [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accumulated toxicity experience has led some to question continued intrathecal use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/12\">",
"     12",
"    </a>",
"    ]. As a result of these concerns, many practitioners have abandoned the use of intrathecal lidocaine in favor of arguably safer alternatives.",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    by the epidural route remains popular in obstetric patients, particularly to provide epidural anesthesia for cesarean delivery. Two percent lidocaine with epinephrine is typically used for this purpose. Lidocaine with epinephrine is also used as a test dose to confirm proper positioning of the epidural catheter (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ropivacaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     Ropivacaine",
"    </a>",
"    is an amide local anesthetic that is a homolog of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    . Unlike bupivacaine and all other local anesthetics that are racemic mixtures, ropivacaine consists of only the s stereoisomer, which is less cardiotoxic than the r enantiomer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/13\">",
"     13",
"    </a>",
"    ]. Although several studies have shown that ropivacaine is less cardiotoxic and results in greater motor sparing than bupivacaine, most studies compared equimolar concentrations of the two drugs. Since ropivacaine is only 60 percent as potent as bupivacaine when administered by the epidural route in laboring patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] and only 50 percent as potent when given intrathecally to volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/16\">",
"     16",
"    </a>",
"    ], the perceived benefits of ropivacaine with regard to systemic toxicity and sensory-motor differential may be explained by differences in potency between the two agents. The issue is not completely resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/17-20\">",
"     17-20",
"    </a>",
"    ], although clinical reports to date indicate that ropivacaine is indeed more forgiving with regard to cardiotoxicity than bupivacaine.",
"   </p>",
"   <p>",
"    The first case reports of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    cardiotoxicity did not appear until 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], and there have only been a few other cases reported since then, all of which were successfully resuscitated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Although there have been no reports of fatalities due to cardiotoxicity of ropivacaine, prudence dictates that it be administered with care. As an example, whenever high concentrations are used to provide anesthesia for cesarean delivery, a test dose should be administered, and the total dose should be fractionated.",
"   </p>",
"   <p>",
"    Systemic toxicity is unlikely to occur with low-dose regional techniques used for labor analgesia, so that from a safety perspective,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    may not offer any advantages over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    in this circumstance. However, if ropivacaine's perceived safety with regard to systemic toxicity is borne out, it may be preferred in situations where high local anesthetic concentrations are required (eg, cesarean delivery).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     Ropivacaine",
"    </a>",
"    may be used instead of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    for spinal anesthesia for cesarean delivery. In one study, use of 20 mg ropivacaine plus 0.1 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    was compared to 15 mg bupivacaine plus 0.1 mg morphine. The duration of both sensory and motor blocks were significantly prolonged after bupivacaine (139",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    37 minutes and 254",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    76 minutes) than after ropivacaine (112",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    27 minutes and 211",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    48 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/26\">",
"     26",
"    </a>",
"    ]. There were no differences in intraoperative quality of anesthesia between the two groups. Although postoperative analgesia was similarly effective in both groups, median consumption of patient-controlled morphine during the first 24 hours after surgery was significantly higher in patients in the ropivacaine group (5 mg; range, 0 to 18 mg) than in patients in the bupivacaine group (2 mg; range, 0 to 7 mg).",
"   </p>",
"   <p>",
"    Although the more rapid recovery of motor function after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    is desirable, the earlier return of sensation is not necessarily beneficial for the post-cesarean patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     2-chloroprocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;2-chloroprocaine is an ester-linked local anesthetic. Unlike amide-linked local anesthetics, which undergo hepatic metabolism, esters are metabolized by plasma pseudocholinesterase, so the level of drug in the fetus is negligible and its metabolites are inactive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/27\">",
"     27",
"    </a>",
"    ]. The rapid metabolism of 2-chloroprocaine confers a safety benefit in the event of an unintentional intravascular injection. Another benefit is its rapid onset of action, starting within a few minutes following epidural injection.",
"   </p>",
"   <p>",
"    2-chloroprocaine's brief duration of action necessitates frequent dosing at 30 to 45 minute intervals. Another disadvantage is 2-chloroprocaine's apparent antagonistic effects on subsequently administered local anesthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/28\">",
"     28",
"    </a>",
"    ] and opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/29\">",
"     29",
"    </a>",
"    ] (although some of these findings have been challenged [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/30\">",
"     30",
"    </a>",
"    ]) and neurotoxicity reported after accidental intrathecal injection of older formulations of 2-chloroprocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/31\">",
"     31",
"    </a>",
"    ]. Laboratory testing revealed that this latter phenomenon may have been due to a preservative, rather than the drug itself, although this explanation has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/32\">",
"     32",
"    </a>",
"    ]; current formulations are preservative-free.",
"   </p>",
"   <p>",
"    2-chloroprocaine does not possess the motor-sensory differential characteristics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    and therefore is more likely to produce an undesirable motor block. For this reason, 2-chloroprocaine is not the preferred local anesthetic for providing labor epidural analgesia. The primary role for 2-chloroprocaine in obstetrics is in situations where it is necessary to achieve anesthesia rapidly, as an example, for an instrumental delivery, or to extend the anesthetic level rapidly to provide anesthesia for an emergency cesarean delivery. However, a study in patients undergoing elective cesarean delivery found that the median speed of onset of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    was comparable to 2-chloroprocaine (five minutes and eight minutes, respectively).",
"   </p>",
"   <p>",
"    Due to the potential for neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/31\">",
"     31",
"    </a>",
"    ], 2-chloroprocaine is no longer favored for spinal anesthesia . However, the recognition of potential neurologic side effects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    has prompted renewed interest in using 2-chloroprocaine as a substitute for intrathecal lidocaine for brief procedures. As an example, a prospective, randomized, double-blind study of non-obstetric patients found that 40 or 50 mg of 2-chloroprocaine produced 45 to 60 minutes of spinal anesthesia, and did not result in any cases of TNS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although 2-chloroprocaine is not widely used to provide spinal anesthesia for cesarean delivery, its relatively brief duration of action and rapid recovery offers advantages over the longer-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , assuming that the surgery is completed in a timely manner. Alternatively, there may be a role for 2-chloroprocaine as part of a combined spinal-epidural procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tetracaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36032?source=see_link\">",
"     Tetracaine",
"    </a>",
"    is an ester-linked local anesthetic that is not used to provide labor analgesia, but is sometimes used intrathecally for cesarean delivery. Its popularity has been diminished because of three major disadvantages: (1) prolonged duration of action (approximately 30 minutes longer than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ), resulting in prolonged postoperative lower extremity motor block, (2) tendency to produce a more profound motor than sensory block, and (3) relatively frequent anesthetic failures due to the inherent instability of ester-linked local anesthetics, failures that are highly unlikely to occur with amide-linked bupivacaine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various opioids have been injected into the epidural and intrathecal spaces to provide and enhance pain relief in parturients. As sole agents, opioids may provide analgesia for the first stage of labor and in the postpartum period. Opioids are not effective as sole agents in relieving the pain of the second stage of labor, which is more intense and involves a somatic component. The exception to this is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , which has local-anesthetic effects, as well as opioid effects. Opioids are often administered neuraxially in combination with other drugs, especially local anesthetics, to enhance pain relief. Opioid receptors are located in the dorsal horn of the spinal cord, thus opioids administered into the epidural space must first traverse the dura and penetrate the spinal cord to exert their effect. Only a fraction of the dose crosses into the intrathecal space following epidural injection because a large proportion of drug is absorbed by the epidural venous plexus. Spinal opioid administration requires a much smaller dose and the onset of action is more rapid.",
"   </p>",
"   <p>",
"    The analgesic effects and side effects differ among the various opioids due to physicochemical differences. The most important physicochemical property is lipid solubility, which influences speed of onset and duration of action. As a rule, the more lipid soluble opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    ) have a more rapid onset of action because their rapid penetration of lipid membranes allows them to quickly reach the opioid receptors in the spinal cord. However, high lipid solubility also results in a relatively short duration of action, as these drugs are readily able to traverse blood vessel walls and undergo systemic redistribution. Other physicochemical characteristics that impact the clinical profile are size and pKa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Morphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    was the first opioid administered into the neuraxis to provide labor analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/34\">",
"     34",
"    </a>",
"    ]. Morphine's poor lipid solubility confers a prolonged duration of action, as it remains in the CSF in the ionized form for many hours, exerting an analgesic effect for up to 24 hours. This attribute makes it an attractive choice for providing analgesia for the entire first stage of labor with a single dose. The prolonged analgesic action of neuraxially administered morphine is also useful for providing prolonged postoperative analgesia following cesarean delivery. However, a high incidence of bothersome side effects (nausea, vomiting, pruritus), observed even with reduced doses, has limited the widespread use of intrathecal morphine for labor analgesia. Although decreasing the dose reduces the incidence and severity of side effects, it also reduces the duration of analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fentanyl",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is a synthetic opioid that has much higher lipid solubility than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    . This property speeds its onset of action, so that analgesia occurs 5 to 10 minutes after epidural administration and less than five minutes after intrathecal injection. However, increased lipid solubility also accounts for a brief duration of action; it is rapidly redistributed from the site of injection due to its systemic absorption. A typical epidural dose is 100 mcg, but even larger doses of 150 to 200 mcg result in a maximum of only 1.5 hours of analgesia.",
"   </p>",
"   <p>",
"    For intrathecal administration, one trial found an analgesic ceiling effect at 25 mcg with 14 mcg the effective dose yielding pain relief in 50 percent of women (ie, ED50) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/35\">",
"     35",
"    </a>",
"    ]. In another study, the ED50 was found to be 18.2 mcg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/36\">",
"     36",
"    </a>",
"    ]. The duration of action following intrathecal administration is approximately 1.5 hours. For labor analgesia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    is often combined with a local anesthetic, typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    1.0 to 2.5 mg. A distinct advantage of a lipid soluble opioid, such as fentanyl, is that spread within the neuraxis is limited in comparison to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , and therefore side effects are less common and often less severe. Fentanyl (2 to 4",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    is often added to a low-dose local epidural anesthetic solution to potentiate the analgesic effect. It is also used intrathecally as the sole analgesic for the first stage of labor, and in combination with an intrathecal local anesthetic to provide analgesia for the second stage of labor. Pruritus is the most common side effect of fentanyl and its congener,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sufentanil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     Sufentanil",
"    </a>",
"    is a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    congener of greater potency and lipid solubility than the parent compound. It is most commonly used to provide labor analgesia alone or in combination with local anesthetics by the intrathecal route, although it has also been used as a sole agent for labor analgesia by the epidural route [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/37\">",
"     37",
"    </a>",
"    ]. The ED50 of intrathecal sufentanil is reported to be 4.1 &plusmn; 0.31 mcg, so sufentanil is 4.4 times as potent as fentanyl when given intrathecally to parturients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/38\">",
"     38",
"    </a>",
"    ]. The duration of analgesic action is similar to fentanyl, approximately 1.5 hours. As for fentanyl, sufentanil is often coadministered with a local anesthetic, eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    1.0 to 2.5 mg.",
"   </p>",
"   <p>",
"    The indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    administration are the same as for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    . Except for relative potency, there do not appear to be significant differences in clinical profiles between the two opioids when administered into the neuraxis, and many clinicians use them interchangeably.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Alfentanil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=see_link\">",
"     Alfentanil",
"    </a>",
"    is another synthetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    congener that has been used as the sole agent for epidural analgesia or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/39\">",
"     39",
"    </a>",
"    ]. However, in one study, single drug infusion at 30",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per hour did not achieve adequate pain relief in late first and second stage labor in 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/40\">",
"     40",
"    </a>",
"    ]. Alfentanil has also been administered intrathecally in a dose of 25 mcg, with and without bupivacaine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/41\">",
"     41",
"    </a>",
"    ]; duration of action was 40 minutes for alfentanil alone. Alfentanil is infrequently used for labor analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Meperidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     Meperidine",
"    </a>",
"    is the only opioid that has local anesthetic effects, and thus produces analgesia on a dual basis when administered into the neuraxis: it interacts with spinal opioid receptors and it also blocks axonal conduction. A dose of 25 mg as the sole agent in the epidural space provides labor analgesia for 50 to 160 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the dose required is comparable to that given parenterally and results in opioid side effects, thus rendering it a less popular choice for labor analgesia. A dose of 50 mg administered epidurally in non-laboring parturients resulted in no maternal hemodynamic changes, but did have local anesthetic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/43\">",
"     43",
"    </a>",
"    ]. A benefit of epidural meperidine is a decrease in the incidence of shivering, a common and bothersome accompaniment of labor and delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/44\">",
"     44",
"    </a>",
"    ]. Intrathecal meperidine, 10 to 20 mg, produces analgesia within a few minutes (two to 12), which may last for up to three hours (range one to three) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/45\">",
"     45",
"    </a>",
"    ]. However, intrathecal meperidine is associated with a high incidence of nausea and vomiting (16 of 21 patients in one study with doses of 15 or 25 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/46\">",
"     46",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     Meperidine",
"    </a>",
"    may provide superior analgesia for transition and second stage of labor than other opioids because of its local anesthetic effects. Its neuraxial use should probably be limited to this indication. Meperidine is not a popular choice for labor analgesia because of its bothersome opioid side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ANALGESIC ADJUVANTS FOR THE NEURAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epinephrine has long been used to increase the duration of local anesthetic effect by inducing vasoconstriction, thereby slowing the redistribution of analgesics from the injection site. This effect was beneficial with single shot techniques, but has become less important with the advent of continuous analgesia infusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37574?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Options\"",
"    </a>",
"    .) In addition, when administered into the neuraxis, epinephrine itself produces analgesia by interacting with spinal cord alpha-2 adrenergic receptors.",
"   </p>",
"   <p>",
"    Another indication for neuraxial epinephrine is to assist in determining whether an epidural catheter is malpositioned within a blood vessel. In this situation, intravenous administration of 15 mcg epinephrine as part of a test dose (as an example, 3 ml of 1.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with 1:200,000 epinephrine) will produce an increase in heart rate, and perhaps more reliably, a sensation of palpitations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H3#H3\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Use of test dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two side effects that have dampened enthusiasm for neuraxial epinephrine use in labor are its potential tocolytic effects on the uterus (a result of its beta-2 adrenergic action on the myometrium after systemic absorption) and potentiation of local anesthetic-induced motor block [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is an alpha-2 adrenergic agonist that produces analgesia when administered into the neuraxis. It has been administered intrathecally and epidurally during labor to potentiate the effects of opioids and local anesthetics. Maternal side effects include hypotension and sedation. The optimal neuraxial clonidine dosing has not yet been determined, nor has its precise role for labor analgesia been defined. Clonidine has an advantage over epinephrine in that it appears not to produce motor block when combined with local anesthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/48\">",
"     48",
"    </a>",
"    ], but it may have other untoward effects including hypotension and new onset fetal heart rate abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    is inadvisable because it is associated with significant hypotension and sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/51\">",
"     51",
"    </a>",
"    ]. Including low-dose clonidine (2",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    as part of an epidural infusion regimen appears to be preferable to administering it as a bolus (60 and 75 mcg) during labor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is not currently widely used as an adjuvant for labor analgesia. An FDA \"black box\" warning against \"routine perioperative and obstetric administration,\" due to the risk of hypotension, will likely temper the enthusiasm of physicians in the United States for using this drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cholinergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     Neostigmine",
"    </a>",
"    , a cholinesterase inhibitor, produces neuraxial analgesia by increasing the local concentration of acetylcholine, which stimulates muscarinic and nicotinic receptors in the spinal cord. In addition to analgesia, intrathecal neostigmine administration produces dose-related nausea, vomiting, and sedation. In volunteers, 50 mcg did not produce side effects, 150 mcg produced mild nausea, and 500 to 750 mcg produced severe nausea and vomiting; sedation was observed with doses &gt;150 mcg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/53\">",
"     53",
"    </a>",
"    ]. In a study of labor pain, intrathecal neostigmine 10 mcg potentiated intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    analgesia, without producing side effects, whereas 20 mcg neostigmine was associated with nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the high incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    side effects observed after intrathecal administration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/54\">",
"     54",
"    </a>",
"    ], the epidural route appears more promising for the management of labor pain. Epidural neostigmine administration does not cause nausea, pruritus, or respiratory depression, but enhances opioid and local anesthetic effects, thus enabling a reduction in the dose of these drugs and minimizing their side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. For labor analgesia, bolus doses of 300 to 500 micrograms are required, in combination with other drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    , local anesthetic) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/58\">",
"     58",
"    </a>",
"    ]. Continuous administration of a lower concentration of epidural neostigmine (4",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    for labor analgesia has a local anesthetic sparing effect, similar to that produced by intrathecal opioids but without side effects except for mild sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25977/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether epidurally administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    will become a popular adjuvant for labor analgesia in the future remains to be seen. Studies addressing dose, safety and drug interactions are necessary prior to the routine use of epidural neostigmine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33873?source=see_link\">",
"       \"Patient information: Managing pain during labor and delivery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of agents may be used to provide neuraxial labor analgesia via the epidural and spinal routes, including local anesthetics, opioids, adrenergic agonists and cholinergic agonists. These agents may be used alone or in various combinations. Physician preferences often dictate the route and the drug, or combination of drugs, used to provide labor analgesia.",
"     </li>",
"     <li>",
"      Low concentrations of the local anesthetics",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"       ropivacaine",
"      </a>",
"      produce greater sensory than motor block; thus, they are preferred for laboring patients, as preservation of muscle strength is desirable. Clinical differences between these two local anesthetics are not significant. With low dose epidural techniques, systemic toxicity is not an issue, so either of these local anesthetics may be used.",
"     </li>",
"     <li>",
"      Neuraxial administration of the opioids",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"       sufentanil",
"      </a>",
"      are used interchangeably to provide labor analgesia, and are clinically indistinguishable. As sufentanil is more potent, smaller doses are required. These opioids provide only about 90 minutes of pain relief.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      may also be administered into the neuraxis to provide labor analgesia. Its duration of action is significantly greater than fentanyl or sufentanil, often lasting for the entire duration of the first stage of labor, but morphine use is accompanied by a high incidence of bothersome side effects including pruritus and nausea. Opioids alone, with the exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      , do not provide reliable analgesia for the second stage of labor. Many clinicians provide labor analgesia with a combination of fentanyl or sufentanil and a low concentration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"       ropivacaine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Epinephrine is added to epidural infusions to potentiate analgesia and decrease local anesthetic requirements, but epinephrine enhances motor block, an undesirable effect for the parturient.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      are two newer adjuvants for labor analgesia that are more suited to the epidural rather than the spinal route. Although their role in obstetric anesthesia has yet to be defined, they may hold promise as efficacious adjuvants to enhance labor analgesia.",
"     </li>",
"     <li>",
"      For cesarean delivery under neuraxial anesthesia, the primary drug used is a local anesthetic. If an epidural approach is used, 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      with epinephrine, 5",
"      <span class=\"nowrap\">",
"       mcg/mL,",
"      </span>",
"      is a reasonable choice, as systemic cardiotoxic effects are relatively unlikely to occur. Alternatively, 0.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      or 0.75 percent or 1.0 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"       ropivacaine",
"      </a>",
"      may also be used. Systemic cardiotoxicity appears more amenable to treatment following ropivacaine than bupivacaine.",
"     </li>",
"     <li>",
"      Local anesthetic cardiotoxicity should be treated aggressively with lipid rescue. An intravenous bolus of 1.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      lean body mass of 20 percent lipid emulsion is given over one minute, followed by an infusion of 0.25",
"      <span class=\"nowrap\">",
"       mL/kg/min",
"      </span>",
"      until at least 10 minutes following successful achievement of circulatory stability. If circulatory stability is not obtained within 5 minutes, a second 1.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      bolus may be administered, followed by an infusion of 0.5",
"      <span class=\"nowrap\">",
"       mL/kg/min.",
"      </span>",
"     </li>",
"     <li>",
"      If a spinal approach is used for cesarean delivery, 10 to 15 mg of hyperbaric",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      provides reliable anesthesia. Hyperbaric",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      has fallen into disfavor because of a high incidence of transient neurological symptoms, even though this complication has been reported primarily in non-pregnant patients.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/1\">",
"      Melzack R. The myth of painless childbirth (the John J. Bonica lecture). Pain 1984; 19:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/2\">",
"      Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979; 51:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/3\">",
"      Johnson ME. Potential neurotoxicity of spinal anesthesia with lidocaine. Mayo Clin Proc 2000; 75:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/4\">",
"      Wong CA, Slavenas P. The incidence of transient radicular irritation after spinal anesthesia in obstetric patients. Reg Anesth Pain Med 1999; 24:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/5\">",
"      Aouad MT, Siddik SS, Jalbout MI, Baraka AS. Does pregnancy protect against intrathecal lidocaine-induced transient neurologic symptoms? Anesth Analg 2001; 92:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/6\">",
"      Philip J, Sharma SK, Gottumukkala VN, et al. Transient neurologic symptoms after spinal anesthesia with lidocaine in obstetric patients. Anesth Analg 2001; 92:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/7\">",
"      Zaric D, Christiansen C, Pace NL, Punjasawadwong Y. Transient neurologic symptoms after spinal anesthesia with lidocaine versus other local anesthetics: a systematic review of randomized, controlled trials. Anesth Analg 2005; 100:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/8\">",
"      YaDeau JT, Liguori GA, Zayas VM. The incidence of transient neurologic symptoms after spinal anesthesia with mepivacaine. Anesth Analg 2005; 101:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/9\">",
"      Rigler ML, Drasner K, Krejcie TC, et al. Cauda equina syndrome after continuous spinal anesthesia. Anesth Analg 1991; 72:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/10\">",
"      Schell RM, Brauer FS, Cole DJ, Applegate RL 2nd. Persistent sacral nerve root deficits after continuous spinal anaesthesia. Can J Anaesth 1991; 38:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/11\">",
"      Loo CC, Irestedt L. Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997. Acta Anaesthesiol Scand 1999; 43:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/12\">",
"      Gaiser RR. Should intrathecal lidocaine be used in the 21st century? J Clin Anesth 2000; 12:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/13\">",
"      Aberg G. Toxicological and local anaesthetic effects of optically active isomers of two local anaesthetic compounds. Acta Pharmacol Toxicol (Copenh) 1972; 31:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/14\">",
"      Capogna G, Celleno D, Fusco P, et al. Relative potencies of bupivacaine and ropivacaine for analgesia in labour. Br J Anaesth 1999; 82:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/15\">",
"      Polley LS, Columb MO, Naughton NN, et al. Relative analgesic potencies of ropivacaine and bupivacaine for epidural analgesia in labor: implications for therapeutic indexes. Anesthesiology 1999; 90:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/16\">",
"      McDonald SB, Liu SS, Kopacz DJ, Stephenson CA. Hyperbaric spinal ropivacaine: a comparison to bupivacaine in volunteers. Anesthesiology 1999; 90:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/17\">",
"      Dony P, Dewinde V, Vanderick B, et al. The comparative toxicity of ropivacaine and bupivacaine at equipotent doses in rats. Anesth Analg 2000; 91:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/18\">",
"      Bj&oslash;rnestad E, Smedvig JP, Bjerkreim T, et al. Epidural ropivacaine 7.5 mg/ml for elective Caesarean section: a double-blind comparison of efficacy and tolerability with bupivacaine 5 mg/ml. Acta Anaesthesiol Scand 1999; 43:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/19\">",
"      Kampe S, Tausch B, Paul M, et al. Epidural block with ropivacaine and bupivacaine for elective caesarean section: maternal cardiovascular parameters, comfort and neonatal well-being. Curr Med Res Opin 2004; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     Halpern, SH, Beilin, Y. Focused review: ropivacaine versus bupivacaine for epidural labor analgesia. Anesth Analg 2010; 111:482.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/21\">",
"      Chazalon P, Tourtier JP, Villevielle T, et al. Ropivacaine-induced cardiac arrest after peripheral nerve block: successful resuscitation. Anesthesiology 2003; 99:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/22\">",
"      Huet O, Eyrolle LJ, Mazoit JX, Ozier YM. Cardiac arrest after injection of ropivacaine for posterior lumbar plexus blockade. Anesthesiology 2003; 99:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/23\">",
"      Gielen M, Slappendel R, Jack N. Successful defibrillation immediately after the intravascular injection of ropivacaine. Can J Anaesth 2005; 52:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/24\">",
"      Khoo LP, Corbett AR. Successful resuscitation of an ASA 3 patient following ropivacaine-induced cardiac arrest. Anaesth Intensive Care 2006; 34:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/25\">",
"      Yoshida M, Matsuda H, Fukuda I, Furuya K. Sudden cardiac arrest during cesarean section due to epidural anaesthesia using ropivacaine: a case report. Arch Gynecol Obstet 2008; 277:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/26\">",
"      Danelli G, Fanelli G, Berti M, et al. Spinal ropivacaine or bupivacaine for cesarean delivery: a prospective, randomized, double-blind comparison. Reg Anesth Pain Med 2004; 29:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/27\">",
"      Kuhnert BR, Kuhnert PM, Prochaska AL, Gross TL. Plasma levels of 2-chloroprocaine in obstetric patients and their neonates after epidural anesthesia. Anesthesiology 1980; 53:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/28\">",
"      Grice SC, Eisenach JC, Dewan DM. Labor analgesia with epidural bupivacaine plus fentanyl: enhancement with epinephrine and inhibition with 2-chloroprocaine. Anesthesiology 1990; 72:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/29\">",
"      Eisenach JC, Schlairet TJ, Dobson CE 2nd, Hood DH. Effect of prior anesthetic solution on epidural morphine analgesia. Anesth Analg 1991; 73:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/30\">",
"      Hess PE, Snowman CE, Hahn CJ, et al. Chloroprocaine may not affect epidural morphine for postcesarean delivery analgesia. J Clin Anesth 2006; 18:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/31\">",
"      Reisner LS, Hochman BN, Plumer MH. Persistent neurologic deficit and adhesive arachnoiditis following intrathecal 2-chloroprocaine injection. Anesth Analg 1980; 59:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/32\">",
"      Taniguchi M, Bollen AW, Drasner K. Sodium bisulfite: scapegoat for chloroprocaine neurotoxicity? Anesthesiology 2004; 100:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/33\">",
"      Casati A, Danelli G, Berti M, et al. Intrathecal 2-chloroprocaine for lower limb outpatient surgery: a prospective, randomized, double-blind, clinical evaluation. Anesth Analg 2006; 103:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/34\">",
"      Baraka A, Noueihid R, Hajj S. Intrathecal injection of morphine for obstetric analgesia. Anesthesiology 1981; 54:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/35\">",
"      Palmer CM, Cork RC, Hays R, et al. The dose-response relation of intrathecal fentanyl for labor analgesia. Anesthesiology 1998; 88:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/36\">",
"      Nelson KE, Rauch T, Terebuh V, D'Angelo R. A comparison of intrathecal fentanyl and sufentanil for labor analgesia. Anesthesiology 2002; 96:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/37\">",
"      Steinberg RB, Powell G, Hu XH, Dunn SM. Epidural sufentanil for analgesia for labor and delivery. Reg Anesth 1989; 14:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/38\">",
"      Nelson KE, D'Angelo R, Foss ML, et al. Intrathecal neostigmine and sufentanil for early labor analgesia. Anesthesiology 1999; 91:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/39\">",
"      Wilhite AO, Moore CH, Blass NH, Christmas JT. Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. Reg Anesth 1994; 19:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/40\">",
"      Heytens L, Cammu H, Camu F. Extradural analgesia during labour using alfentanil. Br J Anaesth 1987; 59:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/41\">",
"      Hughes DA, Hill DA. Intrathecal alfentanil with and without bupivacaine for analgesia in labour. Anaesthesia 2000; 55:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/42\">",
"      Skj&ouml;ldebrand A, Garle M, Gustafsson LL, et al. Extradural pethidine with and without adrenaline during labour: wide variation in effect. Br J Anaesth 1982; 54:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/43\">",
"      Khaw KS, Ngan Kee WD, Critchley LA. Epidural meperidine does not cause hemodynamic changes in the term parturient. Can J Anaesth 2000; 47:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/44\">",
"      Brownridge P. Shivering related to epidural blockade with bupivacaine in labour, and the influence of epidural pethidine. Anaesth Intensive Care 1986; 14:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/45\">",
"      Honet JE, Arkoosh VA, Norris MC, et al. Comparison among intrathecal fentanyl, meperidine, and sufentanil for labor analgesia. Anesth Analg 1992; 75:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/46\">",
"      Booth JV, Lindsay DR, Olufolabi AJ, et al. Subarachnoid meperidine (Pethidine) causes significant nausea and vomiting during labor. The Duke Women's Anesthesia Research Group. Anesthesiology 2000; 93:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/47\">",
"      Calimaran AL, Strauss-Hoder TP, Wang WY, et al. The effect of epidural test dose on motor function after a combined spinal-epidural technique for labor analgesia. Anesth Analg 2003; 96:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/48\">",
"      Mercier FJ, Dounas M, Bouaziz H, et al. The effect of adding a minidose of clonidine to intrathecal sufentanil for labor analgesia. Anesthesiology 1998; 89:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/49\">",
"      Missant C, Teunkens A, Vandermeersch E, Van de Velde M. Intrathecal clonidine prolongs labour analgesia but worsens fetal outcome: a pilot study. Can J Anaesth 2004; 51:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/50\">",
"      Belhadj Amor M, Draief A, Ouezini R, et al. [30 microg intrathecal clonidine prolongs labour analgesia, but increases the incidence of hypotension and abnormal foetal heart rate patterns]. Ann Fr Anesth Reanim 2007; 26:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/51\">",
"      Roelants F. The use of neuraxial adjuvant drugs (neostigmine, clonidine) in obstetrics. Curr Opin Anaesthesiol 2006; 19:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/52\">",
"      Wallet F, Clement HJ, Bouret C, et al. Effects of a continuous low-dose clonidine epidural regimen on pain, satisfaction and adverse events during labour: a randomized, double-blind, placebo-controlled trial. Eur J Anaesthesiol 2010; 27:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/53\">",
"      Hood DD, Eisenach JC, Tuttle R. Phase I safety assessment of intrathecal neostigmine methylsulfate in humans. Anesthesiology 1995; 82:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/54\">",
"      Ho KM, Ismail H, Lee KC, Branch R. Use of intrathecal neostigmine as an adjunct to other spinal medications in perioperative and peripartum analgesia: a meta-analysis. Anaesth Intensive Care 2005; 33:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/55\">",
"      Roelants F, Lavand'homme PM. Epidural neostigmine combined with sufentanil provides balanced and selective analgesia in early labor. Anesthesiology 2004; 101:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/56\">",
"      Roelants F, Lavand'homme PM, Mercier-Fuzier V. Epidural administration of neostigmine and clonidine to induce labor analgesia: evaluation of efficacy and local anesthetic-sparing effect. Anesthesiology 2005; 102:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/57\">",
"      Ross VH, Pan PH, Owen MD, et al. Neostigmine decreases bupivacaine use by patient-controlled epidural analgesia during labor: a randomized controlled study. Anesth Analg 2009; 109:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25977/abstract/58\">",
"      Eisenach JC. Epidural neostigmine: will it replace lipid soluble opioids for postoperative and labor analgesia? Anesth Analg 2009; 109:293.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4465 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.211.0.116-039B397C7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25977=[""].join("\n");
var outline_f25_23_25977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE \"GOLD STANDARD\" FOR LABOR ANALGESIA AND ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Drugs used for epidural and spinal techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Differences between epidural and spinal routes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LOCAL ANESTHETICS USED FOR NEURAXIAL TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bupivacaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Local anesthetic neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ropivacaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      2-chloroprocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tetracaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Opioids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Morphine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fentanyl",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sufentanil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Alfentanil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Meperidine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ANALGESIC ADJUVANTS FOR THE NEURAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clonidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cholinergic agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4465\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4465|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/25/2460\" title=\"table 1\">",
"      Anesthetic drugs in obstetrics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37574?source=related_link\">",
"      Neuraxial analgesia and anesthesia for labor and delivery: Options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33873?source=related_link\">",
"      Patient information: Managing pain during labor and delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_23_25978="Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors";
var content_f25_23_25978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25978/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25978/contributors\">",
"     Lee-may Chen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25978/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25978/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25978/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/23/25978/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/23/25978/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/23/25978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6091373\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of ovarian malignancies (95 percent) are derived from epithelial cells; the remainder arise from other ovarian cell types (germ cell tumors, sex cord-stromal tumors) (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serous carcinoma, the most common histologic subtype of epithelial ovarian carcinoma, is regarded as closely related to fallopian tubal and peritoneal serous carcinoma, based upon similarities in histology and clinical behavior. Some experts have proposed that these carcinomas all originate in the fallopian tubes. This is based upon studies that detected fallopian tubal intraepithelial carcinoma in the fimbria of",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers following risk-reducing bilateral salpingo-oophorectomy. The role of this neoplasm in subsequent progression to invasive cancer of the ovary, peritoneum, or fallopian tube has been suggested but not proven [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, some data suggest that peritoneal carcinoma originates in the fallopian tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Based upon their common features, these carcinomas will be discussed as one clinical entity in this topic review. Distinctions between these conditions will also be addressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=see_link\">",
"     \"Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology and risk factors of epithelial ovarian, fallopian tubal, and peritoneal carcinoma are reviewed here. An overview of these neoplasms can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\"",
"    </a>",
"    .) Related topics are discussed in detail separately, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pathogenesis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=see_link\">",
"       \"Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Histopathology (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"       \"Epithelial ovarian cancer: Pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical features and diagnosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"       \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"       \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Staging and surgical treatment (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adjuvant therapy (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link\">",
"       \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461641\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Serous carcinoma",
"      </strong>",
"      &ndash; Serous carcinomas are a histologic subtype of epithelial carcinoma. This subtype was previously referred to as papillary serous carcinoma, but serous is the preferred term since many carcinomas are papillary, but not serous.",
"     </li>",
"     <li>",
"      <strong>",
"       Peritoneal carcinoma",
"      </strong>",
"      &ndash; This is also referred to as serous carcinoma of the peritoneum or peritoneal serous carcinoma. Histologically, this malignancy is indistinguishable from serous ovarian carcinoma. A feature that distinguishes the condition from ovarian carcinoma is that that ovarian involvement is absent or extraovarian involvement greater than ovarian involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092134\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer is the second most common gynecologic malignancy. Epithelial carcinoma is the most common histologic type (95 percent) and serous is the most common subtype (75 percent of epithelial carcinomas) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Primary fallopian tubal cancer and peritoneal serous carcinoma have been considered rare malignancies. However, as noted above, the incidence of fallopian tubal carcinoma may have been substantially underestimated, since presumptive ovarian and peritoneal carcinomas may derive from the fallopian tube. The rates of reported by currently available studies are included here. (See",
"    <a class=\"local\" href=\"#H6091373\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26443077\">",
"    <span class=\"h2\">",
"     Ovarian carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide in 2008, approximately 225,000 women were diagnosed with ovarian cancer and 140,000 died from this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/7\">",
"     7",
"    </a>",
"    ]. Ovarian cancer is the second most common gynecologic malignancy in developed countries, with an incidence of 9.4 per 100,000 women and a mortality rate of 5.1 per 100,000. In developing countries, it is the third most common gynecologic malignancy (cervical cancer is the most common), with an incidence of 5.0 per 100,000 and a mortality rate of 3.1 per 100,000. &nbsp;",
"   </p>",
"   <p>",
"    In the United States (US), there are approximately 22,000 new cases and 14,000 cancer-related deaths expected from ovarian cancer in 2013, making it the second most common gynecologic malignancy, the most common cause of gynecologic cancer death, and the fifth leading cause of cancer death in women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/1\">",
"     1",
"    </a>",
"    ]. Based upon data from the US national cancer database Surveillance, Epidemiology and End Results, the annual incidence of ovarian cancer from 2005 to 2009 was 12.7 per 100,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/8\">",
"     8",
"    </a>",
"    ]. Incidence rates were higher in whites (13.4 per 100,000) than in Hispanic (11.3 per 100,000), American",
"    <span class=\"nowrap\">",
"     Indian/Alaska",
"    </span>",
"    Native (11.2 per 100,000), black (9.8 per 100,000), or",
"    <span class=\"nowrap\">",
"     Asian/Pacific",
"    </span>",
"    Islander women (9.8 per 100,000) (",
"    <a class=\"graphic graphic_figure graphicRef83400 \" href=\"UTD.htm?9/22/9568\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The average age at diagnosis of ovarian cancer in the US is 63 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/8\">",
"     8",
"    </a>",
"    ]. The incidence by age is [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &lt;20 years old &ndash; 0.2 to 1.4 per 100,000",
"     </li>",
"     <li>",
"      20 to 29 &ndash; 1.8 to 2.2 per 100,000",
"     </li>",
"     <li>",
"      20 to 39 &ndash; 3.1 to 5.1 per 100,000",
"     </li>",
"     <li>",
"      40 to 49 &ndash; 9.0 to 15.2 per 100,000",
"     </li>",
"     <li>",
"      50 to 59 &ndash; 21.8 to 28.3 per 100,000",
"     </li>",
"     <li>",
"      60 to 69 &ndash; 36.2 to 41.5 per 100,000",
"     </li>",
"     <li>",
"      &ge;70 &ndash; 47.6 to 56.7 per 100,000",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lifetime risk of developing ovarian cancer in the US is 1.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age at diagnosis of ovarian cancer is younger among women with a hereditary ovarian cancer syndrome. The risk of ovarian cancer reaches 2 to 3 percent in women with a",
"    <em>",
"     BRCA1",
"    </em>",
"    gene mutation at age 35 and for those with a",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation at age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The typical age at diagnosis of ovarian cancer in women with Lynch syndrome (hereditary nonpolyposis colon cancer) is 43 to 50 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6092214\">",
"     'Genetic factors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link&amp;anchor=H2754911#H2754911\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\", section on 'Timing of surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link&amp;anchor=H8#H8\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of ovarian cancers are diagnosed at an advanced stage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/8\">",
"     8",
"    </a>",
"    ]: confined to primary site (15 percent); spread to regional lymph nodes (17 percent); distant metastases (61 percent); and unstaged (7 percent) (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The majority of primary ovarian malignancies (95 percent) are derived from epithelial cells; the remainder arise from other ovarian cell types (germ cell tumors, sex cord-stromal tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26443084\">",
"    <span class=\"h2\">",
"     Fallopian tubal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fallopian tubal carcinoma comprises 0.2 percent of cancers among women in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/14\">",
"     14",
"    </a>",
"    ]. The annual incidence in the United States from 1998 to 2003 was 0.41 per 100,000 women. The highest incidence was in women ages 70 to 79 (1.63 per 100,000). The incidence was higher in whites (0.41 per 100,000) than blacks (0.27 per 100,000), American",
"    <span class=\"nowrap\">",
"     Indian/Alaska",
"    </span>",
"    Natives (0.26 per 100,000), or Asia or Pacific Islanders (0.25 per 100,000).",
"   </p>",
"   <p>",
"    Stage at diagnosis of primary fallopian tubal carcinoma is fairly evenly distributed: localized (36 percent), regional (30 percent), and distant (32 percent) (",
"    <a class=\"graphic graphic_table graphicRef60565 \" href=\"UTD.htm?14/11/14526\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488992\">",
"    <span class=\"h2\">",
"     Peritoneal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of peritoneal cancer (also referred to a serous carcinoma of the peritoneum) in US from 1995 to 2004 was per 0.46 per 100,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/15\">",
"     15",
"    </a>",
"    ]. The highest incidence was in women ages 70 to 74 (0.27 per 100,000). The incidence was higher in whites (0.50 per 100,000) than blacks (0.18 per 100,000) or Asia or Pacific Islanders (0.27 per 100,000).",
"   </p>",
"   <p>",
"    Peritoneal carcinoma is defined by the presence of intraabdominal disease, so all cases present at an advanced stage (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092142\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenetic mechanism(s) that explains the link between many of the risk factors and development of epithelial ovarian carcinoma (EOC) have not been determined. Traditionally, two main hypotheses were proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Incessant ovulation",
"      </strong>",
"      &ndash; Repeated ovulation results in minor trauma to the ovarian epithelium, which in turn, can lead to malignant transformation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/16\">",
"       16",
"      </a>",
"      ]. Support for this hypothesis is derived from the observation that women with periodic suppression of ovulation as a result of oral contraceptive use, pregnancy, or lactation have a lower incidence of epithelial ovarian carcinoma.",
"     </li>",
"     <li>",
"      <strong>",
"       Exposure to gonadotropins",
"      </strong>",
"      &ndash; Persistent ovarian exposure to gonadotropins and elevated estradiol concentrations may be carcinogenic. This hypothesis is supported by the observation that experimentally induced ovarian tumors contain gonadotropin receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/17\">",
"       17",
"      </a>",
"      ]. In contrast, evidence shows that a history of a multiple gestation is associated with a decreased risk of EOC [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/18\">",
"       18",
"      </a>",
"      ]. According to the gonadotropic hypothesis, women with a history of multiple gestations should be at increased risk of EOC because they have higher levels of gonadotropins during their fertile years and they have a greater incidence of double ovulations per menstrual cycle. Furthermore, one case control study failed to demonstrate a relationship between serum levels of luteinizing hormone and the risk of ovarian cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence suggests that fallopian tubal neoplasia may also play a role in the pathogenesis of EOC and peritoneal cancer, as discussed above. The proportion of case of these carcinomas that are initiated in the fallopian tubes is a topic of investigation. (See",
"    <a class=\"local\" href=\"#H6091373\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=see_link\">",
"     \"Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk factors for fallopian tubal and peritoneal carcinoma are less well defined than for EOC, but they have generally been found to be the same. Available evidence regarding unique risk factors for a particular malignancy will be included in the discussion below. Risk factors for EOC are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The best quality data regarding risk factors for EOC are from two large prospective studies, the United States (US) Nurses&rsquo; Health Study (NHS) that has followed over 200,000 women (with 924 cases of EOC to date) and the European Prospective Investigation into Cancer and Nutrition (EPIC) that has followed over 300,000 women (with 878 cases of EOC to date) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Much of the data cited in the sections below are derived from these two studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488066\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of epithelial ovarian, fallopian tubal, and peritoneal carcinoma increases with increasing age. Incidence data by age is discussed above (see",
"    <a class=\"local\" href=\"#H6092134\">",
"     'Epidemiology'",
"    </a>",
"    above). An analysis of data from NHS found that the risk of EOC increased approximately 2 percent for each additional year of age in women &lt;50 years old and 11 percent in women &ge;50 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092150\">",
"    <span class=\"h2\">",
"     Reproductive and hormonal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reproductive factors are associated with EOC. The risk of ovarian cancer is increased in women with infertility, and reduced in those who take oral contraceptives or are multiparous (see",
"    <a class=\"local\" href=\"#H6092303\">",
"     'Protective factors'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092158\">",
"    <span class=\"h3\">",
"     Early menarche or late menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early menarche (before age 12) has been associated with an increased risk of EOC in some, but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late age at menopause (after age 52) appears to be associated with an increased EOC risk. As an example, EPIC found a statistically significant increase in the risk of EOC in women who became menopausal at &gt;52 years old compared with &le;45 years old (relative risk [RR] 1.46, 95% CI 1.06-1.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the persistent ovulation hypothesis of EOC pathogenesis, either early menarche or late menopause would increase the total number of ovulations in a woman&rsquo;s lifetime. NHS and EPIC found a 2 to 7 percent increase in the risk of EOC for each additional year of ovulation (NHS: RR 1.07, 95% CI 1.05-1.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092166\">",
"    <span class=\"h3\">",
"     Nulliparity and other obstetric factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nulliparous women appear to have an increased risk of EOC. As an example, a retrospective cohort study of over 20,000 women found that parous women had a significantly decreased risk of ovarian cancer (hazard ratio 0.49, 95% CI 0.25-0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In addition, a history of a full term pregnancy is associated with a decreased risk of EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/22,26-28\">",
"     22,26-28",
"    </a>",
"    ]. This was illustrated in EPIC, which found a significantly decreased risk in parous versus nulliparous women (0.27 versus 0.30 percent; RR 0.71, 95% CI 0.59-0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/21\">",
"     21",
"    </a>",
"    ]. Accordingly, the EOC risk appears to decrease with an increasing parity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. As an example, in EPIC, among women with at least one full term pregnancy, the risk of EOC decreased 8 percent for each additional pregnancy (95% CI 0.85-0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that multiparity is also associated with a reduced risk of fallopian tubal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that a history of multiple gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/18,33,34\">",
"     18,33,34",
"    </a>",
"    ] or later age (&gt;35 years old) at last pregnancy are protective against EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous or induced abortion does not appear to be associated with an increased risk of EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092174\">",
"    <span class=\"h3\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility is a risk factor for EOC, but ovulation induction for treatment of infertility does not appear to increase the risk. An analysis of four case-control studies and four retrospective cohort studies, as well as three large meta-analyses including additional studies, found that infertility treatment did",
"    <strong>",
"     not",
"    </strong>",
"    independently increase the risk for ovarian cancer; however, infertility itself was an independent risk factor for this malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. As an example, in a case control study of nulligravid women that included over 5000 women with ovarian cancer, there was a significant increase in the risk of ovarian cancer in women who attempted to conceive a pregnancy for less than one year compared with those who attempted to conceive for more than five years (OR 2.76, 95% CI 1.91-3.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence regarding and ovarian cancer and infertility treatment is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of ovulation induction\", section on 'Ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092182\">",
"    <span class=\"h3\">",
"     Endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis appears to be associated with some histologic subtypes of EOC, but not with others. This was best illustrated in a meta-analysis of 13 case-control studies that included almost 8000 women with EOC and found a statistically significant association between a self-reported history of endometriosis and an increased risk of clear cell (OR 3.05, 95% CI 2.43-3.84), endometrioid (OR 2.04, 95% CI 1.67-2.48), and low grade serous (OR 2.11, 95% CI 1.39-3.20) EOC, but not high grade serous (OR 1.13, 95% CI 0.97-1.32) or mucinous (OR 1.02, 95% CI 0.69-1.50) EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/42\">",
"     42",
"    </a>",
"    ]. A literature review estimated that the risk of malignant transformation of ovarian endometriosis was 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometriosis-associated EOC appears to develop in younger women and have a better prognosis than most cases of EOC. As an example, in one retrospective series of women with clear cell EOC (n = 84), women with carcinoma arising in an area of endometriosis were significantly younger (49 versus 59 years old) and had a better medial overall survival (196 versus 34 months) than women without endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between endometriosis and ovarian cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H8971849#H8971849\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Link to cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092190\">",
"    <span class=\"h3\">",
"     Polycystic ovarian syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with polycystic ovarian syndrome appear to be at an elevated risk of ovarian cancer (OR 2.52, 95% CI 1.08-5.89), based upon a meta-analysis of eight case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092198\">",
"    <span class=\"h3\">",
"     Postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute risk of ovarian cancer with postmenopausal hormone therapy appears to be small. The best data are from the Women's Health Initiative (WHI) randomized trial, which found no statistically significant increase in the risk of ovarian cancer with combined estrogen-progestin therapy compared with placebo (42 versus 27 per 100,000 person-years; HR 1.6, 95% CI 0.8-3.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/46\">",
"     46",
"    </a>",
"    ]. Meta-analyses of observational studies have found small but significant increases in the risk of ovarian cancer; some data suggest that the risk is higher for estrogen-alone compared with estrogen-progestin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that postmenopausal hormone therapy is associated with an increased risk of fallopian tubal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of ovarian cancer associated with postmenopausal hormone therapy is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H256689856#H256689856\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092206\">",
"    <span class=\"h3\">",
"     Intrauterine device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the NHS showed an association between use of an intrauterine device and increased risk of ovarian cancer (RR 1.76, 95% CI 1.08-2.85); the type of intrauterine device was not specified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092214\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several ovarian cancer susceptibility genes have been identified, primarily",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     2",
"    </em>",
"    and the mismatch repair genes (associated with Lynch syndrome); other genes include",
"    <em>",
"     RAD51C",
"    </em>",
"    ,",
"    <em>",
"     RAD51D",
"    </em>",
"    , and",
"    <em>",
"     BRIP1",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/50\">",
"     50",
"    </a>",
"    ]. It is estimated that",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutations and Lynch syndrome account for 10 to 15 percent of ovarian cancer cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092222\">",
"    <span class=\"h3\">",
"     Family history of ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A personal or family history of breast cancer had been thought of as a risk factor for ovarian cancer; however,",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutations appear to account for most of this increased risk. As an example, a prospective study with an average follow-up for three years of 165 women who tested negative for",
"    <em>",
"     BRCA",
"    </em>",
"    mutations and had at least three relatives in the same lineage with breast cancer found no increase in the incidence of ovarian cancer compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/55\">",
"     55",
"    </a>",
"    ]. Another study that included women with breast or ovarian cancer who were negative or untested for a",
"    <em>",
"     BRCA1",
"    </em>",
"    mutation suggested that their female relatives had no increase in the risk of breast cancer and either no or a moderate increase in the risk of ovarian cancer; however, this study lacked statistical power [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092230\">",
"    <span class=\"h3\">",
"     BRCA gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutations have a greatly increased risk of ovarian and breast cancer (",
"    <a class=\"graphic graphic_table graphicRef68548 \" href=\"UTD.htm?7/40/7821\">",
"     table 4",
"    </a>",
"    ). The estimated lifetime risk of ovarian cancer is 35 to 46 percent for",
"    <em>",
"     BRCA1",
"    </em>",
"    mutation carriers and 13 to 23 percent for",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/57\">",
"     57",
"    </a>",
"    ]. Site-specific ovarian cancer syndrome had been described as a distinct entity, but is now considered part of breast and ovarian cancer syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/58\">",
"     58",
"    </a>",
"    ]. The data regarding the risk of cancer associated with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Population-based studies in North America have reported that 13 to 15 percent of women with invasive ovarian carcinoma have a germline",
"    <em>",
"     BRCA",
"    </em>",
"    mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/54,59\">",
"     54,59",
"    </a>",
"    ].",
"    <em>",
"     BRCA",
"    </em>",
"    mutations account for the majority of hereditary ovarian cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Women with",
"    <em>",
"     BRCA1",
"    </em>",
"    gene mutations typically develop ovarian cancer at an earlier age than other women, with an average age at diagnosis of 50 years old and a 2 to 3 percent incidence of ovarian cancer by age 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/10,11,50\">",
"     10,11,50",
"    </a>",
"    ]. The average age at diagnosis of ovarian cancer in",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation carriers is 60 years old, similar to the general population; women with this mutation reach an incidence of 2 to 3 percent by 50 years old.",
"   </p>",
"   <p>",
"    The stage at presentation of ovarian cancer is similar for",
"    <em>",
"     BRCA",
"    </em>",
"    carriers and the general population; approximately 70 percent of patients present with stage III or IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/54\">",
"     54",
"    </a>",
"    ]. However, ovarian cancers in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers are more likely to be of higher grade than ovarian cancers in age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/60\">",
"     60",
"    </a>",
"    ].",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     2",
"    </em>",
"    carriers with ovarian cancer appear to have similar distribution of histologic types to the general population. Serous adenocarcinoma is the most common histopathology phenotype; mucinous or borderline histology are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/54,61\">",
"     54,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers, particularly",
"    <em>",
"     BRCA2",
"    </em>",
"    carriers, appear to have a better prognosis than noncarriers. This was best illustrated in a meta-analysis of 26 observational studies including over 3000 women that found the following stage, grade, and histology-adjusted five-year all-cause mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       BRCA1",
"      </em>",
"      carriers versus noncarriers: 45 versus 47 percent; HR 0.73, 95% CI 0.64-0.84",
"     </li>",
"     <li>",
"      <em>",
"       BRCA2",
"      </em>",
"      carriers versus noncarriers: 36 versus 47 percent; HR 0.49, 95% CI 0.39-0.61",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This improved survival appears to be due to a higher sensitivity platinum-based treatment of these tumors relative to sporadic cases, which is maintained across repeated courses of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest that the improved prognosis for",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers is only in the short term. The median follow-up in the meta-analysis was three years. In contrast, a registry study that compared 281 women with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations to other women with ovarian cancer reported a higher survival rate in the BRCA group at three years (approximately 75 versus 65 percent), but no significant difference at five or more years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/66\">",
"     66",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutation is the most established risk factor for fallopian tubal and peritoneal carcinoma.",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers rarely present with a tumor that is recognized as a primary tubal cancer (0.6 percent lifetime incidence) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/67\">",
"     67",
"    </a>",
"    ].",
"    <em>",
"     BRCA",
"    </em>",
"    mutations, primarily",
"    <em>",
"     BRCA1",
"    </em>",
"    , have been identified in 16 to 43 percent of women with primary fallopian tubal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Therefore,",
"    <em>",
"     BRCA",
"    </em>",
"    mutation testing should be offered to women with these tumors and risk-reduction surgery for BRCA carriers includes salpingectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of five studies including 846 patients with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations concluded the risk of peritoneal cancer after risk-reducing bilateral salpingo-oophorectomy (rrBSO) was 1.7 percent (range 0.5 to 10.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/70\">",
"     70",
"    </a>",
"    ]. Subsequently, a large prospective study including 1045 patients estimated a 4.3 percent cumulative incidence of peritoneal carcinoma in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers at 20 years after rrBSO [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/71\">",
"     71",
"    </a>",
"    ]. The risk appears to be highest in",
"    <em>",
"     BRCA1",
"    </em>",
"    carriers, although an association with",
"    <em>",
"     BRCA2",
"    </em>",
"    cannot be excluded; peritoneal carcinomas have been reported in a few women with",
"    <em>",
"     BRCA2",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092238\">",
"    <span class=\"h3\">",
"     Lynch syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lynch syndrome (hereditary nonpolyposis colorectal cancer; HNPCC) is associated with other cancers, in particular, endometrial, ovarian, urogenital, and other gastrointestinal primaries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/74\">",
"     74",
"    </a>",
"    ]. Colorectal cancer is the hallmark disease for Lynch syndrome; endometrial cancer is the second most common malignancy in affected women (occurring in up to 70 percent), but ovarian cancer is also increased in frequency. The lifetime risk of ovarian cancer in women with Lynch syndrome is 3 to 14 percent compared with 1.5 percent in the general population (",
"    <a class=\"graphic graphic_figure graphicRef57830 \" href=\"UTD.htm?2/0/2049\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Women with Lynch syndrome account for 1 percent of ovarian cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with Lynch syndrome develop ovarian cancer younger than other women (43 to 50 versus 60 years old) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Histopathology and survival are similar in women with Lynch-associated compared with sporadic ovarian cancer. The majority of ovarian cancers in women with Lynch syndrome are epithelial papillary serous, the most common histologic type among all ovarian cancer, but other subtypes, including endometrioid, mucinous and clear cell, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from case-control studies show that women with Lynch syndrome are more likely to have stage I or II disease than the general population; however, there appears to be no difference in five-year overall survival rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The physiologic basis for this discrepancy of early stage without improvement in survival is unknown.",
"   </p>",
"   <p>",
"    Ovarian cancer in women with Lynch syndrome is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092246\">",
"    <span class=\"h3\">",
"     Other genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the genes for Fanconi anemia, FANCD1, is the same as",
"    <em>",
"     BRCA2",
"    </em>",
"    . Data suggest that certain biallelic mutations result in Fanconi anemia, while certain monoallelic mutations result in an increased risk of cancers associated with",
"    <em>",
"     BRCA1",
"    </em>",
"    mutations. This and other genes in the Fanconi anemia-",
"    <em>",
"     BRCA",
"    </em>",
"    pathway play a role in homologous recombination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/59\">",
"     59",
"    </a>",
"    ]. There is evidence that some gene mutations in this pathway are associated with an increased risk of breast cancer. In addition, some data support an association between genes in the Fanconi anemia-",
"    <em>",
"     BRCA",
"    </em>",
"    pathway and ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H5#H5\">",
"     \"Inherited aplastic anemia in children\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092254\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394569\">",
"    <span class=\"h3\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current smoking or past smoking appears to increase the risk of mucinous ovarian cancer, but not other types of EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. The largest systematic review found that current smoking significantly increased the risk of mucinous ovarian cancer over that of nonsmokers (RR 2.1, 95% CI 1.7-2.7), but did not increase the risk of serous ovarian cancer (RR 1.0, 95% CI 0.8-1.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/79\">",
"     79",
"    </a>",
"    ]. For mucinous cancers, the risk increased with increasing levels of cigarette smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092263\">",
"    <span class=\"h3\">",
"     Talc and asbestos",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between genital use of talcum powder (talc) and EOC is controversial. A meta-analysis of 16 observational studies calculated a statistically significant increase in EOC risk with perineal use of talc (relative risk 1.33, 95% CI 1.16-1.45), but the authors themselves raised questions about the validity of the finding, since a subset analysis found a significant increase of risk in population-based studies, but not in hospital-based studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/81\">",
"     81",
"    </a>",
"    ]. NHS found no increase in EOC with increasing frequency of talc use [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One explanation for a possible association between talc and ovarian cancer is that talc is structurally similar to asbestos, a known carcinogen, and also decades ago talcum powder was sometimes contaminated with asbestos. A meta-analysis of 18 cohort studies found that exposure to asbestos significantly increased the risk of EOC (standardized mortality ratio 1.77, 95% CI 1.37-2.28).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394527\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that occupational exposure to paint, welding, and other chemical processes are associated with an increased risk of fallopian tubal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092279\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have addressed the role of diet in EOC risk, but there are few high quality data. More data are needed before any dietary recommendations can be made. A large prospective cohort study found an increased risk of EOC in women with a high intake of fat from animal sources [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/83\">",
"     83",
"    </a>",
"    ]. However, meta-analyses have not found an association between intake of dairy products and EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. A meta-analysis of seven comparative studies found that high soy intake is associated with a decreased EOC risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 10 comparative studies found no association between vitamin D supplementation and ovarian cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092287\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear relationship between physical activity and ovarian cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/20,88\">",
"     20,88",
"    </a>",
"    ]. At best, there is a modest decrease in risk in women with high levels of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]; however, at least two studies suggested an increase in risk with vigorous activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092295\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;High body mass index (BMI) appears to increase ovarian cancer risk. A systematic review of 28 studies reported a small, but statistically significant, association between obesity (BMI 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or more) and ovarian cancer (OR 1.3, 95% CI 1.1-1.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a large prospective cohort study (n = 495,477) followed for 16 years (1982 to 1998) found that the risk of death from ovarian cancer was higher in women with the greatest BMI (35 to 40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    compared with those of normal weight (BMI 18.5 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    (RR 1.51, 95% CI 1.12-2.02) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link&amp;anchor=H28#H28\">",
"     \"Health hazards associated with obesity in adults\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291890\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 27 comparative studies of found no association between alcohol intake and the risk of EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No association was found between use of nonsteroidal anti-inflammatory drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , in a meta-analysis of 10 comparative studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have found an association between a history of pelvic inflammatory disease and ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092303\">",
"    <span class=\"h1\">",
"     PROTECTIVE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors with the strongest association with a reduced risk of ovarian cancer include (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral contraceptives",
"     </li>",
"     <li>",
"      Multiparity (see",
"      <a class=\"local\" href=\"#H6092166\">",
"       'Nulliparity and other obstetric factors'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Salpingo-oophorectomy",
"     </li>",
"     <li>",
"      Tubal ligation",
"     </li>",
"     <li>",
"      Hysterectomy",
"     </li>",
"     <li>",
"      Breastfeeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092311\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown that prolonged use of oral contraceptives (OCs) reduces the risk of ovarian cancer. An analysis of 45 epidemiological studies from 21 countries found that, compared with women who had never used OCs, any use of OCs was associated with a statistically significant reduction in risk of developing ovarian cancer (relative risk [RR] 0.73, 95% CI 0.70-0.76) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/99\">",
"     99",
"    </a>",
"    ]. Larger reductions in ovarian cancer risk occurred with increasing duration of OC use (RR decreased by approximately 20 percent for each five years of use; by 15 years, the risk of ovarian cancer was reduced by 50 percent). Importantly, the protective effect persisted for 30 years after cessation of OCs, although the effect attenuated over time (for women with five years of OC use, the risk reduction in ovarian cancer within 10 years compared with 20 to 29 years after discontinuing OCs was 29 versus 15 percent). Of note, risk reduction was less robust for mucinous tumors.",
"   </p>",
"   <p>",
"    Some data suggest that oral contraceptive use is also associated with a reduced risk of fallopian tubal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OCs with the current standard or low dose (&le;35 mcg ethinyl estradiol) were associated with a similar or lower likelihood of EOC compared with the higher dose OCs used previously, based upon a case-control study (n = 745 women with ovarian cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data regarding the use of non-oral estrogen-progestin contraceptives (ring, patch) for ovarian cancer prevention.",
"   </p>",
"   <p>",
"    Treatment with OCs to reduce the risk of ovarian cancer in women at high risk of this disease is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160184\">",
"    <span class=\"h2\">",
"     Gynecologic surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9532690\">",
"    <span class=\"h3\">",
"     Salpingo-oophorectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral salpingo-oophorectomy (BSO) reduces the risk of ovarian cancer, but some women may still develop peritoneal carcinoma. Oophorectomy performed for ovarian cancer risk reduction should include removal of the fallopian tubes since occult primary fallopian tubal carcinomas have been reported in women undergoing risk-reducing BSO.",
"   </p>",
"   <p>",
"    BSO in a premenopausal woman results in the early onset of menopause, with the associated symptoms and health effects. Some data suggest the BSO may be associated with long-term adverse effects. The health risks and benefits of BSO are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=see_link&amp;anchor=H21231548#H21231548\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data regarding the impact of unilateral oophorectomy or salpingo-oophorectomy on the risk of ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/101\">",
"     101",
"    </a>",
"    ]. Interestingly, a retrospective cohort study of over 20,000 women found an increased risk of ovarian cancer in women who had undergone unilateral salpingo-oophorectomy without hysterectomy (hazard ratio 4.2, 95% CI 1.3-13.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/25\">",
"     25",
"    </a>",
"    ]. This increased risk may be due to the ovarian pathology that was the original indication for the surgery. Further study of this issue is needed. &nbsp;",
"   </p>",
"   <p>",
"    Fallopian tubal neoplasia plays an important role in the pathogenesis of serous ovarian carcinoma, as noted above. The data for the protective effect of oophorectomy includes salpingectomy, since salpingo-oophorectomy is typically performed when the ovaries are removed. There are no data regarding the impact of salpingectomy alone on the risk of ovarian cancer. Removal of the fallopian tubes at the time of hysterectomy or tubal ligation is recommended by one",
"    <a class=\"external\" href=\"file://www.tealjournal.org/preventive-strategy-british-columbia-cancer-agency-bcca-fallopian-tube-study-2/\">",
"     regional health authority in Canada",
"    </a>",
"    . &nbsp;",
"   </p>",
"   <p>",
"    Elective BSO for women at average risk of ovarian cancer and risk-reducing BSO for women at high risk are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\", section on 'Cancer risk reduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=see_link&amp;anchor=H21231548#H21231548\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092319\">",
"    <span class=\"h3\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy without oophorectomy was associated with a reduction in the risk of ovarian cancer (odds ratio [OR] 0.66, 95% CI 0.50-0.86) in a meta-analysis of 12 case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292094\">",
"    <span class=\"h3\">",
"     Tubal ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a history of tubal ligation had a reduction in ovarian cancer risk (RR 0.69, 95% CI 0.64-0.75) in a meta-analysis of 13 case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/103\">",
"     103",
"    </a>",
"    ]. Data were not provided regarding the tubal ligation techniques used. In addition, a case control study by the Hereditary Ovarian Cancer Clinical Study Group found that tubal ligation lowered the rate of ovarian cancer among",
"    <em>",
"     BRCA1",
"    </em>",
"    carriers by 60 percent, after adjustment for oral contraceptive use, parity, history of breast cancer, and ethnic group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/104\">",
"     104",
"    </a>",
"    ]. A history of both oral contraceptive use and tubal ligation was even more protective (72 percent risk reduction). The mechanism for this risk reduction is unknown, but may coincide with research that suggests that tubal neoplasia is a precursor lesion for serous ovarian cancer. (See",
"    <a class=\"local\" href=\"#H6091373\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no data regarding the impact of hysteroscopic sterilization methods on the risk of ovarian cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092327\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of six studies found that breastfeeding for a cumulative duration of &gt;12 months compared with never breastfeeding was associated with a statistically significant decrease in the risk of EOC (OR 0.72, 95% CI 0.54-0.97) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092343\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF WOMEN AT HIGH RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a woman with a strong family history of EOC depends upon her age, reproductive plans, and the extent of risk. Plans must be individualized because the value of screening with transvaginal ultrasound, serum CA 125, or other procedures has not been clearly established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H21#H21\">",
"     \"Screening for ovarian cancer\", section on 'Women at increased risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with a family history suggestive of a hereditary ovarian cancer syndrome (eg,",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutation, Lynch syndrome) should undergo genetic counseling and genetic testing, if appropriate. Risk reducing bilateral salpingo-oophorectomy with or without hysterectomy after completion of childbearing is an important option for these women, although it does not completely eliminate the possibility of peritoneal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/23/25978/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link&amp;anchor=H5411316#H5411316\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'Genetic testing criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Identification of individuals with Lynch syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision of whether to perform a BSO in women at time of hysterectomy for benign indications may depend upon whether ovarian cancer risk factors are present (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 3",
"    </a>",
"    ). This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=see_link&amp;anchor=H21231548#H21231548\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6091381\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian cancer is the second most common gynecologic malignancy in the United States, the most common cause of death among women with gynecologic cancer, and the fifth leading cause of cancer death in all women. The annual incidence of ovarian cancer in the United States is 12.7 per 100,000 women. The lifetime risk of ovarian cancer in the general population is 1.4 percent. (See",
"      <a class=\"local\" href=\"#H26443077\">",
"       'Ovarian carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary fallopian tubal cancer and peritoneal serous carcinoma have been considered rare malignancies. The incidence of fallopian tubal carcinoma may have been substantially underestimated, since presumptive ovarian and peritoneal carcinomas may derive from the fallopian tube. Based upon available data, the annual incidence in the United States of fallopian tubal carcinoma is 0.41 per 100,000 women and of peritoneal carcinoma is 0.46 per 100,000. (See",
"      <a class=\"local\" href=\"#H26443084\">",
"       'Fallopian tubal carcinoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H488992\">",
"       'Peritoneal carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for ovarian cancer include increasing age, nulligravidity, infertility, endometriosis, and hereditary ovarian cancer syndromes (",
"      <em>",
"       BRCA",
"      </em>",
"      gene mutations, Lynch syndrome). (See",
"      <a class=\"local\" href=\"#H6092142\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Protective factors include oral contraceptives, salpingo-oophorectomy, tubal ligation, hysterectomy, and breastfeeding. (See",
"      <a class=\"local\" href=\"#H6092303\">",
"       'Protective factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed., Robboy SL, Mutter GL, Prat J, et al..  (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.601.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/3\">",
"      Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/4\">",
"      Seidman JD, Zhao P, Yemelyanova A. \"Primary peritoneal\" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011; 120:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/5\">",
"      Salvador S, Gilks B, K&ouml;bel M, et al. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009; 19:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/6\">",
"      Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol 1996; 60:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/7\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/ovary.html (Accessed on April 24, 2012).",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/faststats/selections.php?#Output (Accessed on April 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/10\">",
"      King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/11\">",
"      Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/12\">",
"      Crijnen TE, Janssen-Heijnen ML, Gelderblom H, et al. Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005; 4:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/13\">",
"      Watson P, B&uuml;tzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/14\">",
"      Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 2007; 107:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/15\">",
"      Goodman MT, Shvetsov YB. Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact? Int J Cancer 2009; 124:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/16\">",
"      Salehi F, Dunfield L, Phillips KP, et al. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 2008; 11:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/17\">",
"      Kammerman S, Demopoulos RI, Ross J. Gonadotropin receptors in experimentally induced ovarian tumors in mice. Cancer Res 1977; 37:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/18\">",
"      Whiteman DC, Murphy MF, Cook LS, et al. Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 2000; 92:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/19\">",
"      Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Luteinizing hormone, its beta-subunit variant, and epithelial ovarian cancer: the gonadotropin hypothesis revisited. Am J Epidemiol 2001; 154:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/20\">",
"      Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/21\">",
"      Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011; 105:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/22\">",
"      Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer. Curr Treat Options Oncol 2009; 10:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/23\">",
"      Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/24\">",
"      Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995; 76:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/25\">",
"      Stewart LM, Holman CD, Aboagye-Sarfo P, et al. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol 2013; 128:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/26\">",
"      Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 2002; 95:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/27\">",
"      Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/28\">",
"      Hemminki K, Granstr&ouml;m C. Familial clustering of ovarian and endometrial cancers. Eur J Cancer 2004; 40:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/29\">",
"      Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000; 11:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/30\">",
"      Titus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001; 84:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/31\">",
"      Hinkula M, Pukkala E, Kyyr&ouml;nen P, Kauppila A. Incidence of ovarian cancer of grand multiparous women--a population-based study in Finland. Gynecol Oncol 2006; 103:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/32\">",
"      Vicus D, Finch A, Rosen B, et al. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Gynecol Oncol 2010; 118:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/33\">",
"      Lambe M, Wuu J, Rossing MA, Hsieh CC. Twinning and maternal risk of ovarian cancer. Lancet 1999; 353:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/34\">",
"      Olsen J, Storm H. Pregnancy experience in women who later developed oestrogen-related cancers (Denmark). Cancer Causes Control 1998; 9:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/35\">",
"      Pike MC, Pearce CL, Peters R, et al. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 2004; 82:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/36\">",
"      Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/37\">",
"      Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/38\">",
"      Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996; 66:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/39\">",
"      Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004; 103:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/40\">",
"      Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/41\">",
"      Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004; 82:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/42\">",
"      Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/43\">",
"      Van Gorp T, Amant F, Neven P, et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004; 18:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/44\">",
"      Orezzoli JP, Russell AH, Oliva E, et al. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol 2008; 110:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/45\">",
"      Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009; 19:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/46\">",
"      Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/47\">",
"      Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998; 92:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/48\">",
"      Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 2008; 108:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/49\">",
"      Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007; 166:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/50\">",
"      Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 2012; 124:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/51\">",
"      Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 2003; 88:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/52\">",
"      Li AJ, Karlan BY. Genetic factors in ovarian carcinoma. Curr Oncol Rep 2001; 3:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/53\">",
"      Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/54\">",
"      Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/55\">",
"      Kauff ND, Mitra N, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005; 97:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/56\">",
"      Lee JS, John EM, McGuire V, et al. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 2006; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/57\">",
"      Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/58\">",
"      Liede A, Tonin PN, Sun CC, et al. Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet 1998; 75:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/59\">",
"      Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/60\">",
"      Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/61\">",
"      Piver MS. Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 2002; 85:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/62\">",
"      Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/63\">",
"      Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/64\">",
"      Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/65\">",
"      Tan DS, Rothermundt C, Thomas K, et al. \"BRCAness\" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26:5530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/66\">",
"      McLaughlin JR, Rosen B, Moody J, et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013; 105:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/67\">",
"      Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003; 21:4222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/68\">",
"      Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001; 80:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/69\">",
"      Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005; 106:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/70\">",
"      Dowdy SC, Stefanek M, Hartmann LC. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol 2004; 191:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/71\">",
"      Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/72\">",
"      Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002; 94:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/73\">",
"      Casey MJ, Synder C, Bewtra C, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005; 97:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/74\">",
"      Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/75\">",
"      Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009; 10:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/76\">",
"      Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009; 75:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/77\">",
"      Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/78\">",
"      Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007; 7:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/79\">",
"      Jordan SJ, Whiteman DC, Purdie DM, et al. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/80\">",
"      Tworoger SS, Gertig DM, Gates MA, et al. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 2008; 112:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/81\">",
"      Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. Anticancer Res 2003; 23:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/82\">",
"      Riska A, Martinsen JI, Kjaerheim K, et al. Occupation and risk of primary fallopian tube carcinoma in Nordic countries. Int J Cancer 2012; 131:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/83\">",
"      Blank MM, Wentzensen N, Murphy MA, et al. Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study. Br J Cancer 2012; 106:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/84\">",
"      Qin LQ, Xu JY, Wang PY, et al. Milk/dairy products consumption, galactose metabolism and ovarian cancer: meta-analysis of epidemiological studies. Eur J Cancer Prev 2005; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/85\">",
"      Mason DT, Lee G, Chan MC, DeMaria AN. Arrhythmias in patients with mitral valve prolapse. Types, evaluation, and therapy. Med Clin North Am 1984; 68:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/86\">",
"      Myung SK, Ju W, Choi HJ, et al. Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis. BJOG 2009; 116:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/87\">",
"      Yin L, Grandi N, Raum E, et al. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecol Oncol 2011; 121:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/88\">",
"      Carnide N, Kreiger N, Cotterchio M. Association between frequency and intensity of recreational physical activity and epithelial ovarian cancer risk by age period. Eur J Cancer Prev 2009; 18:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/89\">",
"      Bertone ER, Newcomb PA, Willett WC, et al. Recreational physical activity and ovarian cancer in a population-based case-control study. Int J Cancer 2002; 99:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/90\">",
"      Pan SY, Ugnat AM, Mao Y. Physical activity and the risk of ovarian cancer: a case-control study in Canada. Int J Cancer 2005; 117:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/91\">",
"      Tavani A, Gallus S, La Vecchia C, et al. Physical activity and risk of ovarian cancer: an Italian case-control study. Int J Cancer 2001; 91:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/92\">",
"      Bertone ER, Willett WC, Rosner BA, et al. Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst 2001; 93:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/93\">",
"      Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: The Iowa Women's Health Study. Cancer 2004; 100:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/94\">",
"      Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007; 43:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/95\">",
"      Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/96\">",
"      Rota M, Pasquali E, Scotti L, et al. Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis. Gynecol Oncol 2012; 125:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/97\">",
"      Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 2005; 60:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/98\">",
"      Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/99\">",
"      Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/100\">",
"      Lurie G, Thompson P, McDuffie KE, et al. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 2007; 109:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/101\">",
"      Chiaffarino F, Parazzini F, Decarli A, et al. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol 2005; 97:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/102\">",
"      Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/103\">",
"      Cibula D, Widschwendter M, M&aacute;jek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/104\">",
"      Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/105\">",
"      Ip S, Chung M, Raman G, et al. A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. Breastfeed Med 2009; 4 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/106\">",
"      Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/23/25978/abstract/107\">",
"      Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995; :33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83387 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25978=[""].join("\n");
var outline_f25_23_25978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6091381\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6091373\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461641\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6092134\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26443077\">",
"      Ovarian carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26443084\">",
"      Fallopian tubal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H488992\">",
"      Peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6092142\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H488066\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092150\">",
"      Reproductive and hormonal factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092158\">",
"      - Early menarche or late menopause",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092166\">",
"      - Nulliparity and other obstetric factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092174\">",
"      - Infertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092182\">",
"      - Endometriosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092190\">",
"      - Polycystic ovarian syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092198\">",
"      - Postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092206\">",
"      - Intrauterine device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092214\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092222\">",
"      - Family history of ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092230\">",
"      - BRCA gene mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092238\">",
"      - Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092246\">",
"      - Other genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092254\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H394569\">",
"      - Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092263\">",
"      - Talc and asbestos",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H394527\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092279\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092287\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092295\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H291890\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6092303\">",
"      PROTECTIVE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092311\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160184\">",
"      Gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9532690\">",
"      - Salpingo-oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6092319\">",
"      - Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H292094\">",
"      - Tubal ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092327\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6092343\">",
"      MANAGEMENT OF WOMEN AT HIGH RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6091381\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/83387\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/83387|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/22/9568\" title=\"figure 2\">",
"      US ovarian ca incidence age race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/0/2049\" title=\"figure 3\">",
"      Lynch syndrome cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/83387|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/11/14526\" title=\"table 2\">",
"      Staging fallopian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/59/12221\" title=\"table 3\">",
"      Risk factors ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7821\" title=\"table 4\">",
"      Cancer risks BRCA1 and BRCA2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=related_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=related_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=related_link\">",
"      Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=related_link\">",
"      Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=related_link\">",
"      Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_23_25979="Advance directives PI";
var content_f25_23_25979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources that can help you make advance directives",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Address",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phone number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Website",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AARP",
"       </td>",
"       <td>",
"        601 E Street NW",
"        <br/>",
"        Washington, DC 20049",
"       </td>",
"       <td>",
"        Toll-free: (888) OUR-AARP [(888) 687-2277]",
"       </td>",
"       <td>",
"        <a href=\"file://assets.aarp.org/external_sites/caregiving/multimedia/EG_AdvanceDirectives.html\" target=\"_blank\">",
"         file://assets.aarp.org/external_sites/",
"         <br/>",
"         caregiving/multimedia/EG_AdvanceDirectives.html",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aging with Dignity (Five Wishes",
"        <sup>",
"         &reg;",
"        </sup>",
"        form)",
"       </td>",
"       <td>",
"        PO Box 1661",
"        <br/>",
"        Tallahassee, FL 32302",
"       </td>",
"       <td>",
"        Toll-free: (888) 5WISHES [(888) 594-7437]",
"       </td>",
"       <td>",
"        <a href=\"file://www.agingwithdignity.org\" target=\"_blank\">",
"         www.agingwithdignity.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caring Connections",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Toll-free: (800) 658-8898",
"       </td>",
"       <td>",
"        <a href=\"file://www.caringinfo.org\" target=\"_blank\">",
"         www.caringinfo.org",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25979=[""].join("\n");
var outline_f25_23_25979=null;
var title_f25_23_25980="Localization of pediatric respiratory distress";
var content_f25_23_25980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Localization of respiratory distress by physical findings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Upper airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sniffing position: neck is flexed with head extended to open airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal flaring: also seen with lower airway disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged inspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retractions: supraclavicular, suprasternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal voice: hoarseness, hot potato voice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stridor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barking cough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transmitted upper airway sounds (stertor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lower airway disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retractions: intercostal, subcostal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal flaring: also seen with upper airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged expiration: lower airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wheezing: intrathoracic airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grunting: may indicate severe respiratory distress or severe pain from an intraabdominal process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rales (crackles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural rub",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchophony",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsus paradoxus: caused by severe lower airway obstruction or cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gallop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rales (crackles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jugular venous distention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral or periorbital edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsus paradoxus: caused by cardiac tamponade or severe lower airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Central nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal respiratory pattern (Cheyne-Stokes, or ataxic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kussmal respirations",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25980=[""].join("\n");
var outline_f25_23_25980=null;
var title_f25_23_25981="Survival of CF patients";
var content_f25_23_25981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Median predicted survival of patients with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 336px; background-image: url(data:image/gif;base64,R0lGODlh1gFQAeYAAP///xoXGwAAAP8AAIiIiJqZm0RERPHw8SIiIu7u7jMzM3d3d1VVVURCRZmZmYyLjf8PD//f393d3f8/P//v7/9fXxEREbu7u2ZmZv+vr/8vL/8fH/+Pj/+fn8zMzP9/f/9vb/+/v29tcP/Pz/9PT6qqqvEBApoKDEQTFpo/QePj44wMDpoSFGJgY/HS0+QCBIsTFfF5eZqHiZKRk28OEZtRU/EuLkQZHJokJmIuMfHDxJt+gPEQECIfI0QWGZobHfG0tfGlppqQkkI/QvFaW0QyNvHh4m9hZIxbXYw6PWIzNlMSFUQtMJt1d0QfIm9naiIWGkQqLZNnaZtaXFJIS4yDhOPV1VNQU4x6fUQ7P+NWVjEvMvA9PUQwM5otLzEeIkUiJfBLS28+QIxKTUU5PCIeIvFpaoxiZTk3OvEfH5pISgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADWAVABAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/qMGEAwyIECAgX8IEzJbYEEgAAIIEiRAQEChxYvBIEIUxKDiQwYYQ4q8dcGCBAcOETgQ5EDByJcwW0mwcAEASkEqWboU9CCAz59AYwodaulCwaMCJHQUtAAkowBEo0qNdPNhxIkeF0GdyrXroaoACBp0tNWr2bOUyqJdy1aR2rZw/+O+jUsX7dy6eLnezct36N6+gEkdKPCgwIFvfwMr9nSgwc8Gh7slXkw5UwGgAQp4m1y5M6WeQEVs9kx60w7MmiWXXp1ocOHIhjqYQPEY9jbOrCk3fqyCsGFBIAYMCCPkNeLcyAVdBrrlsRESwkGQw50cMGjMP3EI71COenW6rgvMwA6UBoQR5rx/b7vb55AhP79gThHhnPr1a5f/lJICxokXtPkEGTr34XfWdT7RIBwEFQThm23dGbiYfj6xUEEG8BQoYVThWQHGT0VA2I6GGwrVXgA3vHDCGL/JQ2KJMFEYwA8h2PMijCMhGMAT99yIY0gyplaPjz9e5EKAAQxoY/+RbVVgQgrGORKeiKMxiVYEwtUHyYlKhkOklf9UMEAFkgQ5zpdg6uMaCyagF4mOoomDZpr3nHgDlYuYKSedUum5pWMC4nkbn1HBOcmU0xFKlJ/5zKmoPFwKOo+jj8ajwwkwtLgPpZW+o8GY/3DaKTvBQaBlP6KOmk4GwmEYqqohRQDBANIhlCqs5XyqgUK34noNooQcoMYKLLjAq6/2RDrIAUXUllCvyE4TZAQffFADas9GS4+OYgg3wAqYxfmqtuQAe4iMJwwwgbXY2kruOMoeciIKabga77jvgsPoIBR0YMMJK5wQAwXBPnhsvuAYSsgIFcw6AIP1mXsRtAjTIrH/nv1+KpwGHRAMwL0WUVxxLPdGyvCsJrCQxA627ZvtyNK2K4hrMsSwgbc2dOEsT+GGJDLMrigsSMbeMjiCny6bc4ECBSkggSBiHdTIz0CzomcG0HlLgqsACA0yOgQsAEACCogNkUQUTV11NFy60LC3HHs8CKMSsyMBAiUAsNRHaq8NDc1EmADwDzGcWsjX8yAggFM52bSTVn5HE4GYs+0sr8H5kF1R4y0NoiNmkTszubcpyBwSAQft3VTfoR+jQgtU5PCCcBVEILRCS91d0dlYsd66LXUTokIZP0GhhZZJ+0OABQU5FVZBUj/1uysSI05BBjlg1sKygCYpqVlUT394//ddYpwBCBovgRkaBUdZV/jizy2zjkeg7+3GSmjfGfzxd92zcphhE8BwYIYMEEwFPfhJD1Swv/5tInjyA4qQ5vUCJ1judVdoAQMb6EBMIG5m5LONC1IQMB5MwXSs4V++kvcxgw0GCykwAe1s9z/kqPBdt1PEAbLwExQQAXkoXM0NycVCQmSgdBLknuUoAcGoDFFbHxxEBt4GrtC0rwC9cd+fljiVJ0IRc4aYnMMehsSfCClYISxTEJ3YQVKMbkEX+lgaDVFERORQKl4EGgU+4LCtHQ6MhbgjI+oIkzyOqol8FM4EajQJQhoiin5poyS+1oGbDWADQACklOYYiSYSxf+QlfJTCCy5gQ5AsjWa9AwoH2WoEExgQR8AYBIVtUpFyUgGWYNADIpjGEFaqZaEOlEUZDgmF5BvPLMkFDCDWQAksEld9ZHRDDjJp2XyKQQa2wAj/RcaTzLJmmB6IwQ4UAhH/lKSjjBCDfxjggrITYmBaksCBFGCebICnD8Kwg1+QgY8eVMqy5MAQUxyT3QqYgQTOMEa86IABnhAAAiwAAYKalBDUEBMA4BBDQNTNgcIIGyPSwU+DcQBh1VABgvFCwMQQJASLCCkqBjpd0a5sRqdki4lKIhAFDDRVcgUORF45cO4s6xUAsalEpDAAjxAUXSWVDgfeCdrJJA3WPy0NEH/VaThkEMAAdjTFVf1zFPHaaCZSEAiX1VFWCmTVWhKaAFIEYDYfOrAsZJzQ3BFylzVGr+2TmCrBkKrRFqx1r7YtUhhW4Biq8rX1vkVsBLqql6b6rfDMskAFgjIAhrX2LU9Fkxl24hiKQszy4IWAznFgAJgeorCsuWzdNrsRAqyV5ECzbR8mqdSs9LZfMFWUQ4wgAI8oICV0BVhuCWURwuSAAM4z7bv+u2jVtvVBLyUtL5K7nQXkNMEMIC1pnBtVKTbKQxkdnEfxe6otNspsh1FAWmNqa/IC6sEhI0A8ZUvrEYwK7L+s6KJEO9LOrCxiFHzUQRgQE1eIWCRBGcAJPCY/zl/lFcF4HcSKIGePaNGlk5RIGu14pkVVXUB8wrAAgqOBAYqMpPdXSVt0ntUBDRG1AiaEVcekGzzKGGAlewtwb6jUwb66yY0clFRJRCLAMom3EnkGCfG7VyM+fRgDUC2hVqsFFxRvGAAMDUSEugpADj3uM8FhU4zjs7aHMBbSlwgenrzyOqmbKUhP4xrADbE2QjBOxhDDkxVvnKen3cUh3A4yDBKM60GTYoG64O/dxafYAlbpA7MysrT84DijlJb/cLoA8KJsPiUTFv1rgejZIpfQM46WFMnhwI0dmAJrtLq4xpoBDeDwDbjl1dOu5o0rmkCDy5Z5P71utS2Rs68bP8g1f4JNr+t/c6EYWbPZ1O6OlXYqKTlemy5/royFMBBSiOXAG7HtdPRTo4GTOCDI0+v2pP+9mJKpQOjMjrdrGHVAPB8b7DmRlaL7ncsHK2OV+5K4APPd5YEHtzhFlfefKHAzWLZ7+V61bkQzwuoN9BsAFPXq9dNdmWwtG+El6273814XYIzAYQDwLwEYUB6RU6Zm/Gb0e5tGrRLQfBykNzlgrDvAi6s8rhwAMJAH1u8aa4Y6NwV4d2WKNMDs3CXd7sgbea5Z1i1gaS/VCIPdYAFwDuKno8jOCE2+U4kINfV9nYxr7z5vWVugAUQhABuh25lqu7ymRRaAhZ+e17CA4T/SyY96Pettd75ciImmIAEhx9EiRGA7vAGBl1Pd3mOmYZswddFRzTYdb+THNcue54u6PJ68y4A151rHTDz4oLqoUcQ1zdaMa6JYdoRXgIGMA96jF18YGYld4QHt/PC7wurIBD5QkiAAMY9PV7ElOrmJ3wxxLe+LMzujeVrf/uKgXT1v+9vwNgZ0+RnMGAIPAANdDz9yY/Lg8cP/2tPX831typeYL2d/F8/LjOWMmegKf5XdENRUuzmbgVoeW3RVl4wbguoCHZHCIdGZ2dhV74UgYnAdmMhCH2WdYfAfc/wWdOmgR4YPT/2XAGGFqZ1UyaoZ9FDZog2XkL1V3+UZS/I/wioMwgyKGLkIYLJsEcLknk5iAk7yBFypoKIAITHkAGWZINFuAlHaBVoA4KGwITE0FYbUHxROAkciHVQAz0dNhRCCFXv14X2BxNOqFVoaAtY6AtayIVtWH4jkUgDEFVzeAtvqAsjoDFQmIduGBIU8GAQUGOAGIgXQVMQdoaHqH8K8WHCoU2NqAt7OAuWFh2MOImO6A9tpQHFpol66A8XBUugyAuVyAp75DB/WIq5cIqqUEk1xYq94IqngE2RaIiySIn30FYQgIe5OIv18EZjkom/SAu0CAqpGGqCVoyhGA92uEjMGAzHyAmweEmiF43A2A6KWErYOAzTeAmuRIrd6P+N6jACueSL4ygM3ygJ4ThD6VgM6/gIHaAxY7KM72iK49AvlgQx93gM8ZgIyfgw6NiP8PgNYnSLxEiQ2bgNDAM3uKiQxvCPgjCP3gKNELkM8UgtY1QBn3iRyPCNIZA1lzSQHqkMtKiPFZkB/1WSv3CKB/kwtSNHCsiS0vgMGSBUl9QxNuYTZ0STxMCEe2RJEHaNGeiTviCCU1Q0H3BlJWiUtUBwI8ABONl+Dzk+M+mU+BgM/VIBQnlJINCRiLCSWIkLaxUCH0CPD0MCHWCPY/kMMhUBHUACY9R+H3CNbXkN4HQ+XbkBFaCTd1klshCVU6kuHACWfzkor7CVc7kBICD/h4eJmKsQAvZTNGrJlo8JmaYQARwgkhvzAYZ5mXtCCtfDlffDlwYEmuzQKyNwlvcDYRxgmagZmpwAl3J5PxoAAnYZm+vgKBzQlQzil7rpIpyQNRNQmMHZI5wQAo55nO/wImLJnN1QgX82SQcGnePwgTPYCE1pndWQgtnJCEXJndzQg9MZCdspntJAnmb2E0xUnejpDaqjhCFYCc/5ntWAnRZon/kgnW6hn2zkn5EEoEIhkQIKfgVaSAeKoAk6EgS6oGnooCHzgxI6oRRaoRZ6oRiaoRq6oRzaoR76oSAaoiI6oiTqoZvyfw9qgJ9gSHnUoie6iSk6dZ5GhzEaf/TA/6IwWqMzqqP4xqPxgKPql6MyuqNDyoCNgqIquqJCWqSvR6PIuaQ2GqU96qNNSqXNiaRMWqVJ6gkuGqRHCqVEmqVlh6XSN6VLAqZmKqaiAKROqqbs8ACxAKevIKdzCgt0GjR2mqcQuqd82qd+2pYTKAiAt2MU6BCEBmeWEKgAMKiLIwhGcRRSw5+UoKiM6jzEVRALJqmTGj2VGoZI4amIuqmD0KljIxZOA6qaQKmc5xSkeqiXkGEGsWFiiKq0WgmwagCy2oFMAWeaug0cGD0GMFG6MwgM4RD4WQm/OhDCmjZGUQjH6oWzGhbLymIWUFvPCq26GqyL6meCgAEgca1gFv+t2jqsqiUIDUWFvWMJyQo10yqt2+piVWgJK7aoFgCvvYOd4AoJ89pi6Jo269qvVrgNUygAC3aEGuEQ3mmE0UOwJwgAzUoICWsJA1uwBzFngxCxEruwFEsIbPc0GEsJE9uw3soUE/WxIKuxDcuwD5E6HgFkmdBjceaBIOGdJstjPtayzjOFNcsNU4gAPbVZDmsSVUGeGcuDPysQj7pkT0O0J2u0TLFTm4YATMW0TYsTRwuxPUW1ktCzV0s2EoWrYxZlZBcJXPu0Y3a1WisJTxa2OsG2juO2UnYJa0uePSu21xk9mqZTTkMTNpESdquwg5C3EBVSZAMSaQsJUyi4COD/EpTXrYz7t5eQuFH7OEbxNHA7to8guXq7slaxOZBbtIKguC4hupeLCWHGg3Yrg4f7CKcLZW3bsK77tuIwhRC7AEl7FEqRhJlAuxfbaTsYn4BrCAwgNgbgEc0KvMFbCMOrrBeru5EbqnojNnzbtzELABYLusrbacuLvJXwZhCru8DLvW4GZ9yrs84bDrxrvQQ1CFWRr1sbqgzxNPsaeO6LuPBLUBDhsQdRv/ZrCPHrqOsLsMlLrASlAJG6vy8WsP1bCP9LwE/DvzoYEXyWwAIMwYuwZ4NwrFNowdXwhen1qMNVCGDRq5DgwRUBwl8mdoTqquqKFCfcNF+mN01juSTM87ou7LAwzINtVsONYMI4vGRfdqlKW6vIesMo7Kg5TMSTQGqGJq5OrKs8hhRN3IE+zMJ/esVYnMVavMVc3MVe/MVgHMZiPMZkXMZmfMZonMZqvMZsvBoEsRMyh7ltnA1+VwIPpbJzHA5whQAy11O3+jScB8TWaxC1l8fOsGkWME9Gsb9Q3FUCcWy2Z8jDkFMzhwFxZQE2oWSYDFfyKcnIUG4C8GWWLGY4bAEekFOb3Kie3Ayg/GWozFS9h8oPcWKD3MmrXAytzL6BXBGmSsucfMvAHMzCPMzEXMzGfMzInMzKvMzM3MzO/MzQHM3SPM3U3I+BAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154:1229.",
"       </li>",
"       <li>",
"        Cystic Fibrosis Foundation, Bethesda, MD.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25981=[""].join("\n");
var outline_f25_23_25981=null;
var title_f25_23_25982="Details of Ig gene rearrangement";
var content_f25_23_25982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Details of Ig gene rearrangement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The heptamer and nonamer recombination signal sequences. The 3' flanking sequences of&nbsp;Vx genes have the palindromic heptamer recombination signal sequence, a 12 bp spacer, and the AT-rich nonamer signal sequence. The 5' flanking region of&nbsp;Jx genes contain the sequences in the reverse order, and separated by a 23 bp spacer. The immunoglobulin gene recombination mechanism only operates when one flanking sequence has a 12 bp spacer, and the other a 23 bp spacer (the 12-23 bp rule). The flanking sequences of&nbsp;&lambda; gene segments are identical, but transposed. VH genes have 3' 23 bp spacers, D genes are flanked both 5' and 3' with 12 bp spacers, and JH genes have 5' 23 bp spacers. B) Genetic products of rearrangement. Rearrangement proceeds by deletion of intervening DNA. The two gene segments are joined, as are the two signal sequences in a separate circular piece of DNA. The excised circular DNA contains all of the sequence which stood between the gene segments before rearrangement. The arrow within the gene segments indicates the transcriptional orientation of the gene segment (the direction taken by RNA polymerase when synthesizing mRNA). The rearrangement break points are indicated by arrows marked \"X.\" C) Consequences of imprecise gene segment joining. Ig gene segments need not always be spliced together at the same positions within their coding sequences. As long as the reading frame is maintained, a potentially functional protein may be generated. In the example here, four different in- frame splices are possible. Splicing at each position creates a codon for a different amino acid at the union of the two gene segments. Additional diversity may be generated by the random addition of nucleotides forming the N regions between the gene segments during splicing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bona, C, Bonilla, FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright &copy; 1996 Overseas Publishers Association, N.V. Permission granted by Gordon and Breach Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25982=[""].join("\n");
var outline_f25_23_25982=null;
var title_f25_23_25983="Occipital encephalocele";
var content_f25_23_25983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Occipital encephalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A small skin-covered encephalocele is visible in the occipital region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin A Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_23_25983=[""].join("\n");
var outline_f25_23_25983=null;
